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ABSTRACT 
The ability to induce a potent and broadly neutralizing antibody (bNAb) 
response following vaccination is critical in developing an effective HIV-1 
vaccine. To date, no HIV-1 envelope glycoprotein (Env) immunogens have 
elicited bNAbs in preclinical or human clinical trials. This study compared 
the antigenicity and immunogenicity of a panel of HIV-1 subtype B and C 
Env-based immunogens in various immunization regimens in a small animal 
model. The Env-based immunogens used included matched monomeric 
(gp120) and trimeric (gp140GCN4(+)) conformations of 6 subtype C Env’s 
(IN26191, IN25710, IN25925, ZACAP45, ZACAP210 and ZA706010164; all 
designed during the course of this study), and subtype B stabilized Env 
derivatives Cyc4OD gp120 cyclic permutant, gp140 cyclic permutant h-CMP 
V1cyc 144-142, ODECCOBPICS gp120 fragment, VRC01 engrafted scaffold 
peptides 1WR2 and 1ORC, and DNA (Wt-JRFL-Env, JRFL Env-570D and 
JRLF Env-SEKS; all obtained from collaborators).  
 
The six HIV-1 subtype C Env sequences (IN26191, IN25710, IN25925, 
ZACAP45, ZACAP210 and ZA706010164) were selected, matched gp120 
and gp140GCN4(+) constructs were designed, codon optimized and cloned 
into a mammalian expression vector. All 12 env constructs were expressed 
in HEK293T or 293FS cell lines, and the Env purified by lectin affinity 
chromatography, followed by size exclusion chromatography. Additionally, 
two domain soluble CD4 (2dCD4) wildtype, folding defective and an S60C 
mutant were expressed in a bacterial system and purified by nickel affinity 
chromatography. 2dCD4S60C-liganded Env was prepared, and purified 
further, as required. The antigenicity of all 12 Env’s was evaluated against 
2dCD4 and a panel of bNAbs using surface plasmon resonance (SPR). The 
immunogenicity of two of these subtype C Env variants (liganded and 
unliganded to 2dCD4S60C) were subsequently compared to that of the 
subtype B immunogens in rabbits, using various prime-boost regimens. 
Rabbit sera were subsequently tested for anti-Env binding antibody titres by 
enzyme linked immunosorbent assay (ELISA), and neutralization by an in 
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vitro phenotypic neutralization assay against a panel of HIV-1 
pseudoviruses.   
 
All 12 recombinant Envs were successfully expressed and purified to 
homogeneity. Binding of all the gp120/gp140GCN4(+) Env variants to 
2dCD4 variants (Wt and S60C) confirmed that they were all functional and 
conformationally intact with an accessible CD4 binding site (CD4bs). 
Binding to a panel of CD4bs directed bNAbs (IgG1b12, VRC01, HJ16, VRC-
CH31, NIH45-46G54W, VRC03) revealed that overall, the trimeric 
gp140GCN4(+) variants showed higher binding affinities to these bNAbs 
compared to the matched monomeric gp120, attributed to their resemblance 
to the native trimer on the viral surface. With the exception of VRC03 and 
IgG1b12, the Indian Env variants bound with an approximately 10-fold 
higher affinity compared to the South African Env’s. Overall, nine different 
immunization regimens were performed. Immunization of rabbits induced 
high titres of antibodies (Abs) for all the immunogens tested, as determined 
by ELISA, however, minimal neutralization breadth (against Tier 1 
pseudoviruses) was obtained for the Env-only variants for subtype B and C 
immunogens. Of these, the VRC01 engrafted scaffold peptide (1ORC) 
showed improved neutralization of the Tier 1 pseudovirus SF162 compared 
to the other Env only based immunogens. The only promising neutralization 
results were obtained from rabbits immunized with the Env/2dCD4S60C 
liganded immunogens that potently neutralized both subtype B and C, Tier 
1, 2 and 3 pseudoviruses. This response was improved for the trimeric 
Env/2dCD4S60C complexes compared to the monomeric ones and was 
consistently elicited regardless of the Env sequence used. The 
neutralization response is likely either due to Abs targeting one or more 
epitopes on 2dCD4 or Env or both. Therefore, the use of CD4 liganded Env 
immunogens in vaccine design should be investigated further as they 
provide a promising “Ibalizumab-like” neutralization response. Overall, 
based on emerging evidence on how the bNAb responses evolve in HIV-1 
infected individuals, the findings in this study are promising and lay the 
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groundwork for further testing of these HIV-1 Env based immunogens in 
various combinations using sequential prime-boost strategies to optimally 
drive affinity maturation of the appropriate B cell lineages. 
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Chapter 1 : Introduction  
1.1 The HIV-1 pandemic continues to be a major health challenge 
By the end of 2015, approximately 36.7 million people were living with 
Human Immunodeficiency Virus-type 1, (HIV-1) globally and approximately 
2.1 million of these individuals became newly infected during 2015. Thus 
HIV/AIDS (acquired immune deficiency syndrome) remains one of the 
world’s major health challenges UNAIDS (2016). Of these newly acquired 
HIV-1 infections, sub-Saharan Africa remains the most heavily affected 
region, accounting for almost 70 % of new HIV-1 infections (World Health 
Organization, 2016).  
 
Antiretroviral therapy (ART) has had a positive effect on the lives of HIV-1 
infected people and has a host of benefits including: suppression of viral 
replication in HIV-1 infected individuals to such an extent that they are able 
to maintain a healthy immune system; prevention (reduced risk of 95 %) of 
sexual transmission of the virus to a non-infected partner if taken by the 
HIV-1 positive partner; prevention of HIV-1 acquisition by an HIV-1 negative 
person who uses ART as pre-exposure prophylaxis (PrEP); use of ART as 
post-exposure prophylaxis (PEP) to prevent HIV-1 acquisition in cases of 
accidental exposure; and prevention of mother-to-child transmission if ART 
is used during pregnancy (Sued et al., 2016; World Health Organization, 
2016).  
 
HIV-1 prevention strategies such as condom use, voluntary medical male 
circumcision, the antiretroviral (ARV) drug based prevention strategies 
mentioned above, and the use of sterile needle exchange programmes for 
injecting drug users have been widely publicised in education programmes 
(Sued et al., 2016). The implementation of these prevention and treatment 
strategies has had some success, as indicated by the drop in global HIV-1 
infections by 35 %, and the decrease in AIDS-related deaths by 28 % since 
2000. Although ART has played a major role in the decline on the morbidity 
1-2 
 
and mortality associated with HIV-1 infection, it is not curative and as at 
June 2016, only half of people living with HIV-1 were receiving ART 
worldwide. Access to treatment by individuals in low- and middle-income 
countries represent the majority of the treatment gap and this issue remains 
high on the agenda towards obtaining the goal of ending the AIDS epidemic 
by 2030 (UNAIDS, 2016). As a step towards achieving this goal, the 
UNAIDS “90-90-90” programme set 2020 as the target year to achieve the 
following goals (i) successfully diagnose 90 % of people living with HIV, (ii) 
administer antiretroviral treatment to 90 % of the HIV-1 infected individuals 
diagnosed, (iii) attain viral suppression in 90 % of the treated individuals 
(Corey and Gray, 2017). 
 
Despite the positive statistics mentioned above, 1.1 million people died of 
AIDS-related illnesses globally in 2015 (UNAIDS, 2016). Successfully 
diagnosing 90 % of HIV-1 infected individuals, especially during their high-
risk transmission period of infection, in a country such as South Africa that 
has a high burden of disease is proving to be logistically difficult (Corey and 
Gray, 2017). Preventing HIV-1 infection is key in the fight against the 
HIV/AIDS pandemic, and historically viruses have been most effectively 
controlled by vaccination (Agwale et al., 2011). A prophylactic HIV-1 vaccine 
would have a major impact on the transmission rates of the virus and help 
control the HIV/AIDS pandemic (Esparza, 2013). Corey and Gray (2017) 
suggest that an HIV-1 vaccine with a partial efficacy of 50 % could avert 
over 17 million new infections globally. Thus, a vaccine in combination with 
the 90-90-90 programme could substantially reduce HIV-1 incidence. 
However, despite intensive research on vaccine development over the past 
30 years, an HIV-1 prophylactic vaccine remains elusive (Esparza, 2013). 
 
1.2 HIV-1 biology and life cycle 
1.2.1 HIV-1 Structure 
HIV-1 is a lentivirus belonging to the family Retroviridae. It is enveloped by 
a lipid bilayer derived from the host cell which contains host cell proteins 
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such as major histocompatibility antigens, actin and ubiquitin (Figure 1.1). 
The inner surface of the host lipid membrane is lined with viral matrix p17 
protein. A conical capsid core at the centre of the virus, composed of p24 
viral protein, contains two copies of positive, single-stranded RNA 
molecules stabilized by the nucleocapsid protein, as well as three virally 
encoded enzymes ((protease (PR), reverse transcriptase (RT) and 
integrase (IN)). The RNA contains approximately 9,700 basepairs and 
encodes for nine genes (gag, pol, env, tat, rev, nef, vif, vpr and vpu) (Frankel 
and Young, 1998; Goto et al., 1998; Turner and Summers, 1999).  
 
Envelope glycoprotein (Env) viral spikes are projected randomly on the 
surface of the host derived lipid membrane and these are composed of three 
non-covalently associated exterior envelope glycoproteins of approximately 
120 kDa in size (gp120), which are each non-covalently associated with a 
transmembrane envelope glycoprotein of approximately 41 kDa in size 
(gp41), which anchors them into the membrane (Figure 1.1). 
 
 
Figure 1.1: Schematic representation of the HIV-1 virion. Virus envelope glycoproteins 
(gp120) exposed on the outside of the virus are anchored to the virus by a transmembrane 
protein gp41. A conical capsid core at the centre of the virus contains two identical copies 
of RNA and three virally encoded enzymes (protease, reverse transcriptase and integrase) 
(Adapted from University of London, 2016).  
1-4 
 
The full length Env is approximately 160 kDa in size (gp160) and is 
expressed as a gp160 precursor that is subsequently cleaved into the 
functional gp120 and gp140 units (Benjelloun et al., 2012; Berger et al., 
1999; Goto et al., 1998; Kwong et al., 1998; Turner and Summers, 1999). 
 
The molecular structure of gp120 was originally elucidated using X-ray 
crystallography by using a deglycosylated gp120 in complex with a two-
domain fragment of CD4 (Kwong et al., 1998). The gp120 core consists of 
an inner and outer domain and a ß-sheet (Figure 1.2). The inner domain 
faces the trimer axis and gp41 and comprises a two-helix, two-strand bundle 
and a five-stranded ß-sandwich. The V1V2 stem emanates from the distal 
end of this inner domain. The outer domain is mostly exposed on the trimer 
surface and is a stacked double barrel that lies approximately parallel to the 
inner domain and comprises a six-stranded ß-sheet. The variable loops V4 
and V5 are on the proximal end of the outer domain and the base of the V3 
loop is on the distal end. The ß-sheet is an antiparallel four-stranded 
bridging sheet linking the inner and outer domain (Kwong et al., 1998; Wyatt 
and Sodroski, 1998). A depression at the interface of the outer domain with 
the inner domain and the bridging sheet forms the CD4 binding site 
(CD4bs). The CD4 binding residues on gp120 are distributed over six 
segments and binding of these two molecules induces a conformational 
change in gp120 that exposes conserved regions of gp120 (Kwong et al., 
1998).  
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Figure 1.2: Ribbon diagram representation of a deglycosylated gp120 core from the 
perspective of the CD4 glycoprotein. The inner domain is shown in red, the outer domain 
is shown in yellow and the bridging sheet is shown in blue (Wyatt et al., 1998a).   
 
Understanding the structure of Env at a molecular level assists in vaccine 
design since gp120 mediates attachment of the virus to the host cell and is 
an essential step in the life cycle of HIV-1. Additionally, the Env is the only 
“foreign” antigen exposed on the surface of the virion, and is thus an 
antibody target. 
 
1.2.2 HIV-1 Life Cycle  
The HIV-1 virion targets susceptible host cells, primarily CD4 positive 
(CD4+) cells such as T lymphocytes, dendritic cells and macrophages 
(Figure 1.3) and infection with HIV-1 results in the gradual destruction of 
CD4+ cells ultimately leading to immune deficiency and AIDS (Barre-
Sinoussi et al., 1983; Gallo et al., 1984). 
 
As mentioned above, attachment of the virus to the host cell is mediated by 
gp120 which binds to the host’s CD4 surface receptor. This gp120-CD4 
interaction stabilizes the bridging sheet between the inner and outer 
domains of gp120, exposing the co-receptor binding site. The two major co-
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receptors that facilitate virus entry into the target cells are CCR5 or CXCR4, 
with CCR5 being the most common. The co-receptor phenotype has been 
found to be determined by the overall charge of the V3 loop, where neutral 
and/or acidic amino acids at positions 11 and 25 in the V3 loop favour CCR5 
tropism, whereas basic amino acids in these positions favour CXCR4 
tropism (Engelman and Cherepanov, 2012; Feng et al., 1996; Klasse, 2012; 
Kwong et al., 1998; Willey et al., 1988; Xu et al., 2007; Yao et al., 2015).  
 
Once the co-receptor has been engaged, gp120 dissociates from gp41, is 
shed into the peripheral blood and serves as an immune decoy (Moore et 
al., 1990; Moore et al., 2006). The gp41 subunit mediates fusion between 
the viral and cellular membranes by forming a six-helix hairpin structure 
(resulting from the rearrangement of the trimerized amino- and carboxyl-
terminal heptad repeat sequences) which juxtaposes the two membranes 
for fusion (reviewed in Engelman and Cherepanov, 2012). The membrane 
fusion results in the delivery of the viral core capsid into the cytoplasm where 
replication of the virus using the machinery of the infected cell takes place 
(Coetzer et al., 2006; Freed, 1998; reviewed in Sued et al., 2016). 
 
HIV-1 infectivity of host cells has been found to be enhanced by 
complement protein, which is present in human sera and attaches to the 
surface of microorganisms in order for phagocytic cells to bind to the 
pathogen for phagocytosis. HIV-1 infection utilizes this process to increase 
binding of HIV-1 to target cells such as dendritic cells, thereby facilitating 
HIV-1 interaction and infection of these cells. HIV-1 infected cells escape 
complement-mediated neutralization by utilizing the complement’s self-
regulation system and incorporates complement regulating membrane 
proteins into its envelope which down regulate complement activation 
(Bajtay et al., 2004; Yu et al., 2010). 
 
After membrane fusion, the HIV-1 virion p24 capsid is released into the 
cytoplasm of the host cell and uncoated to release viral RNA and enzymes 
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RT, IN and PR (Sierra et al., 2005). The viral enzyme RT transcribes this 
single stranded viral RNA into double stranded complementary DNA (cDNA) 
molecules. This step lacks a proof-reading function making it highly error 
prone and results in mutations and extensive diversity of viral quasispecies. 
The viral cDNA is transported into the nucleus as a preintegration complex 
(PIC), which includes the cDNA, IN and a range of viral and host proteins, 
and moves into the nucleus of the host cell where the viral enzyme IN 
incorporates the cDNA into the host’s genome. The integrated proviral DNA 
becomes the blueprint for producing messenger RNA (mRNA). Initially 
mRNA transcripts are synthesized and transported out of the nucleus into 
the cytoplasm where they are translated into the regulatory viral proteins 
Rev (regulator of expression of virion proteins), Tat (transactivator of 
transcription) and Nef (negative factor). Once the levels of Rev in the 
cytoplasm are sufficiently high, it is imported back into the nucleus where it 
binds to full-length unspliced HIV mRNA forming oligomers and mediates 
their export out the nucleus for translation of the viral proteins, therefore Rev 
acts as a critical shuttle for viral mRNA between the nucleus and cytoplasm 
(Frankel and Young, 1998; Goto et al., 1998; Pollard and Malim, 1998). 
 
The Env precursor (gp160) is synthesized in the endoplasmic reticulum 
where it forms a trimeric glycoprotein complex that is heavily glycosylated. 
It is then post-translationally modified in the endoplasmic reticulum and 
Golgi apparatus and cleaved by a furin-like protease to form the non-
covalently associated gp120-gp41 trimeric glycoprotein complex (Klasse, 
2012; Willey et al., 1988). These meta-stable trimers are transported to the 
host cell membrane and incorporated into the virus when the viral Gag 
protein drives the assembly of the virions before they bud from the infected 
cell. A small minority of the gp160 precursor is cleaved intracellularly to 
produce gp120 and gp41. The remainder is transported to the lysosomes 
and degraded (Willey et al., 1988). The immature virions bud out of the cell 
by folding of the lipid bilayer to form pockets which are pinched off and 
released from the cells. HIV-1 PR cleaves the Gag-Pol polypeptide to 
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construct the enzymes and structural proteins (matrix, capsid, nucleocapsid 
and p6), which rearrange during maturation to form infectious virions (Sued 
et al., 2016; Zheng et al., 2005). The infectious virions are therefore 
encased by the host cell’s lipid bilayer with the viral trimeric Env’s protruding 
from this membrane minimizing recognition by the immune system 
(Checkley et al., 2011).  
 
 
Figure 1.3: Schematic diagram of the life cycle of HIV-1. The virus binds to the CD4 
receptor and fuses with the host’s cell membrane, releasing the capsid into the cell. The 
capsid is uncoated and releases viral RNA into the cytoplasm. Reverse transcription 
converts the RNA into cDNA to form the pre-integration complex which is translocated into 
the nucleus. This cDNA is incorporated into the host’s chromosome by integrase. 
Messenger RNA is synthesised and exported back into the cytoplasm of the host cell where 
it is translated into viral proteins and translocated to the cell surface where they are 
assembled into immature virus particles. These immature virions mature and bud out of the 
cell to form infectious virions (adapted from Barre-Sinoussi et al., 2013).  
 
Since Env mediates viral entry into host cells, this critical role has made it 
an attractive target for vaccine design, aimed at eliciting a broadly 
neutralizing antibody (bNAb) response (Benjelloun et al., 2012). Therefore 
knowledge of the structure and functionality of Env is key to designing an 
immunogen capable of eliciting the appropriate immune response to provide 
sterilizing immunity to the host and this is expanded on in section 1.3 below. 
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1.2.3 Consequences of the viral replication cycle: 
1.2.3.1 Diversity and evolution 
The continual generation of new HIV-1 variants is a consequence of the 
highly error-prone RT enzyme resulting in an extensive genetic diversity of 
HIV-1 and recombination of the resulting quasispecies in an infected 
individual. This coupled with the extremely efficient replication cycle where 
approximately 109 virions can be generated in an infected individual daily, 
assists in the rapid evolution of the virus (Rambaut et al., 2004; Robertson 
et al., 1995; Santoro and Perno, 2013).  
 
The diversity of HIV is demonstrated by the vast number of groups and 
subtypes. HIV can be divided into two types: HIV-1 and HIV-2. HIV-1 is most 
closely related to the simian immunodeficiency virus (SIV) isolated from 
chimpanzees and each group (see below) is thought to have been 
transmitted during a single chimpanzee-to-human incident and diverged in 
humans into the diverse virus it is today (http://www.hiv.lanl.gov, 2012). HIV-
2 is closely related to SIV isolated from sooty mangabeys, suggesting it was 
transmitted from this host (Reeves and Doms, 2002). HIV-2 is largely 
confined to West Africa and is less easily transmitted from person to person 
(Reeves and Doms, 2002).  
 
HIV-1 is the predominant virus worldwide which undergoes rapid viral 
evolution and recombination during replication resulting in an extraordinary 
viral diversity, with HIV-1 being further classified into four groups, namely 
HIV-1 M (Main group), HIV-1 O (Outlier Group), HIV-1 N (Non M, Non O or 
New Group) (http://www.hiv.lanl.gov, 2012) and HIV-1 P (a group of HIV-1 
thought to have been transmitted by the gorilla host) (Plantier et al., 2009). 
Group M is the predominant circulating group worldwide and has been 
further classified into a number of phylogenetically associated subtypes or 
clades namely A1, A2, A3, A4, B, C, D, F1, F2, G, H, J and K. This continual 
diversification of HIV-1 results in mutational escape of the virus from the 
immune system as well as ARV drug treatment, and is therefore one of the 
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major obstacles for the development of an effective vaccine (Taylor et al., 
2008). To overcome this problem, researchers are currently focusing on the 
selection of subtype-specific immunogens that are specific to the 
geographical area where the vaccine is intended to be used. Vaccines will 
also need to be continually updated as viral epitopes evolve (Agwale et al., 
2011). The high genetic variability consequently has proven to be a major 
hurdle in vaccine development (Esparza, 2013). 
 
1.2.3.2 ARV drug escape 
ARV drug therapy using highly active antiretroviral therapy (HAART) in 
which a combination of drugs are used to act against several steps of the 
HIV life cycle, has not completely rid the virus from HIV-1 infected patients 
due to the ability of the virus to establish latent reservoirs, and continual 
evolution of the virus to escape pressure from both the ARV drugs and 
immune system (detailed below in Section 1.3) (Rambaut et al., 2004).  
 
Four classes of antiretrovirals have been developed based on their 
molecular mechanism against various steps in the HIV-1 life cycle namely 
RT inhibitors (nucleoside/tide-analog RT inhibitors (NNRTIs), non–
nucleoside RT inhibitors (NNRTIs)), IN inhibitors, PR inhibitors (PIs), and 
entry inhibitors (fusion inhibitors and coreceptor antagonists) (Arts and 
Hazuda, 2012).  
 
Despite several steps in the life cycle of HIV-1 being targeted at once using 
HAART, HIV-1 continues to evolve escape mutations. The rapid replication 
cycle of HIV-1 means that virus producing cells have a half-life of 
approximately two days (Murray et al., 2011; Zhou et al., 2005). This 
coupled with the high rate of mutation attributed to the error prone nature of 
RT means that HIV-1 variants resistant to antiretroviral agents can replace 
wild-type strains in plasma within 2 – 4 weeks. In addition, genetic 
recombination of two single drug resistant strains leading to multiple drug 
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resistant strains rapidly drives the evolution of drug resistance in HIV-1 
(Santoro and Perno, 2013).  
 
Thus the latent reservoirs which are established within the first couple of 
weeks post transmission, and the ongoing evolution of the virus has 
hindered efforts for the development of a sterilizing cure and rather a 
‘functional’ cure in which viral replication and remission of HIV-1 symptoms 
are controlled, is the current standard of care (Liu et al., 2015a; Rambaut et 
al., 2004). Research efforts focussing on eliminating the reservoir of HIV-1 
using techniques such as “shock and kill” therapy to reactivate dormant 
virus with gene and cell therapy strategies could provide a ‘sterilizing’ cure. 
This could negate the need for the life-long treatment with ARVs and 
subsequent development of ARV resistant strains (Leong et al., 2017; 
Schwartz et al., 2017). 
 
1.3 Natural disease progression to AIDS and immunological 
response to HIV infection 
As occurs in all viral infections, HIV infection first activates the innate 
immune system, which is followed by the development of the B and T cell 
responses of the adaptive immune system (Chang and Altfeld, 2010).  
 
The natural progression of HIV-1 in an average untreated individual is 
shown in Figure 1.4. In the first weeks after infection (acute phase) the virus 
replicates rapidly by targeting CD4+ T lymphocyte cells (CD4+ T cells) which 
results in a severe depletion of the CD4+ T cell population (Tomaras et al., 
2008). The likelihood of HIV-1 transmission from an HIV-1 infected 
individual to another person is highest during this stage of infection 
(Tomaras et al., 2008). During the acute phase, a latent reservoir is 
established and occurs within the first two to three weeks post infection 
(Chun et al., 1999). This occurs when HIV infects CD4+ T cells that are 
naturally reverting into a resting memory state (Eisele and Siliciano, 2012). 
Latency is established in these CD4+ T cells because they are less 
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permissive to HIV-1 gene expression, resulting in CD4+ T cells with 
integrated provirus rather than rapid death of the cell as is normally the case 
(Eisele and Siliciano, 2012). These resting CD4+ T cells have been found to 
contain persistent replication-competent HIV even in patients on 
suppressive HAART (Chun et al., 1997b). HIV reservoirs have been found 
in various tissues including the brain (Churchill and Nath, 2013; Pierson et 
al., 2000), male urogenital tract (Pierson et al., 2000) and in gut-associated 
lymphoid tissue (Chun et al., 2008).  
 
Anti HIV-1 CD8+ cytotoxic T lymphocyte (CTL) cells are produced and this 
response results in the rapid decline of plasma viral RNA to a viral set point, 
the near-recovery of CD4+ T cells and is the start of the 
chronic/asymptomatic phase of infection characterized by sustained 
immune activation and viral replication (Borrow et al., 1994; Koup et al., 
1994; Maartens et al., 2014; Moir et al., 2011). This initial control of the HIV 
viral load by anti HIV-specific CD8+ CTLs is short-lived as the virus quickly 
evolves escape mutations (Betts et al., 2006). Viral replication continues 
and HIV-specific CD8+ T cells continue to proliferate during the chronic 
phase of HIV infection. The highly error prone step in which RT transcribes 
the RNA to DNA continually results in a diverse quasispecies of the virus 
(Betts et al., 2006). Without treatment, the chronic stage of infection can last 
several years depending on the infected individual’s viral load set point and 
immune response. The onset of AIDS occurs when the CD4+ T cells are 
depleted to such low levels that they can no longer fight off opportunistic 
infections (Maartens et al., 2014; Okoye and Picker, 2013). Within two years 
of an AIDS diagnosis, and in the absence of HAART, the individual will die 
from opportunistic infections. 
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Figure 1.4: Natural progression of HIV-1 infection in an average untreated individual. The 
HIV viral load (red line) increases to high levels a few weeks after infection, and in a very 
short period establishes latently infected cells. The HIV RNA levels decrease as the host 
immune system responds to infection, then slowly increases again. The high mutation rate 
of HIV-1 results in a highly diverse quasispecies as HIV infection progresses. The CD4+ T 
cells (blue line) become depleted to a point where they can no longer fight opportunistic 
infections, signifying the onset of AIDS (adapted from Maartens et al., 2014).   
 
1.3.1 Innate immune response to HIV-1 infection 
Early after infection, the dendritic cells, natural killer cells and macrophages 
of the innate immune system respond with a “cytokine storm” inflammatory 
response to the virus (Stacey et al., 2009). 
 
The complement system is activated as one of the first-line defenders 
against HIV-1 by: a) binding of complement protein C3 present in human 
sera to the virus; b) binding of mannose binding lectin (MBL) present in 
human sera to carbohydrates on the surface of the virus; or c) binding of 
HIV-1 specific antibodies (Ab) to HIV-1 which is initiated by binding of the 
Ab’s Fc tail to the complement protein C1. Once the complement system 
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has been activated, C3-convertase cleaves and activates C3 into C3a and 
C3b which leads to a cascade of reactions resulting in inflammation, 
recruitment of phagocytic cells, the formation of the membrane attack 
complex (MAC) which forms lytic pores and ultimately lysis of the virus. In 
addition, the complement system links the innate and adaptive immune 
response by enhancing and regulating humoral immunity. HIV-1 escapes 
complement-mediated neutralization by utilizing the complement’s self-
regulation system by incorporating complement regulating membrane 
proteins in the membrane as it buds from the infected cell, which down 
regulate complement activation (reviewed in Ballegaard et al., 2014; Lund 
et al., 1995; and Yu et al., 2010). 
 
1.3.2 Adaptive immune response to HIV-1 infection 
1.3.2.1 CD8+ Cytotoxic T-lymphocyte response 
The adaptive immune system responds with a CD8+ CTL response as early 
as three weeks post infection in which CD8+ T-lymphocytes kill infected cells 
expressing viral antigens (Borrow et al., 1994; Koup et al., 1994; Streeck et 
al., 2009). This CTL response is co-ordinated by CD4+ T cells by priming 
the CD8+ T-cell responses, maintaining the CD8+ T-cell memory and 
maturing CD8+ T-cell function. HIV-1 attacks these CD4+ T-cells early in 
infection resulting in a drastic decline in their numbers thereby limiting this 
immune response (reviewed in McMichael and Rowland-Jones, 2001).  
 
1.3.2.2 CD4+ T cell response 
In addition to mediating the CD8+ CTL and B cell responses of the immune 
system, the CD4+ T cells produce a host of cytokines, specifically IFNγ, 
TNFα and IL-2 that stimulate macrophages, natural killer cells and the 
differentiation of T helper (Th1) cells that assist in fighting viral infection. 
However, HIV-1 infection disrupts the optimal balance of costimulatory 
signals required for optimal immune function. T cells have been found to 
express higher levels of inhibitory receptors designed to reduce harmful 
inflammatory responses, contributing to the loss of CD4+ T cell function 
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(Kassu et al., 2010; Ostrowski et al., 2006). The loss of immunological 
control is therefore a result of CD4 dysfunction and loss of CD4+ T cells. 
 
This loss of CD4+ T cells has been associated with the presence of bNAbs. 
It’s hypothesized that the loss of CD4+ T cells and resulting higher viremia 
contributes to bNAb development due to increased exposure to the virus 
(Doria-Rose et al., 2010; Euler et al., 2010; Sather et al., 2009). 
Interestingly, this correlation seems to be true only for adults, whereas in 
children antibody-mediated anti-HIV-1 neutralization correlates with a lower 
CD4+ T cell population (Agthe et al., 2014). 
 
1.3.2.3 Humoral immune response 
The humoral arm of the immune response is activated approximately one 
week after infection when the host’s virus-specific B-cells recognize an 
antigen of HIV-1 (Li et al., 2007). The initial response of the B cells is to the 
gp41 region of Env, and results in non-neutralizing antibodies (Tomaras et 
al., 2008). These Abs bind to linear epitopes of Env, but are unable to bind 
to an epitope on the correctly folded native functional Env trimer spike, 
resulting in the inability to neutralize the virus and have little control of 
viraemia (Tomaras et al., 2008). Having said this, non-neutralizing Abs do 
display some neutralizing properties to Env because the Env spikes decay 
over time, resulting in epitopes being revealed that these Abs can recognise 
(Burton and Mascola, 2015).  
 
A second Ab response approximately 14 days later results in the production 
of gp120 specific antibodies which have limited neutralizing breadth, and 
again, the virus acquires escape mutations. This second Ab response 
encompasses neutralizing antibodies that commonly target regions with 
high sequence variation such as the variable loop regions. However, these 
neutralizing Abs are strain specific and emerge early in infection before 
changes in the variable epitopes lead to Ab escape by the virus (Tomaras 
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et al., 2008). The B cell response is coordinated by the CD4+ T cells, and 
again, their decline directly impacts the Ab response (Oxenius et al., 1998). 
 
Some HIV-1 infected individuals develop bNAbs which can neutralize a 
broad range of HIV-1 strains and typically develop years after infection 
(Mikell et al., 2011) and these bNAbs evolve with the virus to target 
conserved regions of Env (Burton and Mascola, 2015; Li et al., 2007; Mikell 
et al., 2011).  
 
It has been determined that bNAbs mature from an unmutated common 
ancestor (UCA) B-cell receptor post binding to the transmitted founder virus 
early after infection. BNAb development occurs as a result of complex or 
prolonged maturation pathways, which is driven by Env evolution. 
Understanding the developmental pathways of these Abs has important 
implications for vaccine development since a successful immunogen or 
immunization protocol would likely need to reproduce such a maturation 
pathway. First, an Env immunogen would need to target UCAs to trigger the 
appropriate Ab lineage, and second, this would need to be followed by 
vaccination with Env immunogens that stimulate the somatic mutation 
pathways required for the development of breadth and potency against the 
virus (Doria-Rose et al., 2014; Liao et al., 2013b).  
 
BNAbs target several conserved sites on the highly diverse HIV-1 envelope 
spike. The glycoprotein gp120 consists of five variable regions (V1 – V5) 
interspersed with five conserved regions (C1 – C5) (Figure 1.5), and these 
regions are extensively glycosylated (Kwong et al., 1998).  
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Figure 1.5: Generalized schematic representation of the arrangement of HIV-1 gp120 
glycoproteins as a native trimer, viewed from the perspective of the target cell membrane. 
The areas shaded in dark green represent the variable loops as indicated (V1/V2, V4 and 
V5). The yellow loops represent the V3 region. The black arrows indicate CD4 binding 
pockets and the areas shaded in red represent the conserved chemokine-receptor-binding 
region (adapted from Wyatt et al. (1998b)). 
 
Further CD4 induced (CD4i) conserved regions are presented during the 
entry process when gp120 binds to CD4, resulting in conformational 
changes of gp120 that orients and exposes the co-receptor binding site 
(Kwong et al., 1998). During this process the V2 loop which partially 
occludes the V3 loop and CD4i epitope moves and this stabilizes the 
bridging sheet on which these epitopes are situated. The V3 region changes 
to expose altered V3 epitopes, which together with the CD4i epitope make 
up the co-receptor binding site (Kwong et al., 1998). This is followed by 
fusion between the viral and cellular membranes mediated by gp41 
(reviewed in Engelman and Cherepanov, 2012).  
 
1.4 Using bNAbs to identify vulnerable epitopes on Env  
Each of the epitopes targeted by bNAbs provides a conserved region that 
can block HIV-1 infection. BNAbs isolated from B cells of HIV-1 infected 
patients has facilitated the identification and analysis of vulnerable epitopes 
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on Env which in turn can aid the template-based design of vaccine 
immunogens, or reverse vaccinology (Corti et al., 2010). Some important 
bNAbs are discussed below. 
 
1.4.1 Antibodies targeting the variable V1/V2 region of gp120 
Despite the high diversity and heavy glycosylation of this region, a number 
of bNAbs have been isolated that are directed to this region including PG9, 
PG16, CH01-CH04, PGT141-145 and PGDM1400. These bNAbs 
preferentially bind to a quaternary epitope that spans V1/V2 on gp120 and 
they generally share dependence upon  the N-linked glycan at position 160 
in the V1/V2 region (McLellan et al., 2011; Sok et al., 2014b).   
 
1.4.2 Antibodies targeting the variable V3 loop and associated 
glycans 
BNAbs have been identified that target an epitope in the V3 loop in which 
the N-linked glycan at position 332 is directly involved. These bNAbs include 
PGT121-123, 125-126, 130 and 131 (Walker et al., 2011). PGT127 and 
PGT128 share a similar mode of epitope recognition in that they rely on two 
glycans for binding, one at position 332 and the other at 301, as well as the 
C-terminal end of the V3 loop binding epitope. The two glycans N332 and 
N301 have been found to be conserved in 93% and 73% of HIV isolates 
respectively, which explains the broad neutralization profiles of these 
antibodies (Pejchal et al., 2011). However, the neutralization potency of 
these bNAbs is not solely restricted to these two glycans, as described by 
Sok et al. (2014a). Their research described these bNAbs as “promiscuous” 
since many of them were still able to neutralize variants in which the glycan 
at N332 was shifted to N334, as well as variants in which the glycan was 
missing and suggests that these bNAbs have the ability to use other glycan 
sites in proximity (N136/N137 or N295) to the N332 glycan.  
 
An unusual bNAb 2G12, targets a host cell-derived glycan on the gp120 
outer domain and blocks membrane fusion as a consequence of steric 
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hindrance. 2G12 differs to the bNAbs described above because it’s binding 
to the conserved N-linked glycans is dependent on N332. In addition, it is 
less potent and broad in neutralization compared to the above bNAbs 
(Doores et al., 2010; Li et al., 2007; Murin et al., 2014).  
 
1.4.3 Antibodies targeting the CD4 binding site 
The CD4bs is a functionally conserved site on gp120 and antibodies that 
target this region are often induced in an HIV-1 infected person within the 
first four to 16 weeks post infection. However, it takes years to develop 
potent antibodies with the affinity or serum concentration required for 
neutralization of the virus (Lynch et al., 2012; Mascola and Haynes, 2013). 
The CD4bs is recessed in a depression of gp120 hidden by glycosylation 
and variable loops and binding of gp120 with CD4 relies on electrostatic 
potential at the contact surfaces between the two molecules (Kwong et al., 
1998).  
 
The bNAb IgG1b12, originally generated from the lymphocyte of an 
asymptomatic person who had been HIV-positive for 6 years, has a 
protruding finger-like third complementarity determining region of the heavy 
chain variable regions (CDRH3) that is able to penetrate the CD4bs on Env 
(Burton et al., 1991; Saphire et al., 2001). IgG1b12 recognizes a 
discontinuous epitope that overlaps the CD4 binding region and has been 
reported to neutralize 30 – 40 % of primary isolates of subtype B and C 
viruses by inhibiting its entry into the cell (Burton et al., 1994; Georgiev et 
al., 2013). However IgG1b12 is far less potent than the more recently 
isolated bNAbs that target the CD4bs as discussed below (Bures et al., 
2002; McInerney et al., 1997; Zwick et al., 2003).  
 
The somatically related bNAbs VRC01, VRC02 and VRC03 were isolated 
from a subtype B HIV-1 infected individual classified as a long term non-
progressor (LTNP) since this patient had been infected with the virus for 
more than 15 years and still maintained a CD4+ T-cell count of over 500 
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cells/µl plasma despite being treatment naïve (Wu et al., 2010). The crystal 
structure of VRC01 in complex with gp120 has shown that VRC01 partially 
mimics the interaction of CD4 with gp120 by targeting a highly conserved 
region of the CD4bs on gp120 and enables it to achieve potent 
neutralization of over 90 % of circulating HIV-1 isolates. The neutralization 
of VRC03, a somatic variant of VRC01, is less broad than that of VRC01. 
VRC03 is able to neutralize 50 % of circulating HIV-1 isolates (Wu et al., 
2010; Wu et al., 2011). This group of antibodies is able to access a highly 
conserved region of the CD4bs without the Env conformational change that 
occurs after gp120 binding, giving them a unique property distinct from other 
CD4bs antibodies (Georgiev et al., 2013; Li et al., 2011; Zhou et al., 2010).  
 
HJ16 was isolated from an individual who had been infected for 12 years, 
had a CD4+ T-cell count of 274 cells/µl and was on HAART (Corti et al., 
2010). HJ16 is a glycan-dependant CD4bs specific antibody that binds to 
an epitope that partially overlaps the IgGb12 epitope and is dependent on 
the interaction with the glycan at position 276 (Balla-Jhagjhoorsingh et al., 
2013).  
 
The somatically related bNAbs VRC-CH30, VRC-CH31, VRC-CH32, VRC-
CH33 and VRC-CH34 were isolated from an individual chronically infected 
with subtype A of HIV-1 (Wu et al., 2011). These antibodies have been 
classed as VRC01-like antibodies since they bind to the same CD4bs 
epitope as VRC01. VRC-CH31 is able to neutralize 75% – 95% of HIV-1 
viruses of multiple subtypes (Bonsignori et al., 2012; Wu et al., 2011).  
 
NIH45-46G54W is a CD4 directed bNAb originally isolated from the same 
patient as VRC01. A single amino acid substitution of glycine to tryptophan 
in the second heavy chain complementarity-determining region (CDRH2) of 
this antibody increased the breadth and potency of this antibody by 
increasing the surface contact with the gp120 bridging sheet (Diskin et al., 
2011). 
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The CD4bs bNAb 3BNC117 was isolated from a patient classified as an 
elite controller. It has been shown to prevent and control HIV-1 infection in 
animal models and is currently showing promise as treatment in early phase 
clinical trials in humans (Scheid et al., 2016; Schoofs et al., 2016). 
 
1.4.4 Antibodies targeting the gp41 membrane proximal membrane 
(MPER) region 
The initial B-cell response is to the gp41 region of Env and is mostly non-
neutralizing but it is thought that the function of these early Abs is to activate 
the complement system (Tomaras et al., 2008). BNAbs that target this 
region have been isolated though, such as 2F5 which has been found to 
neutralize HIV-1 subtype B but not those of subtype C, 4E10 which is 
directed against the C terminus of the gp41 ectodomain (Binley et al., 2004) 
and 10E8 which binds to highly conserved residues within MPER and is 
distinct from the other gp41 bNAbs in that it does not bind lipids and is not 
autoreactive (Huang et al., 2014). The gp41 region has been found to be 
poorly immunogenic and therefore research efforts shifted their focus to the 
other conserved regions of Env (Binley et al., 2008; Corti et al., 2010). 
However, recent findings suggest the gp41 region may be more 
immunogenic than previously thought. Falkowska et al. (2014) isolated the 
bNAbs PGT151-152, which specifically recognise a glycan-dependent 
epitope on gp41 of a cleaved Env trimer. In addition, Williams et al. (2017) 
reported the isolation of a DH511 bNAb lineage directed to the distal portion 
of the gp41 region. 
 
1.5 Challenges of HIV-1 vaccine development 
The development of a preventative HIV-1 vaccine has proven challenging. 
Challenges include extensive viral diversity, establishment of latent viral 
reservoirs early after infection, multiple strategies for evading immune 
responses, the immune correlates of protection are unclear, there is no 
small animal model that can be used to study the virus and to date the 
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immunogens tested have not successfully elicited broadly reactive 
neutralizing antibodies (bNAbs) (Barouch, 2008; Chun et al., 1997a).  
 
In addition, HIV-1 harbours a number of structural immune evasion 
strategies including low density surface expression of Env, antigenic 
variability, glycan shielding, transient epitope exposure, conformational 
masking, steric occlusion and the expression of non-functional Env (Figure 
1.6).  
 
The exposed surfaces of Env are expressed at low densities on the virus 
surface and are heavily glycosylated with an enormous diversity of N-linked 
oligosaccharides which shield it from neutralizing antibodies (NAbs). 
Accessibility of conserved epitopes is available only transiently prior to co-
receptor binding and membrane fusion, allowing HIV-1 to escape host 
immune humoral responses. In addition, antibodies are prevented from 
binding to these conserved epitopes due to steric restriction during gp120 
receptor binding and membrane fusion (Burton et al., 2012; Douek et al., 
2006; Mizuochi et al., 1988; Mouquet, 2014; Zanetti et al., 2006).   
 
After co-receptor binding, gp120 is shed into the peripheral blood, and 
serves as an immune decoy. Non-functional Env such as non-cleaved 
precursors or decaying gp120 monomers are expressed on the virus 
surface which results in the generation of non-neutralizing antibodies 
(Burton et al., 2012; Douek et al., 2006; Mizuochi et al., 1988; Mouquet, 
2014; Zanetti et al., 2006).  
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Figure 1.6: Structural immune evasion strategies of HIV-1. Low density expression of Env 
on the virus surface; heavy glycan shielding of conserved epitopes; non-functional Env 
including non-cleaved precursors or decaying gp120 monomers on the virus surface; 
conformational changes during CD4 binding resulting in conformational masking of 
conserved epitopes; brief epitope exposure during CD4 binding; steric restriction of binding 
by antibodies to conserved epitopes during gp120 receptor binding and membrane fusion 
(adapted from Mouquet, 2014).  
 
One of the major challenges in HIV-1 vaccine design is the lack of an animal 
model for the development and preclinical testing of effective vaccines. This 
is because HIV-1 is highly specific to humans and traditional animal models 
fail to provide a suitable environment for HIV-1 replication because they lack 
the cellular proteins that support it (Hatziioannou and Evans, 2012). Animal 
models have been developed to study HIV-1 infection such as  the 
humanised mouse, in which genetically immunocompromised mice 
engrafted with human tissues have enabled the study of HIV-1 infection as 
well as virus-specific humoral and cellular immune responses (Brainard et 
al., 2009). However, humanised mice have a non-functional immune system 
requiring them to live in an artificially sterile environment with specialised 
housing and handling procedures, and since only parts of the human 
immune system can be generated in these mice, the effects of HIV-1 
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infection are limited. An important limitation of the humanized mouse model 
is its size limitation for the study of latent reservoirs of HIV-1. Large amounts 
of cells are required for this which necessitates the use of a large number 
of animals (Policicchio et al., 2016). In addition, humanised mice cannot be 
bred, requiring them to be generated de novo for each experiment, which is 
costly (Hatziioannou and Evans, 2012).  
 
Overall, non-human primates (NHP) are the closest animal model to 
humans. HIV-1 does not replicate in NHP’s and if it does, such as in some 
chimpanzees, it is non-pathogenic (Ambrose et al., 2007). By using the NHP 
equivalent of HIV in macaques, namely SIV, and modifying SIV to represent 
the challenges of HIV, a useful tool in HIV research has been developed 
(Hatziioannou and Evans, 2012). However, HIV and SIV are still different 
viruses, and although some of the immune responses to infection have been 
elucidated in NHP models, the biological properties of SIV and HIV and 
those of their respective hosts differ, often making the results incomparable 
to human HIV-1 biology. The recent work by Li et al. (2016) however, 
reported that substituting residue 375 of the chimeric SIV-HIV’s with that of 
the naturally occurring SIV, enhanced binding to rhesus macaque CD4. This 
allows for improved viral entry and replication of SHIV in the rhesus 
macaque model, and ultimately may provide an improved animal model for 
HIV pathogenesis and vaccine research (Hatziioannou and Evans, 2012). 
 
While the NHP and humanized mouse models present challenges for 
studying the complete pathogenesis of HIV-1, combinations thereof provide 
important insights into the study of specific aspects of the viral life cycle, and 
critically the development and evaluation of prophylactic vaccines, cure 
strategies and novel ARVs.   
 
The lack of a suitable animal model has further hindered the elucidation of 
the immune correlates of protection against HIV. In order to design an 
effective immunogen, the correlates of protection need to be elucidated, 
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therefore the only approach available is to test promising vaccine 
candidates that have undergone preclinical trials in animal models, in 
human efficacy trials (Esparza, 2015). 
 
1.6 HIV-1 vaccine efficacy trials 
Historically vaccines have proven to be the most cost effective way to save 
lives against disease with very little knowledge of the immunological 
mechanisms they involve to induce protective immunity (Pulendran and 
Ahmed, 2011). Unlike other viruses such as smallpox, natural infection with 
HIV-1 does not result in sterilizing immunity, therefore understanding the 
immunological factors required to control HIV-1 infection have proven 
difficult.  
 
HIV-1 vaccines can be been grouped into three groups: (1) vaccines that 
induce NAbs to confer protection against viral entry using Env based 
immunogens; (2) vaccines that induce CD8+ T-cell responses using live 
recombinant viral vectors and DNA vaccines; (3) vaccines that induce 
multiple immune responses using prime-boost combinations (Esparza, 
2015).  
 
The development of a vaccine undergoes three phases of clinical trials. In 
the first phase, the vaccine is given to a small group of healthy individuals 
for safety assessment. The second phase can be performed in two stages 
where the vaccine is given to a large group of approximately 100 individuals 
from the vaccine target population to assess safety, dosage and 
immunogenicity (Phase 2a) as well as proof-of-concept (Phase 2b). In the 
third phase, the vaccine is administered to thousands of individuals of the 
vaccine target population to test the safety and efficacy of the vaccine (CDC, 
2016). 
 
To date, 284 HIV-1 vaccine candidates have been tested in Phase I clinical 
trials worldwide. Of those, 59 have advanced to Phase 2 trials but only six 
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Phase 2b or Phase 3 clinical efficacy trials have been completed namely 
VAX 003, VAX 004, Step, HVTN (HIV Vaccine trials network) 503 
(Phambali), RV144 and HVTN 505 (Buchbinder et al., 2008; Flynn et al., 
2005; Gray et al., 2011; Hammer et al., 2013; IAVI, 2017; Pitisuttithum et 
al., 2006; Vanichseni et al., 2004). The VAX 003 and VAX004 trials used a 
recombinant expressed gp120 subunit vaccine containing a bivalent 
preparation from subtypes B and E (VAX003) and two gp120s from subtype 
B (VAX004). These trials aimed to induce an HIV-1 Env-specific antibody 
response in trial participants, however they were found to be ineffective 
(Excler and Michael, 2016; Sheets et al., 2016; Shin, 2016). 
 
The HVTN 502 (STEP) and HVTN 503 (Phambili) trials aimed to induce 
HIV-1 specific CD8+ CTL cell responses in trial participants by using a 
trivalent replication-incompetent Merck Adenovirus type 5-vectored vaccine 
(Ad5) vector expressing the gag, pol and nef genes derived from HIV-1 
subtype B. These trials showed no vaccine efficacy and in addition, had to 
be terminated early due to safety concerns as the trial participants showed 
an increased trend towards infectiousness to HIV-1 (Excler and Michael, 
2016; Sheets et al., 2016; Shin, 2016). 
 
The RV144 and HVTN505 trials focussed on using a prime-boost approach 
to elicit both arms of the immune response, the HIV-1 antibody response as 
well as a specific T-cell response. In the RV144 trial, the vaccine consisted 
of a canarypox vector prime expressing the HIV-1 subtype B gag and 
protease genes followed by a boost with a recombinant gp120 subunit 
vaccine derived from subtypes B and E. This approach conferred a modest 
31.2 % (95% CI, 1.1 to 52.1; P=0.04) efficacy with post-hoc analyses 
indicating a vaccine efficacy of 60 % one year after initial vaccination (95 % 
CI 22-80 %) which declined quickly. To date this is the only HIV-1 vaccine 
trial showing a degree of efficacy (Excler and Michael, 2016; Robb et al., 
2012; Sheets et al., 2016; Shin, 2016). Analysis of the Ab responses to this 
vaccine revealed they were mainly directed against a conserved region of 
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the V1/V2 loop of Env and were correlated inversely with HIV-1 risk of 
infection whereas plasma IgA Abs directed to Env correlated directly with 
HIV-1 infection, possibly mitigating the effect of the protective Abs. The lack 
of NAbs turned the field’s attention to the possible protective role of non-
neutralizing Abs in antibody-dependent cell-mediated cytotoxicity (ADCC) 
in protective immunity to HIV-1 (Esparza, 2013; Haynes et al., 2012; 
Karasavvas et al., 2012; Wren and Kent, 2011). 
 
The HVTN 505 trial tested a DNA vaccine prime consisting of six DNA 
plasmids expressing HIV-1 subtype B gag, pol, nef and env genes as well 
as two Env proteins from subtype A and C followed by a boost using Ad5-
vectors expressing Env from subtypes A, B and C as well as a Gag-Pol 
fusion derived from subtype B. This study too was halted due to safety 
concerns and this trial showed no efficacy (Excler and Michael, 2016; 
Sheets et al., 2016; Shin, 2016).  
 
The HVTN 702 Phase 2b/3 efficacy trial is currently ongoing in southern 
Africa (AVAC: AIDS Vaccine Advocacy Coalition; Global Advocacy for HIV 
Prevention, 2016). The trial aims to confirm and extend the RV144 trial’s 
partial protection, and will test a recombinant canarypox vector prime 
(ALVAC-HIV vCP2438) expressing a subtype C HIV-1 Env linked to subtype 
B gp41, and subtype B gag and protease genes. The boost immunogen is 
a bivalent gp120 subunit vaccine, both gp120’s derived from subtype C 
isolates (Andersen-Nissen, 2015; Zolla-Pazner et al., 2016). 
 
The result from the efficacy studies have not led to an HIV vaccine but 
lessons learnt from the trials are valuable in driving the design of future 
vaccines (Sheets et al., 2016). 
 
1.7 Structure-based reverse vaccinology 
It has been found that approximately 15–30 % of HIV-1 infected humans 
develop bNAbs against the virus, and some of these bNAbs are able to 
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neutralize 80-90% of circulating HIV-1 viruses (Moore et al., 2015). As 
discussed above, these bNAbs are important in defining conserved epitopes 
on Env and which can be used for the structure-based reverse vaccinology 
to develop HIV-1 vaccines (Van Regenmortel, 2016).  
 
In structure-based reverse vaccinology, the crystal structure of Env in 
complex with a bNAb is used to identify the epitope recognized by that 
bNAb, and this epitope is reconstructed as an immunogen with the hope 
that it will elicit a bNAb response with the same neutralizing capacity as the 
bNAb originally isolated (Van Regenmortel, 2016). The ability of these 
designed immunogens to elicit an immune response in animal models is 
tested, leading to the development of a vaccine antigen (Burton, 2010). 
Understanding the structural and biological information with regards to 
bNAb interactions with gp120 can be used in this way to design 
immunogens (Nabel et al., 2011).  
 
If the bNAbs that develop in patients’ years after infection could be induced 
prior to infection, they may be able to prevent the establishment of latent 
infections and provide protective immunity. Studies of the passive 
administration of NAbs in NHP’s have provided proof-of-concept that NAbs 
directed to Env can protect against HIV-1 infection (Halper-Stromberg and 
Nussenzweig, 2016; Hessell et al., 2009a; Hessell et al., 2009b; Hessell et 
al., 2010; Mascola et al., 2000; Shibata et al., 1999; Tomaras et al., 2008). 
 
1.8 Env-based immunogens for vaccine design 
As discussed above, the high host cell specificity of HIV-1 is as a result of 
Env which mediates viral entry by binding to the host’s CD4 receptor. The 
conserved regions of Env provide important target sites that are vulnerable 
to neutralization by bNAbs (Halper-Stromberg and Nussenzweig, 2016; 
Tomaras et al., 2008).  
 
1-29 
 
Of particular interest is the CD4bs since binding to CD4 is vital for viral entry. 
The contact residues on CD4 that have been found to be crucial for gp120 
binding are phenylalanine-43 (Phe43) on the opening of the deep cavity and 
arginine-59 (Arg59) which forms a salt bridge with amino acid residue 
aspartic acid-368 (Asp368) on gp120. Other important contact residues on 
gp120 that bind to CD4 are tryptophan (Trp112), valine (Val255), threonine-
257 (Thr257), glutamic acid (Glu370) and isoleucine (Ile371) (Kwong et al., 
1998; Wyatt and Sodroski, 1998). The conformational change resulting from 
gp120-CD4 binding triggers high-affinity binding to CD4 and the structural 
rearrangement required to expose the co-receptor binding surface and at 
the same time exposes glycan-free conserved regions on the viral spike 
(Mascola and Haynes, 2013).  
 
The lability of the Env trimer, a result of the noncovalent bond between 
gp120 and gp41, has made it extremely difficult to present a functional Env 
immunogen to the immune system. It is thought that interdomain flexibility 
disrupts the CD4bs epitopes. In addition, the variable loops and 
glycosylation of Env mask the CD4bs. Overall, protection from HIV-1 
infection by Abs elicited against Env are limited (Wyatt and Sodroski, 1998). 
 
The immunogenic requirements for bNAb development are poorly 
understood since it is thought that during natural infection bNAbs only 
develop in the chronic stage of infection, a result of years of co-evolution 
between the virus and maturing bNAb lineages (Doria-Rose et al., 2014; 
Liao et al., 2013b). Somatic hypermutation that leads to the development of 
bNAb’s appears to be driven by the co-evolution of antibody and virus as 
described by Doria-Rose et al. (2014) who carried out a longitudinal study 
of NAbs that developed in a CAPRISA-donor (CAP256) that was super-
infected at week 15. The unmutated ancestor of the V1V2-directed NAbs 
developed between 30-38 weeks post infection shortly after virus 
diversification of the super infecting virus. Further improvement of 
neutralization breadth occurred at 59 weeks post infection, again after virus 
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diversification. This relatively rapid maturation of V1V2 directed NAbs 
demonstrates that the initial engagement of an appropriate B-cell receptor 
with the relevant attributes (in this case protruding CDR H3s) along with 
limited somatic hypermutation can result in an Ab with the breadth and 
potency required to neutralize the virus. This implies that the development 
of an antigen capable of engaging the appropriate naïve B-cell receptor in 
combination with sequential immunogens to drive affinity maturation of the 
Ab are required for an effective vaccine (Doria-Rose et al., 2014). 
 
As mentioned previously, the HIV-1 Env glycoprotein (gp120 and gp41) is 
the only viral protein to protrude through the host-derived surface of the 
virion. It is essential for viral entry and is the target of bNAbs, therefore it 
has been the subject of intensive immunogen design for an HIV-1 vaccine 
(Burton et al., 2012; Nabel et al., 2011).  
 
The HIV vaccine field has attempted numerous approaches to develop 
immunogens by stabilizing Env in a native conformation while at the same 
time exposing conserved regions to the humoral arm of the immune 
response in the hope of eliciting bNAbs. Although great advances have 
been made over time in this area, the neutralizing responses elicited in small 
animals, NHP or humans have been autologous in nature, showing only 
strain specific neutralization activity (Sanders et al., 2015). 
 
Initial studies using gp120 as an immunogen were disappointing because 
they resulted in antibodies being elicited to linear epitopes of gp120 and not 
against the tertiary or quaternary epitopes on the correctly folded monomer 
when they are part of the native trimer (Schultz and Bradac, 2001; VanCott 
et al., 1995a). Attempts to modify gp120 to enhance stability and present 
only important epitopes to the immune system have had limited success 
and include fusing gp120 to a hepatitis B surface carrier protein (Berkower 
et al., 2004), designing peptides that bind to important epitopes on gp120 
(Mester et al., 2009), engineering gp120 molecules with extra N-linked 
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glycans to mask decoy epitopes and minimize the conformational flexibility 
of gp120 (Pantophlet et al., 2003), removal of glycans such as the CD4bs 
proximal N197 glycan from a stabilised trimer to expose conserved epitopes 
and increase binding to CD4bs antibodies, and removal of variable loops 
V1 and V2 to expose the CD4bs epitope (Cao et al., 1997; Liang et al., 
2016).  
 
Slightly improved neutralizing antibody responses directed to various 
epitopes on gp120 and gp41 have been obtained by using soluble gp140 
trimers. These are generated by excluding the hydrophobic membrane-
spanning domain of gp160. However Env is extremely labile and removing 
the transmembrane region results in the disintegration of the gp120 and 
gp41 subunits (Earl et al., 1994; Sanders et al., 2015). 
 
Over time, this has led to various approaches to stabilise gp140 to mimic 
the native Env trimer and includes mutations to eliminate the cleavage site 
between gp120 and gp41, covalent cross-linking of the gp160 subunits by 
introducing cysteines to form a disulphide bond and/or the addition of a 
trimer-stabilizing motif to extend the N-terminus or C-terminus of gp41 
(Sanders et al., 2013; Yang et al., 2000). Env has been stabilized in a 
trimeric conformation by introducing several trimerization motifs such as the 
GCN4 leucine zipper peptide derived from a yeast transcriptional activator 
(Harbury et al., 1993); h-CMP, derived from the C-terminus of human 
cartilage matrix protein (Saha et al., 2012); a trimerization domain derived 
from the C-terminus of bacteriophage T4 fibritin (T4F) (Yang et al., 2002); 
the catalytic chain of aspartate transcarbomoylase (ATC) (Chen et al., 
2004); and a trimerization domain derived from chicken cartilage matrix 
(CART) (Selvarajah et al., 2008).  
 
Of particular interest are coiled coil proteins such as GCN4 and h-CMP. The 
GCN4 motif has a characteristic seven-residue repeat containing 
hydrophobic residues at the first and fourth positions of each repeat with the 
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remainder residues being polar. Buried residues in the GCN4 leucine zipper 
direct dimer formation and manipulation of the heptad repeat residues can 
direct the conformation of the protein as monomer, dimer or trimer (Harbury 
et al., 1993; O'Shea et al., 1989). When trimers stabilized with trimerization 
motifs have been used as vaccine immunogens, they have shown marginal 
improvement in bNAb breadth over monomeric gp120 (Du et al., 2009).  
 
The h-CMP trimerization motif contains three subunits linked by disulphide 
bonds and forms a homotrimer. The C-terminal domain of CMP serves as 
the trimerization site, and two cysteine residues preceding the C-terminal 
domain stabilize the complex (Beck et al., 1996; Jenkins et al., 1990). This 
trimerization motif has been used to trimerize monomeric cyclic permutants 
which bound bNAbs IgG1b12, PG9, PG16 and PGT145 with slightly higher 
affinities compared to monomeric gp120 (Saha et al., 2012) 
 
Proteolytic cleavage of gp160 into gp120 and gp41 has since been shown 
to be essential for the native conformation of gp140 (gp120 with the gp41 
ectodomain) and the elicitation of bNAbs (Ringe et al., 2013; Yasmeen et 
al., 2014). A properly folded and proteolytically cleaved trimer denoted the 
SOSIP trimer has been generated by introducing an intermolecular disulfide 
bond (SOS) between gp120 and the gp41 ectodomain as well as an amino 
acid substitution from isoleucine to proline at residue 559 (IP) on the N-
terminal heptad repeat region of gp41 to strengthen the interactions 
between the gp41 subunits. These modifications have resulted in 
consistently tri-lobed propeller-shaped trimers. Unfortunately the Abs 
elicited using this immunogen lack the breadth of activity required for 
neutralization of heterologous primary isolates of the virus (Beddows et al., 
2007; Sanders et al., 2013; Sanders et al., 2015; Sanders et al., 2002). 
 
Another approach to elicit bNAbs has been to cross-link gp120 or gp140 
with CD4 to stabilize Env in a conformation that exposes the conserved 
CD4i epitopes to the immune system and this method has been shown to 
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elicit polyclonal antibody responses in animal models (Devico et al., 1996; 
Fouts et al., 2002). It has been found that although immunization using this 
approach in guinea pigs resulted in neutralizing activity, subsequent 
analysis revealed the response was directed to CD4 and not an epitope on 
Env (Varadarajan et al., 2005). Rhesus macaques primed with HIVBaL gp120 
linked to rhesus macaque 2dCD4, followed by boosts with rhFLSC protein 
elicited neutralizing antibodies, however protection following rectal 
challenge with SHIVSf162P4 was not attained (Thomas et al., 2014).  
Recently, our laboratory published findings of Env/2dCD4 liganded 
complexes, in which a soluble CD4 protein containing the first two domains 
of CD4 (2dCD4S60C, serine at position 60 is substituted with cysteine) was 
used to generate the complexes (Killick et al., 2015). The S60C mutation 
allows for the Env/2dCD4S60C complex to be stabilized through an inter-
molecular disulphide formation, and has previously been shown in our 
laboratory to have a higher binding affinity to gp120 than wild-type 2dCD4 
(Cerutti et al., 2010).  Although preliminary results indicate that the 
Env/2dCD4 induced response is directed to CD4, ongoing work is currently 
attempting to map the epitopes responsible for the neutralization of the 
virus. The use of recombinant soluble CD4 to bind to cell-free virus has been 
tested in clinical trials as an inhibitor of HIV-1 and shown to be safe. 
Research groups are still trying various modifications of CD4 to improve its 
efficacy (Chen et al., 2014; Kahn et al., 1990; Schacker et al., 1995). 
 
The stabilization of gp120 and exposure of CD4i epitopes has also been 
performed by generating cyclic permutants of gp120 by covalently linking 
the N- and C-termini of gp120 with an amino acid linker and introducing new 
termini into one of the variable loops by complete or partial deletion of that 
loop. In addition, a trimerization motif added to the new N-termini results in 
a native-like trimer that presents loop-derived neutralization epitopes (Saha 
et al., 2012).  
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An alternative approach to stabilizing gp120 in a native trimer conformation 
while exposing the CD4bs, is to introduce a mutation to destabilize the post 
fusion conformation of gp41. This prevents the post fusion six-helix bundle 
formation after the co-receptor has been engaged by gp120, effectively 
halting Env in a stable CD4bs exposed conformation (Kesavardhana and 
Varadarajan, 2014). 
 
Additionally, techniques to design a peptide that mimics a pre-determined 
epitope recognized by bNAbs on Env has been described. The target 
epitope is grafted onto a scaffold protein to replicate the antigenic surface 
recognized by the bNAb of interest. This type of antigen is designed in silico 
by searching the Protein Data Bank for a suitable peptide with backbone 
similarity to segments of the Env-antibody epitope. The scaffold peptide 
selected is then modified to enhance epitope exposure but at the same time 
minimize non-epitope interactions with the antibody. The antibody binding 
epitope on Env is then transplanted into the acceptor scaffold resulting in a 
mimicry of the target epitope in its recognized conformation (Burton, 2010; 
Ofek et al., 2010; Zhou et al., 2014). 
 
A further strategy is to use plasmid DNA encoding fully cleaved trimers as 
an antigen. The plasmid DNA contains the gene of interest as well as 
promoter/enhancer and transcript polyadenylation/termination sequences 
to allow expression of the gene in mammalian cells. NHP’s vaccinated with 
plasmid DNA can elicit both the cellular and humoral arms of the immune 
system. Such DNA vaccines are usually boosted with an antigenic protein 
similar to the protein produced after expression from the DNA plasmid 
(Chakrabarti et al., 2013; Shiver et al., 1996). 
 
1.9 Designing immunogens to elicit the desired immune response  
The results from the HIV-1 vaccine trials, especially the RV144 trial, suggest 
that eliciting both arms of the adaptive immune response, one in which Abs 
are generated to inactivate the virus thereby aborting productive infection in 
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the host cell and the other in which HIV-1 specific CD8+ T cell responses 
are elicited to control breakthrough infections, is the best approach (Picker 
et al., 2012).  
 
1.9.1 How can you elicit bNAbs?  
The ideal HIV-1 vaccine should be able to induce bNAbs that can neutralize 
a diverse range of HIV-1 subtypes (Moore et al., 2015) to prevent viral entry 
into cells as well as stop replication once cells have been infected.  
 
The elicitation of a NAb response requires that: an immunogen binds to the 
appropriate naïve B-cell receptor to induce antibodies; autoreactive B cells 
are deleted by clonal deletion; and the immunization process drives affinity 
maturation in which somatic mutations result in high-affinity antibodies 
specific to its cognate antigen (Kwong et al., 2011). In the case of anti-HIV 
bNAbs, they are highly somatically mutated and the mutations typically 
occur in the complementarity determining region (CDR) loops and take 
years to develop (Klein et al., 2013).  
 
By using the structure-based design of immunogens, specific epitopes can 
be presented to the immune system. However, this does not guide the 
affinity maturation process. A way to overcome this is could be to prime the 
immune response with a restricted epitope to stimulate the correct naïve B 
cell receptor (BCR) followed by boosts using the native form of Env (gp120 
or gp140) to drive the affinity maturation process (Mascola and Haynes, 
2013).  
 
1.9.2 The bNAb problem  
The anti-HIV-1 bNAbs isolated to date have all been found to target specific 
regions of Env (Halper-Stromberg and Nussenzweig, 2016; Tomaras et al., 
2008). However native Env has proven to be poorly immunogenic mainly 
due to its conformational flexibility and its vast genetic diversity as well as 
the fact that extensive somatic hypermutations that evolve over time are 
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required (Kwong et al., 1998; Liao et al., 2013b; Rambaut et al., 2004; 
Robertson et al., 1995; Santoro and Perno, 2013; Wyatt and Sodroski, 
1998). 
 
The structural improvements discussed in section 1.7 attempt to overcome 
the flexibility by stabilizing Env, subunits of Env or important epitopes of Env 
that will focus the immune response and assist in affinity maturation of the 
humoral immune response. In addition, by focussing the immune response 
to conserved regions of Env, it is hoped to overcome the genetic diversity 
of Env at least within one subtype. The ability of various Env-based 
immunogens to elicit bNAbs in a small animal model is thus the focus of this 
thesis. 
 
1.10 Justification 
People infected with HIV in India and South Africa are predominantly 
infected with HIV-1 subtype C. Currently, approximately 7 million (6.7-7.4 
million) and 2.1 million (1.7-2.6 million) people are HIV-1 infected in South 
Africa and India, respectively. In addition, South Africa and India had a 
combined new infection rate of approximately 466 000 in 2015, accounting 
for 1300 new HIV-1 subtype C infections daily (UNAIDS, 2017). Overall, 
South Africa and India account for 25% of the global burden of HIV-1 
infection, thus targeting HIV-1 subtype C to prevent new infections would 
have a significant global impact on the disease. In this case, a vaccine that 
could target all HIV-1 subtype C infections would be required. A smaller 
proportion of HIV-infected individuals are infected with subtype B 
(approximately 11 %). However this subtype has a greater geographic 
distribution than subtype C (Hemelaar, 2012), and is the most widely 
studied. Our collaborators focused their research efforts on providing proof-
of-concept of Env-based immunogens based on the subtype B isolate JRFL. 
We therefore included immunogenicity testing of these subtype B stabilized 
Env derivatives, as comparators in our study. 
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The use of antibody pools or plasma samples in resistance studies has 
found greater neutralization when assayed against a matched subtype-
specific virus isolate compared to a non-matched isolate (Brown et al., 2008; 
Jacob et al., 2012; Seaman et al., 2010). This warrants the development of 
a subtype-specific vaccine. 
 
In addition, our laboratory has recently shown potent and bNAb responses 
in rabbits immunized with an Env immunogen stabilized by the first 2 
domains of CD4 (2dCD4) (Killick et al., 2015). This has raised an interest in 
utilizing the CD4 and CD4i epitopes as a target for the development of 
bNAbs. Further understanding of the antigenicity and immunogenicity of 
immunogens exposing this region may elucidate the biochemistry of a 
vulnerable site conserved amongst all HIV-1 subtype C Env that could be a 
target for a geographically specific vaccine. 
 
Thus, the overall aim of this study was to evaluate and compare the 
antigenicity and immunogenicity of South African and Indian 
gp120/gp140GCN4(+) Env variants  (unliganded and liganded with 2dCD4) 
and to compare their immunogenicity to gp120/gp140 Env derivative 
immunogens (proteins, peptides and DNA constructs).  
 
The specific objectives of this study were: 
a) To express, purify and biochemically characterize recombinant 
subtype C gp120/gp140GCN4(+) Env variants (2dCD4-liganded and 
2dCD4-unliganded) of Indian and South African origin. 
b) To select one representative from each region and evaluate the 
immunogenicity of a recombinant gp120/p140GCN4(+) Env variant 
(2dCD4-liganded and 2dCD4-unliganded) in rabbits, and determine 
the breadth and titres of NAb’s elicited.  
c) To evaluate the immunogenicity of structurally improved subtype B 
Env based immunogens using gp120/gp140 Env derivative 
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immunogens (proteins, peptides and DNA constructs) and determine 
the breadth and titres of NAbs elicited in rabbits. 
d) To compare the immunogenicity of the vaccine immunogens tested 
in b and c.  
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Chapter 2 : Materials & Methods 
2.1 Env selection and generation of recombinant gp120 and gp140 
constructs 
2.1.2 Selection of env and generation of recombinant gp120 and 
gp140 constructs  
Full length HIV-1 env oligonucleotide sequences from patients infected with 
HIV-1 subtype C transmitted/founder viruses, originating from India 
(Kulkarni et al., 2009) and South Africa (Abrahams et al., 2009) were 
obtained and downloaded from the Los Alamos database (Unknown, 2016). 
These gp160 sequences were aligned in Clustal X (Larkin, 2007), 
extensively analysed and representative sequences were selected. A 
consensus sequence was designed for the South African patients selected, 
namely CAP210 (CAP210.1.00T and P), CAP45 (CAP45.1.05A and 1.05B) 
and 706010164 (706010164_A to 706010164_G) (Abrahams et al., 2009) 
(hereinafter designated ZACAP210, ZACAP45 and ZA706010164 to 
indicate South African origin). Sequences selected from Indian patients 
were 26191 (26191-2 clone 48), 25925 (25925-2 clone 22) and 25710 
(25710-2 clone 43) (Kulkarni et al., 2009) (hereinafter designated IN26191, 
IN25925 and IN25710 to indicate Indian origin) (Table 2.1). These patients 
all acquired their HIV-1 infection through heterosexual contact. The three 
Indian sequences were selected based on resistance and sensitivity to 
neutralization to IgG1b12. Virus from patient IN26191 was susceptible to 
neutralization with IgG1b12, whereas IN25925 and IN25710 were resistant 
(Kulkarni et al., 2009).  
 
These 6 env sequences formed the basis for the design of monomeric 
gp120 and matched gp140GCN4(+) constructs. Sequences were codon 
optimized for mammalian expression as either monomeric gp120, or as 
trimeric gp140GCN4(+) containing the gp120 envelope sequence, the gp41 
ectodomain, with an intact cleavage site between the gp120 and gp41 
ectodomains, plus the addition of a 32 amino acid form of the GCN4 
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transcription factor (Harbury et al., 1993) fused to the carboxyl terminal of 
the gp41 ectodomain that allows for trimerization of the recombinantly 
expressed Env. A heterologous human CD5 antigen leader peptide 
sequence (NH3-MGMGSLQPLATLYLLGMLVASVLA-COOH) was used to 
replace the native N-terminal Env leader peptide to increase Env protein 
expression in mammalian cell culture (Aruffo et al., 1990; Haas et al., 1996; 
Killick et al., 2015).  
Table 2.1: Clinical and demographic information of the Indian and South African patients 
(infected via heterosexual transmission) from which HIV-1 subtype C envelope glycoprotein 
(Env) sequences were selected for design of monomeric and trimeric Env constructs.  
Participant ID Gender Age 
Geographical 
location 
Fiebig 
stage1 
Sampling 
date 
Viral load 
(RNA 
copies/ml) 
Nucleotide 
Accession 
numbers 
ZACAP45 Female 41 South Africa I/II 04/2005 12,500 FJ443292-297 
FJ443149-158 
ZACAP210 Female 43 South Africa I/II 05/2005 468,000 FJ443186-195 
FJ443509-510 
FJ443307-315 
ZA706010164 Male 27 South Africa IV 08/2007 23,600 FJ444058-076 
IN25925 Male NA2 India I – V 09/1999 616,531 EF117273 
IN26191 Male NA India I – V 05/2000 5,346,070 EF117274 
IN25710 Male NA India I – V 03/1999 3,523 EF117271 
1. Fiebig laboratory stages of HIV infection (days post infection): Stage I (5 – 10 days); Stage II (7 – 13 
days); Stage III (10 – 17 days); Stage IV (15 – 22 days); Stage V (47 – 129 days); Stage VI (open-
ended) (Fiebig et al., 2003).  
2. NA, not available  
 
The codon optimized nucleotide sequences were synthesized and sub-
cloned into the pcDNA3.1 mammalian expression vector by GeneArt 
(Regensburg, Germany). The pcDNA™3.1 vector expresses the HIV-1 Env 
using the human cytomegalovirus (CMV) enhancer-promoter with a bovine 
growth hormone (BGH) polyadenylation signal and transcription termination 
sequence for enhanced mRNA stability. It contains the ampicillin resistance 
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gene and pUC origin for selection and maintenance in Escherichia (E.) coli 
(Invitrogen, Life Technologies, Carlsbad, CA, USA).  
 
2.2 Expression and purification of the recombinant Env and 
recombinant 2dCD4 proteins 
The six gp120 and six matched gp140GCN4(+) constructs were purified and 
used for large scale expression of the recombinant Envs in mammalian 
cells, followed by purification.   
 
2.2.1 Transformation of recombinant Env plasmid DNA into E. coli 
DH5α cells 
The lyophilized pcDNA™3.1-containing env constructs from GeneArt were 
diluted with 50 µl sterile water to a final concentration of 0.1 µg/µl. 
Chemically competent E. coli DH5α (Invitrogen, Life Technologies, 
Carlsbad, CA, USA) cells were incubated with 0.2 µg of DNA on ice for 20 
minutes. The cells were then heat shocked at 42 °C for 1 minute and 
immediately returned to ice for 2 minutes, before adding 100 µl sterile Luria 
Bertani (LB) broth (10 g/l tryptone (Merck, Darmstadt, Germany); 5 g/l yeast 
extract (Merck-Millipore, Darmstadt, Germany) and 10 g/l sodium chloride 
(NaCl) (Sigma-Aldrich, St. Louis, MO, USA)). Transformed E. coli DH5α 
were cultured on selective LB agar plates (35 g/l LB Agar (Sigma-Aldrich, 
St. Louis, MO, USA) containing ampicillin (Roche, Mannheim, Germany) at a 
final concentration of 100 µg/ml (1000 x ampicillin stock solution (100 
mg/ml) made up in 70% [v/v] ethanol (Merck-Millipore, Darmstadt, 
Germany) after incubation overnight at 37 °C. 
 
2.2.2 Recombinant Env plasmid isolations 
Recombinant plasmids were purified from the transformed E.coli DH5α 
using the Maxi plasmid purification kit (Qiagen, Hilden, Germany) as per the 
manufacturer’s instructions. Briefly, a single colony was selected from the 
selective ampicillin-containing LB plate and was used to inoculate a 5 ml 
starter culture of LB medium containing ampicillin (100 µg/ml). The culture 
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was incubated for approximately 8 hours at 37 °C with vigorous shaking in 
a high-rotation, shaking incubator. The starter culture was then diluted 
(1:1000) in a sterile, one liter, Erlenmeyer flask containing 250 ml ampicillin-
supplemented (100 µg/ml) LB broth and incubated at 37 °C for a further 12 
– 16 hours with vigorous shaking in a high-rotation, shaking incubator. 
 
Bacterial cells were harvested by centrifugation at 6,000 x g for 15 minutes 
at 4 °C and re-suspended in 10 ml buffer P1 containing RNase A. The cells 
were lysed in an alkaline lysis buffer by adding 10 ml buffer P2 (NaOH-SDS) 
and incubating at room temperature for 15 minutes. Ten milliliters of chilled 
buffer P3 (acidic potassium acetate) was added to the lysate to neutralize it 
and incubated for 20 minutes to allow for precipitation of the potassium 
dodecyl sulphate. The bacterial chromosomal DNA, cellular debris and 
proteins, which become trapped in the salt-detergent complexes, were 
removed from the plasmid DNA by centrifugation at 16,000 x g for 10 
minutes. The plasmid DNA, which remains in the supernatant, was loaded 
onto a pre-equilibrated, anion-exchange chromatography Qiagen-tip and 
was bound to the resin by gravity flow. Any remaining contaminants were 
removed by washing twice with 30 ml buffer QC (a medium-salt buffer). The 
plasmid DNA was eluted from the resin with 15 ml buffer QF (high salt 
buffer). The plasmid DNA was precipitated by centrifugation with 0.7 
volumes of isopropanol (Merck-Millipore, Darmstadt, Germany) in 
approximately 7.0 ml volumes, at 9,200 x g for 30 minutes at 4 °C. Any 
residual salt was removed from the pellet by washing with 70 % ethanol 
[v/v], which was then removed by centrifugation at 9,200 x g for 10 min in a 
microcentrifuge and discarding the supernatant. After air-drying the DNA 
pellet, the purified plasmid DNA was re-suspended in sterile distilled water. 
The yield of the plasmid DNA was determined by UV absorption at A280nm 
using a Nanodrop ND 1000 spectrophotometer (ThermoFischer Scientific, 
Waltham, MA, USA) and stored in 500 µg/ml aliquots at -20 °C.  
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2.2.3 Expression of recombinant monomeric and trimeric Env  
2.2.3.1 General mammalian cell culture 
Mammalian cells used included the HEK293T cell line (available in our 
laboratory) which was used for the transient expression of the recombinant 
Env glycoproteins and the generation of HIV-1 pseudoviruses, the 293F 
suspension cell line (Invitrogen, Thermo Fisher Scientific Inc., Carlsbad, CA, 
USA) which was used for generating stable cell lines expressing Env and 
the TZM-bl (JC53-bl) reporter cell line (Dr John C. Kappes, Dr Xiaoyun Wu 
and Transzyme Inc.), (obtained from the NIH AIDS Research and 
Reference Reagent Program, division of AIDS, NIAID, NIH, contributor in 
parenthesis) which were used to determine the TCID50s of pseudoviruses 
and for pseudovirion neutralization assays. TZM-bl is a HeLa cell clone 
engineered to express CD4 and CCR5, making it highly sensitive to most 
strains of HIV infection. It also contains separate integrated copies of the 
Photinus pyralis (firefly) luciferase and E. coli ß-galactosidase genes under 
control of the HIV-1 long terminal repeat (LTR) promoter (Platt et al., 1998; 
Wei et al., 2002).  
 
Unless otherwise stated, all mammalian cell culture was carried out at 37°C 
in a humidified, water jacketed incubator (ThermoFischer Scientific, 
Waltham, MA, USA) and the atmospheric CO2 was maintained at 5 % 
(Medical CO2, Afrox, Selby, South Africa). 
 
HEK293T mammalian cells used to transiently express recombinant Env 
and TZM-bl cells used for pseudovirion assays were maintained in 
Dulbecco’s modified Eagles Medium (DMEM) (Sigma-Aldrich, St. Louis, 
MO, USA) supplemented with 10% fetal calf serum (FCS) (Gibco™, Thermo 
Fisher Scientific Inc, Waltham, MA) and 2 mM GlutaMax (Gibco™, Thermo 
Fisher Scientific Inc, Waltham, MA), referred to as complete DMEM. 
Cryopreserved cells were thawed rapidly at 37 °C and seeded in a T25 
tissue culture flask (Nunc, Roskilde, Denmark) and made up to a final 
volume of 10 ml of supplemented DMEM medium as described above. Cells 
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were examined for general cell health and microbial contamination by 
microscopic observation and passaged twice a week. Passaging the cells 
was done by removing the spent media, followed by washing the cells with 
1 x Dulbecco’s Phosphate Buffered Saline (PBS, without calcium and 
magnesium) to remove spent media and fetal calf serum. This was followed 
by treatment with trypsin/EDTA solution (0.25% [w/v] trypsin and 0.02% 
[w/v] ethylenediaminetetraacetic acid (EDTA) (Sigma Aldrich, St. Louis, MO, 
USA)) and incubated at 37 °C for a maximum of five minutes to release the 
cells from the vessel surface. Complete DMEM was used to mechanically 
wash any remaining cells off the vessel surface. One-tenth of the cells were 
re-seeded in the vessel and the remaining cells discarded and replaced with 
fresh complete DMEM media. Cells were enumerated by staining with 0.4% 
Trypan Blue solution (Sigma-Aldrich, St. Louis, MO, USA) (1:5 ratio) to 
determine viability and were manually counted by microscopic examination 
using a Neubauer haemocytometer (Roth, Karlsruhe, Germany). HEK293T 
and TZM-bl cells were sub-cultured up to passage 30 and then discarded.  
 
FreeStyle™ 293-F cells (Thermo Fisher Scientific Inc., Carlsbad, CA, USA) 
were used to generate stable cell lines for large scale expression of the 
recombinant Env proteins. These cells have been adapted for suspension 
culture and were maintained in FreeStyle™ 293 Expression Medium 
(Thermo Fisher Scientific Inc., Carlsbad, CA, USA). Cryopreserved cells 
were thawed rapidly at 37 °C, seeded in a T25 tissue culture flask (Nunc, 
Roskilde, Denmark) and made up to a final volume of 10 ml in FreeStyle™ 
293 Expression Medium (Gibco, Life Technologies, Carlsbad, CA, USA). 
Cells were examined for general cell health and microbial contamination by 
microscopic observation and passaged twice a week. Sub-culturing of the 
cells was done by re-suspending the cells in their spent media by pipetting 
action, and one-tenth of the cells volume was re-seeded in the vessel and 
fresh media was used to replace the discarded media. Cells were 
enumerated by staining with 0.4% Trypan Blue solution (Sigma-Aldrich, St. 
Louis, MO, USA) (1:5 ratio) to determine viability and were manually 
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counted by microscopic examination using a Neubauer haemocytometer 
(Roth, Karlsruhe, Germany). FreeStyle™ 293-F cells were sub-cultured to 
passage 30 and then discarded. 
 
Cryogenic preservation of cells was performed for long-term storage of 
HEK293T cells, TZMbl cells and 293F stable cell lines by preparing a sub-
cultured cell suspension concentration of 1 to 2 x 106 cells/ml in fresh 
medium used for the particular cell type, and freezing in a final volume of 
10% [v/v] dimethyl sulphoxide (DMSO) (Fluka Chemika, Buchs, 
Switzerland). The cells were stored in cryovials (Nunc, Roskilde, Denmark) 
and cooled at a rate of -1°C/minute using a Mr Frosty™ freezing container 
(ThermoFischer Scientific, Waltham, MA, USA) according to the 
manufacturer’s instructions.  
 
2.2.3.2 Expression of the recombinant Env 
Each of the 12 recombinant Env proteins (six gp120 and six matched 
gp140GCN4(+)) were expressed in HEK293T mammalian cells by transient 
transfection using Polyfect® Transfection Reagent (Qiagen), as per the 
manufacturer’s instructions. Optimal transfection conditions were 
determined. Briefly, 24 hours prior to transfection, T175 flasks were seeded 
with 8.0 – 8.5 x 106 cells in complete DMEM. Polyfect (125 µl) was added 
to 25 µg plasmid DNA in a total volume of 500 µl OptiMEM media (Gibco™, 
Thermo Fisher Scientific Inc, Waltham, MA). Samples were mixed and 
incubated for 5 minutes to allow complex formation, after which they were 
added to the cells. Approximately 8 hours post transfection, the media was 
replaced with serum free media (SFM II, Gibco™, Thermo Fisher Scientific 
Inc, Waltham, MA), supplemented with a final concentration of 2 mM 
GlutaMax (Gibco™, Thermo Fisher Scientific Inc, Waltham, MA) that was 
warmed to 37°C prior to use. The spent media was collected daily for 
approximately seven days and the supernatant was harvested by 
centrifugation at 1,000 x g for 5 minutes, filtered (0.45 µm Low protein 
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binding, Acrodisc® Syringe Filters with Supor® Membrane, PALL 
Corporation) and stored at -20°C until purification. 
 
In addition, stable cell lines using the 293F suspension cells (Invitrogen, 
Thermo Fisher Scientific Inc., Carlsbad, CA, USA) were generated for these 
recombinant proteins in order to express them on a large scale. Each 
recombinant plasmid was used to express the recombinant proteins in 
FreeStyle™ 293-FS cells (Thermo Fisher Scientific Inc., Carlsbad, CA, 
USA). Polyfect® Transfection Reagent (Qiagen) was used to transfect the 
cells as per the manufacturer’s instructions. Briefly, 24 hours prior to 
transfection, T25 flasks were seeded with 1.2 x 106 cells in FreeStyle™ 293 
Expression Medium (Thermo Fisher Scientific Inc., Carlsbad, CA, USA). 
Polyfect (25 µl) was added to four micrograms of plasmid DNA in a total 
volume of 500 µl Serum Free Media (SFMII) (Thermo Fisher Scientific Inc., 
Carlsbad, CA, USA). Samples were incubated for 5 minutes to allow 
complex formation, after which they were added to the cells. Approximately 
8 hours post transfection, the media was replaced with FreeStyle™ 293 
Expression Medium (Thermo Fisher Scientific Inc., Carlsbad, CA, USA). A 
final concentration of 500 μg/ml Geneticin® selective antibiotic (G418 
Sulphate, Gibco™, Thermo Fisher Scientific Inc, Waltham, MA) was used 
to select stable cells expressing the recombinant proteins. Sodium-dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE; see section 
2.5.2) and Western blot (see section 2.5.3) analysis was performed to 
confirm expression of the recombinant proteins. For large scale expression 
of Env, stably transfected cell lines were transferred to roller flasks. 
Approximately 6.0 x 106 stably transfected cells were seeded in a 1,700 cm2 
Roller Bottle (Corning® CellBIND® Cell Culture Surface) in a final volume 
of 100 ml FreeStyle™ 293 Expression Medium supplemented with 250 
μg/ml G418 Sulphate. The spent media was collected every second day for 
approximately one month and the supernatant was harvested by 
centrifugation at 1,000 x g for 5 minutes, filtered (0.45 µm sterile, low protein 
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binding, Acrodisc® Syringe Filters with Supor® Membrane, PALL Life 
Sciences) and stored at -20°C until purification. 
 
2.3 Purification of Env  
2.3.1 Primary purification of Env by lectin-affinity chromatography 
The recombinant protein was pre-purified from the filtered culture media 
using lectin-affinity chromatography. A volume of up to 1000 ml of pooled 
media for each recombinant protein was incubated separately with 4 ml of 
lectin-agarose conjugated resin from Galanthus nivalis (snowdrop) (Sigma; 
St Louis, MO) overnight with continuous stirring at 4°C. The slurry was 
loaded onto a luer-lock, non-jacketed liquid chromatography column 
(Dimensions: internal diameter (i.d.) 2.5 × 10 cm) (Sigma-Aldrich, St. Louis, 
MO, USA) to collect the recombinant Env-bound resin. The flow through 
was retained and re-incubated with the resin overnight for a second round 
of purification to ensure complete capture of expressed Env. All buffers used 
for washing and elution were maintained on ice. The resin was washed 
manually with 50 column bed volumes (200 ml) of 0.65 M NaCl in 
Dulbecco’s 1 x PBS (Sigma-Aldrich, St. Louis, MO, USA), followed by 50 
column bed volumes (200 ml) of 1 M NaCl in Dulbecco’s 1 x PBS. A final 
wash step was performed using 25 column bed volumes (100 ml) of 
Dulbecco’s 1 x PBS. The column was inverted in-between each wash step 
to re-suspend the resin. The recombinant Env proteins were eluted from the 
resin, using 6.25 column bed volumes (25 ml) of Dulbecco’s 1 x PBS 
containing 1.0 M methyl α-D-mannopyranoside (MMP) (Sigma-Aldrich, St. 
Louis, MO, USA). The eluted recombinant Env protein was concentrated 
using an Amicon® Ultra Centrifugation Filter Unit (Millipore, Billerica, MA, 
USA) with a 50 kDa molecular weight cut-off to approximately 1 ml in volume 
and washed five times (40 ml per wash) with Dulbecco’s 1 x PBS. The 
partially purified recombinant Env was snap-frozen in liquid nitrogen and 
stored at -80˚C for further purification by Size Exclusion chromatography 
(SEC). 
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2.3.2 Secondary purification of Env by SEC 
To separate the monomers and trimers from any aggregates from the lectin-
purified recombinant Env eluate, they were further purified using SEC with 
the ÄKTA FPLC (fast protein liquid chromatography) platform (GE 
Healthcare Bio-Sciences AB, Uppsala, Sweden). The lectin purified Env 
was thawed on ice and centrifugation was performed (16,000 x g for 10 
minutes) to remove any particulate matter. Initially, protein purification was 
carried out using a size exclusion column (Dimensions: i.d. 2.5 × 50 cm) 
that was packed according to the manufacturer’s instructions with Superdex 
200 prep-grade resin (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). 
Following further optimization, a pre-packed column (HiLoad 16/600 
Superdex 200 prep grade, GE Healthcare Life Sciences) was obtained and 
used in all subsequent experiments. Env was loaded onto the column and 
resolved at 1 ml/min in sterile, filtered (0.45 µm) Dulbecco’s 1 x PBS. 
Fractions were collected to obtain the monomeric gp120 and trimeric 
gp140GCN4(+) forms of the recombinant Env proteins (Guo et al., 2013). 
The column was cleaned in-between each different Env purification using 
the cleaning protocol recommended by the manufacturer. Briefly, the 
column was cleaned with one-half column volume of 0.5 M NaOH (Sigma-
Aldrich, St. Louis, MO, US) at a flow rate of 1.5 ml/min to remove non-
specifically bound proteins from the resin, and equilibrated with two to three 
column volumes of sterile, filtered (0.45 µm) Dulbecco’s 1 x PBS at a flow 
rate of 1.5 ml/min until the UV baseline stabilised. The purity of the purified 
protein was assessed by SDS-PAGE (section 2.5.2) and quantified using a 
BCA™ Protein Determination Kit as described in section 2.5.1. 
 
2.4 Expression and purification of recombinant 2dCD4Wt/S60C/FD 
variants 
A soluble CD4 protein containing the first two domains of CD4 (2dCD4), in 
which the serine at position 60 is substituted with cysteine (S60C) was used 
to generate gp120/2dCD4S60C and gp140/2dCD4S60C complexes. The S60C 
mutation allows for the complex to be stabilized through an inter-molecular 
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disulphide formation, and it has previously been shown in our laboratory to 
have a higher binding affinity to gp120 than wild-type 2dCD4 (Cerutti et al., 
2010). A wild-type 2dCD4 (2dCD4Wt) and folding-defective 2dCD4 
(2dCD4FD) were used as controls. The recombinant pET15-2dCD4 
(Wt/S60C/FD) vectors (available in our laboratory) were expressed in E. coli 
BL21 (DE3) using a “leaky”, IPTG-free (isopropyl-beta-D-
thiogalactopyranoside) induction protocol (Cerutti et al., 2010). Freshly 
transformed bacteria were cultured in standard LB broth medium (10 g/l 
tryptone (Merck, Darmstadt, Germany); 5 g/l yeast extract (Merck-Millipore, 
Darmstadt, Germany) and 5 g/l sodium chloride (NaCl) (Sigma-Aldrich, St. 
Louis, MO, USA)) containing ampicillin (Roche, Mannheim, Germany) at a 
final concentration of 100 μg/ml (1000 × ampicillin stock solution (100 
mg/ml) made up in 70% [v/v] ethanol (Merck-Millipore, Darmstadt, 
Germany) at 37 °C with vigorous shaking until the absorbance at A600 nm 
was between 0.6 and 0.8, cultures were then transferred to a 20°C incubator 
for a further 20 hours to allow for protein expression. The recombinant 
2dCD4S60C, 2dCD4Wt and 2dCD4FD were purified using a denaturing 
purification protocol and refolded in glutathione-containing buffers as 
described previously (Cerutti et al., 2010). Briefly, cells were collected by 
centrifugation (6,000 x g for 30 minutes, 4°C) and re-suspended in a 
minimum of 25 ml sterile Dulbecco’s 1 x PBS per litre of culture. The cells 
were lysed by incubating with lysozyme (0.5 mg/ml chicken egg lysozyme 
(53,000 units/mg) (Sigma-Aldrich, St. Louis, MO, USA) on ice for 1 hour with 
gentle shaking, followed by three freeze/thaw cycles using liquid nitrogen 
and three x 1 minute sonication cycles at 1.9 kilojoules/min sonication on 
ice (Sonopuls, Bandelin, Berlin, Germany). The inclusion bodies containing 
the expressed 2dCD4 protein were  pelleted by centrifugation (20,000 x g 
for 45 minutes, 4°C) and resuspended thoroughly using a tissue 
homogenizer (Omni International, GA USA) in 25 ml solubilisation buffer 
((Dulbecco’s 1 x PBS (pH 7.4) containing 8 M urea (Sigma-Aldrich, St. 
Louis, MO, USA), 50 mM glycine (Sigma-Aldrich, St. Louis, MO, USA), 2 
mM β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA), 20 mM 
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imidazole (Merck-Millipore, Darmstadt, Germany) and 0.5 M NaCl (Sigma-
Aldrich, St. Louis, MO, USA)). After a 30 minute incubation period at room 
temperature with gentle shaking to allow unfolding of the 2dCD4, the 
remaining cellular debris was removed by a second round of centrifugation 
(20,000 x g for 30 minutes, 4°C). The supernatant containing the solubilized 
2dCD4 proteins were filtered (0.45 µm Low protein binding, Acrodisc® 
Syringe Filters with Supor® Membrane, PALL Corporation) before 
purification by immobilized metal ion affinity chromatography.  
 
Standard Ni2+-affinity chromatography was used to purify the recombinant 
2dCD4s. The supernatant was incubated with 1 ml of Ni2+ charged resin 
overnight at 4°C with stirring. The slurry was loaded onto a luer-lock, non-
jacketed liquid chromatography column (Dimensions: internal diameter (i.d.) 
2.5 × 10 cm) (Sigma-Aldrich, St. Louis, MO, USA) to collect the recombinant 
2dCD4-bound resin and washed manually with 250 column bed volumes 
(250 ml) of wash buffer 1 ((PBS (pH 7.4) containing 8 M urea, 50 mM 
glycine, 2 mM β-mercaptoethanol, 20 mM imidazole and 0.5 M NaCl)). This 
was followed by 250 column bed volumes (250 ml) of wash buffer 2 ((PBS 
(pH 7.4) containing 8 M urea, 50 mM glycine, 2 mM β-mercaptoethanol, 50 
mM imidazole and 0.5 M NaCl)). The recombinant 2dCD4 protein was 
eluted from the resin in 2 x 10 ml elution buffer ((PBS (pH 7.4) containing 8 
M urea, 50 mM glycine, 2 mM β-mercaptoethanol, 500 mM imidazole and 
0.5 M NaCl)) with a five minute incubation period at room temperature for 
each elution.  
 
The eluted recombinant 2dCD4 was refolded overnight at 4°C by dialysis 
using SnakeSkin® dialysis tubing, 10 kDa MWCO, 35 mm dry i.d. 
(ThermoFischer, Rockford, IL, USA) against 1 litre of folding buffer A (50 
mM glycine, 10% sucrose, 1 mM EDTA (BDH, Merck-Millipore, Darmstadt, 
Germany), 1 mM reduced glutathione (GSH) (Sigma-Aldrich, St. Louis, MO, 
USA), 0.1 mM oxidized glutathione (GSSG) (Sigma-Aldrich, St. Louis, MO, 
USA) and 4 M urea (Sigma-Aldrich, St. Louis, MO, USA), adjusted to pH 9.6 
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with NaOH). The following day folding buffer A was replaced with folding 
buffer B (50 mM sodium carbonate (pH 9.6) (BDH, Merck-Millipore, 
Darmstadt, Germany), 10% sucrose, 1 mM EDTA, 0.1 mM GSH and 0.01 
mM GSSG) for a second round of dialysis overnight at 4°C. The final dialysis 
step was performed against 1 litre volumes of Dulbecco’s 1 x PBS (pH 7.4) 
three times for a minimum of 2 hours for the first two dialysis steps and 
overnight for the final dialysis step. All buffers were cooled to 4°C before 
use. The purified recombinant 2dCD4s were recovered and any precipitate 
was removed by centrifugation (3,200 x g for 10 minutes, 4°C) and filtration 
(0.45 µm Low protein binding, Acrodisc® Syringe Filters with Supor® 
Membrane, PALL Corporation). The recombinant 2dCD4s were 
concentrated using a centrifugation filter device (Amicon® Ultra 
Centrifugation Filter Unit with a 10 kDa molecular weight cut-off), snap 
frozen and stored at -80°C. The purity of the each recombinant 2dCD4 was 
assessed by SDS-PAGE as described in section 2.5.2 and quantified using 
a BCA™ Protein Determination Kit as described in section 2.5.1.  
 
2.5 Protein biochemical characterisation 
2.5.1 Total protein concentration determination 
The purified protein was quantified using a BCA™ Protein Determination Kit 
(Pierce, ThermoFischer, Rockford, IL, USA), as per the manufacturer’s 
instructions. Briefly, a set of protein standards was prepared by serially 
diluting the 2 mg/ml Albumin Standard (containing bovine serum albumin, 
supplied with the kit) two-fold in Dulbecco’s 1 x PBS to obtain a range of 
eight concentrations from 500 µg/ml to 7.8125 µg/ml, and a 0 µg/ml blank 
standard. Twenty-five microliters of each standard and the protein to be 
assayed was transferred into a flat bottomed, 96-well, polysorb Immuno 
plate (Nunc, Roskilde, Denmark) well in duplicate. The working reagent was 
prepared by mixing 50 parts of BCA Reagent A with 1 part of BCA Reagent 
B, and 200 µl of this working reagent was added to each well that contained 
standard or protein sample. The microplate was incubated at 56 °C on an 
orbital shaker (THERMOstar Microplate incubator, BMG Labtech, 
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Ortenberg, Germany) at 300 rpm for 30 minutes. The microplate was 
allowed to cool to room temperature and absorbance was determined at 
570 nm using a microplate reader (BioRad Model 680, BioRad, Hercules, 
CA, USA). A standard curve was prepared using the A570nm readings 
obtained and the protein concentration of the unknown samples was 
determined by interpolating the A570nm against the standard curve. 
 
2.5.2 SDS-PAGE 
The expression of the recombinant Env by transiently transfected cells and 
stably transfected cells lines was confirmed by SDS-PAGE followed by 
Western blot analysis (2.5.3 below). Mammalian cell culture supernatants 
containing the Env were mixed with 2 x Laemmli sample buffer (0.125 M 
Tris-HCl (Tris - (hydroxymethyl) aminomethane) (Sigma-Aldrich, St. Louis, 
MO, USA), 4% [w/v] SDS (Sigma-Aldrich, St. Louis, MO, USA), 20% [v/v] 
glycerol (Merck-Millipore, Darmstadt, Germany), 0.2 M dithiothreitol (DTT) 
(Sigma-Aldrich, St. Louis, MO, USA) and 0.02% bromophenol blue 
(Saarchem, Merck-Millipore, Darmstadt, Germany), pH 6.8.) and boiled for 
5 minutes in a water bath. The samples were briefly centrifuged and loaded 
onto a 10 % SDS-PAGE gel (10% SDS-PAGE gel (separating gel - 10% 
acrylamide (Sigma-Aldrich, St. Louis, MO, USA), 0.9% NN-
methylenebisacrylamide (Sigma-Aldrich, St. Louis, MO, USA), 0.1% SDS 
(Sigma-Aldrich, St. Louis, MO, USA), 0.375 M Tris-HCl, pH 8.8; stacking gel 
– 4% acrylamide, 0.36% NN-methylenebisacrylamide, 0.1% SDS, 0.125 M 
Tris-HCl, pH 6.8) for separation. Gel electrophoresis was performed in tank 
buffer (0.025 M Tris-HCl (Tris - (hydroxymethyl) aminomethane) (Sigma-
Aldrich, St. Louis, MO, USA), 0.192 M glycine (Sigma-Aldrich, St. Louis, 
MO, USA), 0.1 % SDS, pH 8.3) at 10 mA until the samples had migrated 
through the stacking gel, after which the current was increased to 20 mA. 
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2.5.3 Western blot 
Clarified serum from an HIV-1 infected patient (obtained from the SANBS, 
presumably infected with HIV-1 Subtype C) was used as the primary 
antibody in the relevant Western blots. 
 
Once resolved, the SDS-PAGE gel was equilibrated in transfer buffer (20% 
[v/v] methanol (Merck-Millipore, Darmstadt, Germany), 0.025 M Tris, 0.192 
M glycine and 0.1% SDS) at room temperature for approximately 10 
minutes. The samples were transferred from the SDS-PAGE gel onto a 
nitrocellulose membrane (Hybond-C extra, Amersham, GE Healthcare Bio-
Sciences AB, Uppsala, Sweden) at 400 mA for 1 hour-20 minutes, using the 
Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell (BioRad, Hercules, 
CA, USA). The nitrocellulose membrane was incubated overnight at 4°C in 
Tris-buffered saline containing Tween-20 (T-TBS) (0.25 mM Tris-HCl, 17 
mM NaCl, 3 mM potassium chloride (KCl) (Sigma-Aldrich, St. Louis, MO, 
USA) pH 7.4 and 0.1% Tween-20 (Sigma-Aldrich, St. Louis, MO, USA)) and 
5 % fat free milk powder to block non-specific binding sites. The membrane 
was probed with 1:2,000 dilution of serum from an HIV-1 infected patient in 
T-TBS. The membrane was washed 5 times, each wash being five minutes 
long, in T-TBS on an orbital shaker to remove non-specific antibodies. A 
1:25,000 dilution of secondary antibody (goat anti-human IgG (Fc specific) 
alkaline phosphatase conjugated antibody (Sigma-Aldrich, St. Louis, MO, 
USA) was used to detect bound antibodies. After washing (5 x five minute 
washes in T-TBS) to remove unbound probes, the membrane was 
incubated in SIGMFAST 5-bromo-4-chloro-3-indolyl phosphate/nitro blue 
tetrazolium (BCIP/NBT) tablets (Sigma-Aldrich, St. Louis, MO, USA) 
prepared according to the manufacturer’s instructions, for approximately 10-
20 minutes in the dark, at room temperature, until a precipitation reaction 
resulted in clear visualization of bands. The remaining BCIP/NBT substrate 
was rinsed off with water to terminate the reaction. 
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2.5.4 Surface Plasmon Resonance (SPR) 
2.5.4.1 Reagents used for SPR 
The panel of CD4bs directed mAbs used for Surface Plasmon Resonance 
(SPR) were obtained from the NIH AIDS Research and Reference 
Reagents Program (contributor in parenthesis). HIV-1 monoclonal 
antibodies used include IgG1b12 (Dr. Dennis Burton and Carlos Barbas 
(Barbas et al., 1992; Burton et al., 1991; Roben et al., 1994)), VRC01 
(Xueling Wu, Zhi-Yong Yang, Yuxing Li, Gary Nabel, John Mascola (Wu et 
al., 2010)), HJ16 (Dr. Antonio Lanzavecchia (Corti et al., 2010; Pietzsch et 
al., 2010)), VRC-CH31 (Duke Human Vaccine Institute, Duke University 
Medical Center (Bonsignori et al., 2012)) NIH45-46G54W IgG (Pamela 
Bjorkman (Diskin et al., 2011)), and VRC03 (Xueling Wu, Zhi-Yong Yang, 
Yuxing Li, Gary Nabel, John Mascola (Wu et al., 2010)). In addition, the 
quaternary-structure-specific antibody directed to the V1V2 region of Env, 
PGT145 was kindly obtained from Prof Raghavan Varadarajan, (Indian 
Institute of Science, Bangalore, India). All reagents used for SPR were 
ProteON™ reagents supplied by BioRad, with the exception of the PBS 
running buffer. 
 
All 12 purified recombinant Envs were biochemically characterized to 
confirm they were functional (binding to CD4) and conformationally intact 
(binding to a conformational dependent monoclonal antibody (MAb) and 
CD4bs directed mAbs) by SPR.  The antibody and CD4 interaction studies 
of the recombinant Env proteins were investigated on a ProteOn XPR36 
protein interaction array system (Bio-Rad Laboratories, Hercules, CA, USA) 
at 25 °C in PBS-T running buffer (1 x PBS (274 mM NaCl; 54 mM KCl; 20.29 
mM Na2HPO4; 3.53 mM KH2PO4) autoclaved and filtered (0.45 µm) and 
supplemented with 0.05 % Tween 20). 
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2.5.4.2 Env/2dCD4Wt/S60C interactions 
The ProteON™ instrument was used to determine binding kinetics of the 
2dCD4-Env interactions. A ProteOn™ GLM Sensor Chip was activated by 
injecting a freshly prepared 1:1 solution of NHS (N-hydroxysuccinimide) and 
EDAC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide). 2dCD4Wt and 
2dCD4S60C were covalently captured onto separate flow cells on the chip at 
a concentration of 0.02 mg/ml in 10 mM sodium acetate buffer pH 4.5 at a 
flow rate of 30 µl/min for 300 s to a final response units (RU) of 2000. One 
Molar ethanolamine chloride was injected at a flow rate of 30 µl/ml for 300 
s to deactivate any residual active sites. The six gp120 (IN25925, IN26191, 
IN25710, ZACAP45, ZACAP210 and ZA706010164) as well as six 
gp140GCN4(+) (IN25925, IN26191, IN25710, ZACAP45, ZACAP210 and 
ZA706010164) were passed over the ligands at a flow rate of 30 µl/min for 
300 s with a dissociation time of 600 s. Binding kinetics was calculated for 
the different Env’s by injecting a serial dilution of five concentrations over 
the ligands. The concentrations used were such that the highest Env 
concentration resulted in a RU of approximately 200 and varied between 
the different Env’s in a range of 30 nM to 3000 nM. The chip was 
regenerated after each Env injection using 4mM MgCl2 at a flow rate of 100 
µl/min for 18 s.  
 
2.5.4.3 Antibody-Env interactions 
Binding kinetics of the recombinant Env to CD4bs monoclonal antibodies 
and the quaternary-structure-specific antibody PGT145 was performed 
using the ProteON™ XPR36 platform. A ProteOn™ GLC Sensor Chip, (Bio-
Rad Laboratories, Inc) was activated by injecting a freshly prepared 1:1 
solution of NHS (N-hydroxysuccinimide) and EDAC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide). Approximately 2000 response units 
(RU) of each antibody (IgG1b12, VRC01, HJ16, VRC-CH31, NIH45-46G54W, 
VRC03 and PGT145) was covalently captured onto separate flow cells on 
the chip at a concentration of 0.02 mg/ml in 10 mM sodium acetate buffer 
pH 4.5 and a flow rate of 30 µl/min for 300s. One Molar ethanolamine 
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chloride was injected at a flow rate of 30 µl/ml for 300 s to deactivate any 
residual active sites. The six gp120 (ZACAP45, ZACAP210, ZA706010164, 
IN26191 and IN25925 and IN25710) as well as six gp140GCN4(+) 
(ZACAP45, ZACAP210, ZA706010164, IN25925 and IN25710) were 
passed over the bound antibodies at a flow rate of 30 µl/min for 300 s with 
a dissociation time of 600s. The chip was regenerated in between Env 
batches using 4 mM MgCl2 at a flow rate of 100 µl/min for 18 s. The 
concentrations of each Env passed over the coupled antibodies were 
initially started at 500 nM and adjusted according to binding. If binding of 
the recombinant Env glycoprotein and antibody was observed, and a 
sufficient quantity of Env was available, a set of 5 serially diluted 
concentrations of the Env glycoprotein was injected over the antibodies to 
calculate binding kinetics. The concentrations used were such that the 
highest Env concentration resulted in a RU of approximately 200 and varied 
between the different Env’s in a range of 0.9 nM to 1500 nM. In some cases 
(gp120 IN25710) the flow rate was adjusted to 65 µl/min for 160s with a 
dissociation time of 600s. 
 
2.5.4.4 SPR data analysis 
The binding kinetic data obtained from SPR experiments was fitted to a 
1:1 Langmuir model using the ProteOn Manager software, version 3.1.0.6 
(Bio-Rad Laboratories Inc., CA, USA). 
 
2.6 Generation of Env/2dCD4 complexes 
Two protocols were followed for the generation of the Env/2dCD4 
complexes, one in which ß-mercaptoethanol was used to generate the 
complex and one without ß-mercaptoethanol. The two protocols were 
followed in order to determine whether the presence or absence of a low 
concentration of reducing agent made a difference in the formation of the 
inter-molecular disulphide bridge. 
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The Env/2dCD4 complexes were generated by incubating 1 mg of Env 
glycoprotein with 1 mg of 2dCD4 with a final concentration of 1 mM ß-
mercaptoethanol for one hour at room temperature. For complexes 
generated without ß-mercaptoethanol, the same protocol was followed but 
the ß-mercaptoethanol was omitted. Any precipitate formed was removed 
by centrifugation (16,000 x g for 10 minutes, 4°C). Any unbound 2dCD4 was 
removed from the complex using Size Exclusion Chromatography (as 
described in section 2.3.2). Briefly, the Env/2dCD4 complex was loaded 
onto a pre-packed column (HiLoad 16/600 Superdex 200 prep grade, GE 
Healthcare Life Sciences) and resolved at 1 ml/min in sterile, filtered (0.45 
µm) Dulbecco’s 1 x PBS. Peak fractions corresponding to the Env used in 
the complex were collected and concentrated using a centrifugation filter 
device (Amicon® Ultra Centrifugation Filter Unit with a 50 kDa molecular 
weight cut-off). The purified Env/2dCD4 complex was snap frozen and 
stored at -80°C. The purity of the complexed protein was assessed by SDS-
PAGE (see section 2.5.2) and quantified using a BCA protein assay (Pierce, 
ThermoFischer, Rockford, IL, USA), as per the manufacturer’s instructions 
(section 2.5.1). 
 
2.7 Immunogenicity study of recombinant monomeric, trimeric 
envelope glycoproteins (Env) and Env/2dCD4 complexes 
Following biochemical characterization, gp120/gp140GCN4(+)ZACAP45 and 
gp120/gp140GCN4(+)IN25925 were expressed and purified on a large scale 
required for immunizations.  
 
The following stabilized gp120/gp140 derivative immunogens (proteins, 
peptides and DNA constructs) were received from our collaborators 
((Professor Virander Chauhan, International Centre for Genetic Engineering 
and Biotechnology (ICGEB), New Delhi, India; and Prof Raghavan 
Varadarajan, Indian Institute of Science, Bangalore, India)), as part of the 
South African Department of Science and Technology/TIA India-SA bilateral 
on HIV Vaccine Development: 
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i. Cyc4OD gp120, a cyclic permutant based on HIV-1 subtype B JRFL, 
in which the N- and C- termini were joined with a GSAG linker and 
the V4 loop was removed to create new N and C termini. 
ii. gp120JRFL cyclic permutant protein (h-CMP V1cyc 144-142), a cyclic 
permutant based on HIV-1 subtype B JRFL, in which the native N 
and C-termini of gp120 were joined with a linker, and the V1 loop 
was removed to create new N and C termini at residues 144 and 
142, respectively. The h-CMP trimerization domain was used to 
extend the termini and stabilize gp120 in a trimeric conformation. 
iii. ODECCOBPICS gp120, an outer domain fragment based on a 
consensus sequence of subtype B viruses. 
iv. DNA immunogen consisting of wild type gp120 based on HIV-1 
subtype B, JRFL (Wt-JRFL-Env DNA) 
v. DNA immunogen consisting of a trimer based on HIV-1 subtype B 
JRFL, stabilized by a V570D mutation in the N-heptad repeat region 
of gp41 (JRFL Env-570D DNA) 
vi. DNA immunogen consisting of an uncleaved trimer based on HIV-1 
subtype B JRFL (JRLF Env-SEKS DNA). 
vii. 1WR2, a monomeric scaffold peptide from Pyrococcus horikoshii 
with the VRC01 epitopes engrafted on it. 
viii. 1ORC, a monomeric scaffold peptide of the Cro protein from 
bacteriophage lambda with the VRC01 epitopes engrafted on it. 
 
The gp140FV Env glycoprotein (gp140FVGCN4t(+)) has been described 
previously and was available in our laboratory (Killick et al., 2015).  
 
All immunogens were formulated with Adjuplex™ (Advanced BioAdjuvants, 
Omaha, Nebraska, USA) from a concentrated starting solution according to 
manufacturer’s instructions. Adjuplex™ adjuvant is a nanoliposomal mixture 
of carbomer homopolymer and highly purified natural phospholipids.       
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2.7.1 Rabbit Immunizations 
New Zealand White Rabbits (Oryctolagus cuniculus) ranging from 3 to 12 
months of age (1.7 – 4.1 kg) were provided by the Central Animal Service 
(CAS), University of the Witwatersrand, Johannesburg, South Africa. The 
rabbits were housed individually at CAS, given food and water ad libitum 
and all immunization procedures and care of the rabbits were carried out by 
the CAS staff. Rabbits were allowed to acclimatise to their experimental 
housing environment for a minimum of one week prior to immunizations.  
 
Animal ethics clearance certificates (2010/12/03/A; 2010/12/03C and 
2015/51/B) (Appendix A) were obtained for the immunizations by the Animal 
Ethics Screening Committee, University of the Witwatersrand), and all 
animal work was conducted in strict accordance with University and 
National/International Recommendations.  
 
Three to five rabbits were assigned to each group and groups were matched 
for gender, age and weight where possible. Rabbits were immunized 
intramuscularly in their hindquarters, (alternating between the left and right 
hindquarter for each immunization) per immunogen as indicated in Table 
2.2 and 2.3 below. Blood was drawn from the rabbit’s marginal ear vein by 
venipuncture prior to immunization as a pre-bleed negative control, and 
post-immunization bleeds were collected at 4 week intervals, starting at 
week 2 post immunization, so that each bleed was performed 2 weeks after 
an immunization. Approximately 10 ml of whole blood was drawn from each 
rabbit per bleed and collected in a serum tube (BD Vacutainer® red-capped 
tubes, Becton, Dickinson and Company, Franklin Lakes, NJ, USA). 
Terminal bleeds were carried out at week 14 for experiment 1; week 22 for 
groups 1-4 in experiment 2; and week 30 for groups 5 – 8 in experiment 2 
(see Table 2.2 and 2.3). Four to five x 10 ml tubes of whole blood were 
collected per rabbit, followed immediately by euthanasia with 1 ml/kg 
sodium pentobarbitone (supplied by CAS), administered intravenously. 
Serum tubes were inverted several times immediately post collection to 
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activate clotting, and the clot was pelleted by centrifugation (1,000 x g, for 
10 minutes). The serum was collected and stored at -80 °C until further 
characterisation.  
 
Table 2.2: Immunization schedule for the gp120/gp140GCN4(+) Env variants to compare 
Env’s of South African and Indian origin.  Each rabbit was administered with a dose of 20 
µg of the immunogen per immunization. 
Immunogen 
No. of 
rabbits 
Immunization 
(weeks) 
Serum sample 
collection (weeks) 
2dCD4Wt 5 0, 4, 8, 12 0, 2, 6, 10, 14 
2dCD4S60C 5 0, 4, 8, 12 0, 2, 6, 10, 14 
2dCD4FD 5 0, 4, 8, 12 0, 2, 6, 10, 14 
gp120IN25925 5 0, 4, 8, 12 0, 2, 6, 10, 14 
gp120IN25925/2dCD4S60C 5 0, 4, 8, 12 0, 2, 6, 10, 14 
gp120IN25925/2dCD4S60C  
(No β-mercaptoethanol) 
5 0, 4, 8, 12 0, 2, 6, 10, 14 
gp140IN25925GCN4(+) 3 0, 4, 8, 12 0, 2, 6, 10, 14 
gp140IN25925GCN4(+)/2dCD4S60C 3 0, 4, 8, 12 0, 2, 6, 10, 14 
gp120ZACAP45 3 0, 4, 8, 12 0, 2, 6, 10, 14 
gp120ZACAP45/2dCD4S60C 3 0, 4, 8, 12 0, 2, 6, 10, 14 
gp140ZACAP45GCN4(+) 3 0, 4, 8, 12 0, 2, 6, 10, 14 
gp140ZACAP45GCN4(+)/ 
2dCD4S60C 
3 0, 4, 8, 12 0, 2, 6, 10, 14 
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Table 2.3: Immunization schedule for the gp120/gp140 Env derivative immunogens 
(proteins, peptides and DNA constructs).  
Immunogen 
(number of doses) 
No. of 
rabbits 
Immunization 
(weeks) 
Dose 
Serum sample 
collection 
(weeks) 
1 Prime CycV4OD protein 
(2) 
3 0, 4, 20 µg -1, 2, 6, 10, 14, 
18, 22 
Boost gp120JRFL cyclic 
permutant protein 
(2) 
 12, 20 20 µg 
2 Prime ODECCOBPICS-
C protein (2) 
4 0, 4 20 µg -1, 2, 6, 10, 14, 
18, 22 
Boost gp120JRFL cyclic 
permutant protein 
(2) 
 12, 20 20 µg 
3 Prime 1WR2 peptide (3) 3 0, 4, 8 20 µg -1, 2, 6, 10, 14, 
18, 22 
Boost ZA gp140FV 
protein (2) 
 12, 20 20 µg 
4 Prime 1ORC peptide (3) 4 0, 4, 8 20 µg -1, 2, 6, 10, 14, 
18, 22 
Boost ZA gp140FV 
protein (2) 
 12, 20 20 µg 
5 Prime Wt-JRFL Env DNA 
(3) 
4 0, 4, 8 2 mg -1, 2, 6, 10, 14, 
18, 22, 26, 30 
Boost gp120JRFL cyclic 
permutant protein 
(2) 
 20, 28 45 µg 
6 Prime JRFL Env-V570D 
DNA (3) 
4 0, 4, 8 2 mg -1, 2, 6, 10, 14, 
18, 22, 26, 30 
Boost gp120JRFL cyclic 
permutant protein 
(2) 
 20, 28 45 µg 
7 Prime JRFL Env-SEKS 
DNA (3) 
3 0, 4, 8 2 mg -1, 2, 6, 10, 14, 
18, 22, 26, 30 
Boost gp120JRFL cyclic 
permutant protein 
(2) 
 20, 28 45 µg 
8 Prime JRFL Env-V570D 
DNA (3) 
4 0, 4, 8 2 mg -1, 2, 6, 10, 14, 
18, 22, 26, 30 
Boost ZA gp140FV 
protein (2) 
 20, 28 45 µg  
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2.7.2 Immunogenicity testing of rabbit sera 
2.7.2.1 End-point antibody titer Enzyme Linked Immunosorbent 
Assays (ELISA) 
Binding antibody titres were determined for the rabbit serum by ELISA. 
Terminal bleed and prebleed rabbit sera were heat inactivated at 56 °C for 
one hour. One hundred microlitres of 1 µg/ml matched Env immunogen or 
2dCD4S60C was coated onto medium binding 96-well plates (Greiner Bio-
One, Frickenhausen, Germany) overnight at 4°C. The coating solution was 
aspirated from the wells the following day and the plate was blocked for 1 
hour at room temperature with 250 µl of Dulbecco’s 1 x PBS containing 
0.05% Tween 20 and 1% [w/v] lyophilized bovine serum albumen (BSA; 
Sigma-Aldrich, St. Louis, MO, USA). The plates were washed three times 
with 300 µl wash buffer (Dulbecco’s 1 x PBS containing 0.05% Tween 20). 
Heat-inactivated rabbit sera (50 µl) was prepared in assay buffer 
(Dulbecco’s 1 x PBS containing 0.05% Tween 20 and 1% [w/v] lyophilized 
BSA) using a two-fold serial dilution starting at 1:400 up to 1:1,638,400. In 
cases where the titres were very high, dilutions were first prepared to obtain 
a dilution of 1:2,560,000, and further diluted using a two-fold dilution series 
up to 1:327,680,000. The samples were added to the wells in triplicate and 
incubated at room temperature for 1 hour. The plates were washed five 
times with 300 µl wash buffer to remove unbound antibodies. Anti-rabbit 
IgG, Horseradish peroxidase linked whole antibody (from donkey) (AEC 
Amersham) was added to each well (50 µl, 1:5000 dilution) and incubated 
for 45 minutes at room temperature. After five plate washes with wash 
buffer, bound antibodies were detected using TMB peroxide substrate (100 
µl per well for 20 minutes at room temperature) (1-Step™ Ultra TMB-ELISA 
Substrate Solution, ThermoFisher Scientific) and the reaction was stopped 
using 1M H2SO4 (Sigma-Aldrich, St. Louis, MO, USA).  
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2.7.2.2 Neutralizing antibody assays  
Neutralisation breadth and potency of the antibodies raised in rabbits was 
evaluated using neutralising antibody assays. 
 
2.7.2.2.1 PhenoSense™ neutralising antibody assay 
Neutralizing antibody responses in rabbit sera of groups immunized with 
gp120/gp140GCN4(+) Env variants gp120IN25925, gp120IN25925/2dCD4S60C, 
gp120IN25925/2dCD4S60C (No β-mercaptoethanol) and 2dCD4Wt, 2dCD4S60C, 
2dCD4FD  control groups (Table 2.2) were measured using the PhenoSense 
Neutralising Antibody Assay at Monogram Biosciences Inc. (San Francisco, 
CA, USA) (Li et al., 2005). All terminal bleed rabbit sera and one prebleed 
serum sample per group were heat inactivated at 56 °C for one hour and 
sent to Monogram Biosciences Inc. for evaluation against a panel of 12 HIV-
1 pseudovirus isolates (Tier 1: SF162, BaL, NL43; Tier 2: 93IN905, 
93MW959, 97ZA012, IAVI_C22, JRCSF, MGRM-C-004, MGRM-SC-B-012, 
MGRM-C-015; Tier 3: MGRM-SC-B-005). The reciprocal of the dilution of 
serum required to achieve 50% (ID50; 1/dilution) inhibition of viral infection 
was used to assess neutralisation activity.  
 
2.7.2.2.2 In-house HIV Neutralizing Antibody Assay 
Reagents used for pseudovirion assays 
The following reagents were obtained from the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID (contributor in 
parentheses): TZM-bl (JC53-bl) reporter cell line (Drs. John C. Kappes, 
Xiaoyun Wu and Transzyme Inc.). Reagents for pseudovirus production 
pSG3Δenv (Dr. John C. Kappes and Xiaoyun Wu) and ZM53M.PB12 (Drs 
E. Hunter and C. Derdeyn). The gp160-expressing plasmid SF162.LS was 
kindly provided by Dr. D. Montefiori (Duke University Medical Center, North 
Carolina, USA).  
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The four gp160 expressing plasmids for the generation of pseudoviruses 
included HIV-1 subtype B BaL and SF162.LS (obtained from Dr. D. 
Montefiori, Laboratory for AIDS Vaccine R&D, Duke University Medical 
Center) and the HIV-1 subtype C ZM53M.PB12 (Drs E. Hunter and C. 
Derdeyn) and ZACAP210 (Drs. L. Morris, K. Mlisana and D. Montefiori) 
which were obtained from the NIH Research and Reference Reagents 
Program (catalogue numbers 11313 and 11317, respectively).  
 
Pseudovirus production 
Recombinant HIV-1 pseudoviruses capable of a single round of infection 
were generated by co-transfecting HEK293T cells with pSG3Δenv (an env-
deficient backbone expression plasmid, which contains a defective vpu 
gene) and the five gp160-expressing plasmids being tested as described (Li 
et al., 2005). Briefly, a total of 5 µg DNA at a ratio of 1:2 µg equivalents (Env 
: Backbone) was incubated for 10 minutes at room temperature with 
FuGENE® HD Transfection Reagent (Promega Corporation, Madison, WI 
53711 USA) at a ratio of 1:6 (total plasmid DNA : FuGENE) in a final volume 
of 500 µl Opti-MEM®/Reduced Serum Media (Gibco™, Thermo Fisher 
Scientific Inc, Waltham, MA). This was added dropwise to 60-65 % confluent 
HEK293T cells in a T25 tissue culture flask (Nunc, Roskilde, Denmark) and 
incubated as described in 2.3.4 above. The supernatant was replaced 
approximately 12 hours post-transfection with 7 ml of complete DMEM. 
Pseudovirus-containing supernatants were harvested 48 and 72 hours post 
transfection, and FCS (Gibco™, Thermo Fisher Scientific Inc, Waltham, 
MA) was added to a final concentration of 20% before filtering through a 
0.45 µm syringe filter and storing in 1 ml aliquots at - 80°C.  
 
A single thawed aliquot from each pseudovirus batch was titred to determine 
the 50% Tissue Culture Infectious Dose (TCID50) in TZM-bl cells (Li et al., 
2005). The pseudovirus was serially diluted five-fold in a 96-well tissue 
culture plate (Nunc, Roskilde, Denmark) in a final volume of 100 µl complete 
DMEM across 11 columns of the 96 well plate in quadruplicate. The wells 
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of the 12th column contained cell-only controls. TZM-bl cells were 
trypsinized and enumerated as described in 2.3.4 above. Ten thousand 
cells in 100 µl complete DMEM, supplemented with 40 µg/ml 
diethylaminoethyl-dextran hydrochloride (DEAE Dextran, Sigma-Aldrich, St. 
Louis, MO, USA) to give a final DEAE Dextran concentration of 20 µg/ml, 
were added to each well.  
 
After 48 hours of incubation the cell culture media was aspirated from each 
well and 80 µl Glo-Lysis buffer (Promega, Madison, WI, USA) was added to 
the cells and incubated for five minutes at room temperature to allow cell 
lysis. Fifty microliters of cell lysate was transferred to a 96-well white solid 
luminometer plate (Promega, Madison, WI, USA) and 50 µl Bright-Glo™ 
Luciferase reagent (Promega, Madison, WI, USA) was added. 
Luminescence was measured immediately using a GloMax® Explorer 
luminometer (Promega, Madison, WI, USA) and the TCID50 was calculated 
using a Microsoft Excel macro available online at the Los Alamos National 
Laboratory HIV immunology database (http://www.hiv.lanl.gov/). 
 
Neutralising antibody assay  
In-house neutralizing antibody responses of week 0 (prebleed) and week 
14 (terminal bleed) in rabbit sera of groups immunized with 
gp120/gp140GCN4(+) Env variants gp140GCN4(+)IN25925, 
gp140GCN4(+)IN25925/2dCD4S60C ,gp120ZACAP45 , gp120ZACAP45/2dCD4S60C, 
gp140GCN4(+)ZACAP45, gp140GCN4(+)ZACAP45/2dCD4S60C (Table 2.2) were 
evaluated in-house using a luciferase-based assay in TZM-bl cells (Li et al., 
2005). The same assay was used to evaluate neutralizing antibody 
responses of week 0 (prebleed) and week 10 (post prime) and terminal 
bleed rabbit sera of all the groups immunized with the stabilized 
gp120/gp140 Env derivatives (Table 2.3). The assay was carried out as 
described in (Li et al., 2005). Briefly, the rabbit sera from time points 
mentioned above and matched prebleed sera (included as baseline control), 
were heat inactivated at 56 °C for one hour in a water bath. Rabbit sera was 
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serially diluted three-fold (range 1:20 to 1:43,740), in duplicate, in a 96-well 
tissue culture plate (Nunc, Roskilde, Denmark). Two hundred TCID50 of 
each HIV-1 pseudovirus in a final volume of 50 µl complete DMEM 
supplemented with penicillin (100 units/ml) and streptomycin (0.1 mg/ml) 
(Sigma-Aldrich, St. Louis, MO, USA) was added to the appropriate wells 
and the plate was incubated at 37°C, 5% CO2 for 1 hour. TZM-bl cells were 
trypsinised and enumerated as described in 2.3.4 and 104 cells in 100 µl 
complete DMEM, supplemented with 50 µg/ml DEAE Dextran (Sigma-
Aldrich, St. Louis, MO, USA) to give a final concentration of 20 µg/ml, were 
added to each well. One column of 8 wells contained cells only (cell control) 
and another column contained virus and cells (virus control). Plates were 
incubated for 48 hours and luminescence was measured as described 
above, and the reciprocal of serum dilution required to achieve 50% 
inhibition (ID50) after normalizing against the cell only and virus only control, 
was calculated by fitting a variable-slope, non-linear regression curve using 
GraphPad Prism version 5.00 for Windows (GraphPad Software, San 
Diego, CA, USA). 
 
  
3-67 
 
Chapter 3 : Results 
3.1 Env selection and generation of recombinant gp120 and gp140 
constructs 
To characterize and compare HIV-1 subtype C Env immunogens from 
South Africa and India, twelve envelope glycoprotein constructs were 
designed after extensive bioinformatic analysis of Env sequences derived 
from South African and Indian HIV-1 subtype C infected patients. This led 
to the selection of sequences from six patients, three from India and three 
from South Africa (including matched gp120 and gp140GCN4(+)) and 
formed the basis of our immunogen design. 
 
The sequences were synthesized and successfully cloned by GeneArt into 
the pcDNA3.1 mammalian expression vector, and included the codon 
optimised monomeric gp120 for each sequence (pcDNA-gp120ZACAP45, 
pcDNA-gp120ZACAP210, pcDNA-gp120ZA706010164, pcDNA-gp120IN26191, 
pcDNA-gp120IN25925, pcDNA-gp120IN25710) and trimeric gp140 with an intact 
cleavage site for each sequence (pcDNA-gp140GCN4(+)ZACAP45, pcDNA-
gp140GCN4(+)ZACAP210, pcDNA-gp140GCN4(+)ZA706010164, pcDNA-
gp140GCN4(+)IN26191, pcDNA-gp140GCN4(+)IN25925, pcDNA-
gp140GCN4(+)IN25710. A representation of the gp120 and gp140GCN4(+) 
derived constructs are depicted in Figure 3.1. 
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Figure 3.1: Schematic representation of the native HIV-1 envelope glycoprotein and the 
derived Env constructs used in this study. A) Full length native gp160 precursor. The gp160 
comprises three sets of a gp120 monomer, REKR cleavage site, gp41 ecto-domain 
(gp41ecto), the transmembrane (TM) and the cytoplasmic tail (CT) with the native leader 
peptide sequence (NLP). B) Representation of the monomeric gp120 with a REKR 
cleavage site and CD5 leader sequence. C) Representation of the trimeric gp140GCN4(+), 
which includes three sets of the gp120 monomer, REKR cleavage site and the gp41 ecto-
domain, with a trimeric GCN4 leucine zipper sequence and an intact furin cleavage amino 
acid sequence (GCN4(+)) to form the trimer. 
 
Differences in amino acids and position of potential N-linked glycosylation  
sites (PNLGs) result in differences in the size and structure of the variable 
loops of Env, directly influencing epitope exposure to mAbs (Huang et al., 
2012; Kumar et al., 2011; Patil et al., 2014). Therefore the amino acid 
sequences of the six selected Env sequences (a gp120 and matched 
gp140GCN4(+) of each Env) were examined. The sequences were aligned 
to HXBc2 for conventional numbering and orientation purposes, the CD5 
leader sequence is highlighted in red, the GCN4 motif is highlighted in grey, 
the cleavage site (REKR) is highlighted in green, gp120 contacts for CD4 
are highlighted in yellow (Foley et al., 2015), signature amino acids for 
Indian isolates are highlighted in purple, and PNLGs as predicted by the N-
Glycosylate tool are highlighted in blue (Figure 3.2).  
 
The gp120 sequences ranged from 488 to 510 amino acids, and the 
gp140GCN4(+) sequences ranged from 694 to 716 amino acids. The PNLG 
sites were predicted using the Los Alamos HIV databases tool N-GlycoSite 
(https://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html) 
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where an oligosaccharide chain may be attached to asparagine (N) 
occurring in the tripeptide sequence N-X-S or N-X-T, where X can be any 
amino acid except Proline (Zhang et al., 2004). The number of PNLGs 
ranged between 19 and 29 for the monomeric Env’s which is within the 
expected range for gp120s (Yao et al., 2015) and 23 to 33 for the trimeric 
Env’s. Nine conserved PNLG sites occur in the sequences according to the 
N-GlycoSite tool, in the conserved and variable regions of Env at amino acid 
positions N88, N202 (HXBc2 position 197), N267 (HXBc2 position 262), 
N281 (HXBc2 position 276), N306 (HXBc2 position 301), N345 
(HXBc2 position 339), N362 (HXBc2 position 356), N392 (HXBc2 position 
386) and N454 (HXBc2 position 442). 
 
No major deviations were found between the lengths of the variable loop 
regions of the Env variants, except the V2 loop in which Env variant IN26191 
was found to have a shorter V2 loop of 40 amino acids compared to 45 
amino acids in the other Env variants. All the variable loop lengths were 
within the expected range according to the results published by Yao et al. 
(2015). 
 
Sequence analysis of Indian derived HIV-1 subtype C Env revealed three 
conserved amino acids at positions 346E (HXBc2 position 340) (glutamic 
acid), 357A (HXBc2 position 350) (alanine) and 441E (HXBc2 position 429) 
(glutamic acid), which are highlighted in purple in Figure 3.2 (Shankarappa 
et al., 2001). Only Env IN25710 contains all three amino acids at the 
corresponding positions. 
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Figure 3.2: Amino acid sequence alignment of the HIV-1 envelope glycoprotein (Env) 
sequences (gp120 and gp140GCN4(+)) derived from the selected Indian and South African 
patients. The CD5 leader sequence is highlighted in red, the GCN4 motif is highlighted in 
grey, cleavage site REKR is highlighted in green, gp120 contacts for CD4 are highlighted 
in yellow, the relative position of the signature amino acids for the Indian isolates are 
highlighted in purple, and PNLGs are highlighted in blue. Contact residues important for 
selected bNAb targeting the CD4bs are indicated by symbols as follows: open circles for 
VRC03, club suit for important resides shared by VRC01 and IgG1b12, closed circles for 
IgG1b12, heart for HJ16, diamond for NIH45-46G54W and spade suit sign for VRC-CH31. 
 
                |-----signal peptide---------|gp120 start---------C1--------       
                         *        20         *        40         *        60       
HXBc2         : MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKA :  60 
gp120ZACAP45  : --MPMGSLQPLATLYLL.MLVASV.AV-M--GN...............KA........R. :  55 
gp140ZACAP45  : --MPMGSLQPLATLYLL.MLVASV.AVM---GN...............KA........R. :  55 
gp120ZACAP210 : --MPMGSLQPLATLYLL.MLVASV.ASGM--GN...............K..........G :  56 
gp140ZACAP210 : --MPMGSLQPLATLYLL.MLVASV.ASGM--GN...............K..........G :  56 
gp120ZA706010 : --MAMGSLQPLATLYLL.MLVASV.AVGN--L--..............K........... :  54 
gp140ZA706010 : --MAMGSLQPLATLYLL.MLVASV.AVG---NL-..............K........... :  54 
gp120IN26191  : --MPMGSLQPLATLYLL.MLVASV.AVG---GN...............K........... :  55 
gp140IN26191  : --MPMGSLQPLATLYLL.MLVASV.AVG---GN...............K........... :  55 
gp120IN25925  : --MAMGSLQPLATLYLL.MLVASV.AVGN--L--..............KA.......... :  54 
gp140IN25925  : --MAMGSLQPLATLYLL.MLVASV.AVG---NL-..............KA.......... :  54 
gp120IN25710  : --MPMGSLQPLATLYLL.MLVASV.AVG---GN........................... :  55 
gp140IN25710  : --MPMGSLQPLATLYLL.MLVASV.AVG---GN........................... :  55 
 
                                                                                   
                -----------------------------C1-----------------------------       
                                                    ○                              
                         *        80         *       100         *       120       
HXBc2         : YDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCV : 120 
gp120ZACAP45  : .EK....................IY.G..............D.................. : 115 
gp140ZACAP45  : .EK....................IY.G..............D.................. : 115 
gp120ZACAP210 : .......................I..E..............D...Q.............. : 116 
gp140ZACAP210 : .......................I..E..............D...Q.............. : 116 
gp120ZA706010 : ..R....................MD.E..............D.................. : 114 
gp140ZA706010 : ..R....................MD.E..............D.................. : 114 
gp120IN26191  : .EK....................I..G....D.........D.....V............ : 115 
gp140IN26191  : .EK....................I..G....D.........D.....V............ : 115 
gp120IN25925  : .E.....................I..E.........E....N.....V............ : 114 
gp140IN25925  : .E.....................I..E.........E....N.....V............ : 114 
gp120IN25710  : ..K....................M..G...........E..N.....V............ : 115 
gp140IN25710  : ..K....................M..G...........E..N.....V............ : 115 
 
                                                                                  
                ---------|--V1---------------------|-------------V2---------       
                  ○○                                                ●           
                         *       140         *       160         *       180       
HXBc2         : KLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLD : 180 
gp120ZACAP45  : .......T.R..NATING---.LTEEV-------.......T.EL.D.K..A..L..RP. : 165 
gp140ZACAP45  : .......T.R..NATING---.LTEEV-------.......T.EL.D.K..A..L..RP. : 165 
gp120ZACAP210 : .......T.N.S.AT-YN.GTN.TDT.-------.I....AT.EL.D.KK....L..R.. : 168 
gp140ZACAP210 : .......T.N.S.AT-YN.GTN.TDT.-------.I....AT.EL.D.KK....L..R.. : 168 
gp120ZA706010 : .......T.N..TAIAHNAS.QNITD.-------.S....AT.E..D.KH.VQ.L..... : 167 
gp140ZA706010 : .......T.N..TAIAHNAS.QNITD.-------.S....AT.E..D.KH.VQ.L..... : 167 
gp120IN26191  : .......T.D.ANVTSNITNGEEI----------......AT.DV.D.KKTVS-L..R.. : 164 
gp140IN26191  : .......T.D.ANVTSNITNGEEI----------......AT.DV.D.KKTVS-L..R.. : 164 
gp120IN25925  : .......T.D.ENVDGND-.YNGTNE.-------......TT.EL.D.K..VS.L..R.. : 166 
gp140IN25925  : .......T.D.ENVDGND-.YNGTNE.-------......TT.EL.D.K..VS.L..R.. : 166 
gp120IN25710  : .......T.E.SNVT----Y.E.MKEV-------......LT.EL.D.K..VH.L..R.. : 164 
gp140IN25710  : .......T.E.SNVT----Y.E.MKEV-------......LT.EL.D.K..VH.L..R.. : 164 
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Figure 3.2: Continued 
 
 
                -------------------|--------------------C2------------------       
                  ●●  ●               ○○ 
                         *       200         *       220         *       240       
HXBc2         : IIPIDNDTTSYKLTS-----CNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNG : 235 
gp120ZACAP45  : VV.LNKNSP.GNSSEYILIN....T..........D...........Y............ : 225 
gp140ZACAP45  : VV.LNKNSP.GNSSEYILIN....T..........D...........Y............ : 225 
gp120ZACAP210 : .V.LK.ESE.QNFSEYILIN....T.A........D...........Y............ : 228 
gp140ZACAP210 : .V.LK.ESE.QNFSEYILIN....T.A........D...........Y............ : 228 
gp120ZA706010 : .V.LRENE.NNSF.EYRLIN....A.......I..D...........Y.....K....S. : 227 
gp140ZA706010 : .V.LRENE.NNSF.EYRLIN....A.......I..D...........Y.....K....S. : 227 
gp120IN26191  : .VQLGR-SNTSN---YRLIN....T..........D...........Y............ : 220 
gp140IN26191  : .VQLGR-SNTSN---YRLIN....T..........D...........Y............ : 220 
gp120IN25925  : .V.LNRSSS.NSSDYYRLIS....A........T.D........................ : 226 
gp140IN25925  : .V.LNRSSS.NSSDYYRLIS....A........T.D........................ : 226 
gp120IN25710  : .V.LNDTEKKNSSRPYRLIN....A........T.D.......T...Y......D.K... : 224 
gp140IN25710  : .V.LNDTEKKNSSRPYRLIN....A........T.D.......T...Y......D.K... : 224 
 
                                                                                   
                -------------------------------C2--------------------------|       
                                                ●       ♣♣♣♣♣♣♣♣ 
                                                        ♥  ♦ 
                                     ○                  ○ ○○○○○○ 
                                                        ♠ 
                         *       260         *       280   ♠♠    *       300       
HXBc2         : TGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEIN : 295 
gp120ZACAP45  : ....N...........K................DII.K.E.L.N.I.....H..K....V : 285 
gp140ZACAP45  : ....N...........K................DII.K.E.L.N.I.....H..K....V : 285 
gp120ZACAP210 : ....N...........K......................E.ISN.V.....H..E..N.T : 288 
gp140ZACAP210 : ....N...........K......................E.ISN.V.....H..E..N.T : 288 
gp120ZA706010 : I...N...........K.................II...E.L.N.V.....H..E....V : 287 
gp140ZA706010 : I...N...........K.................II...E.L.N.V.....H..E....V : 287 
gp120IN26191  : K...H.I.........K.................II...E.L.N.V.....H..KP.K.V : 280 
gp140IN26191  : K...H.I.........K.................II...E.L.N.V.....H..KP.K.V : 280 
gp120IN25925  : ....H...........K...............K.II...K.LS..V.....H..E....V : 286 
gp140IN25925  : ....H...........K...............K.II...K.LS..V.....H..E....V : 286 
gp120IN25710  : ....HK..........K...............G.II...E.L.N.......H..Q....V : 284 
gp140IN25710  : ....HK..........K...............G.II...E.L.N.......H..Q....V : 284 
 
                                                                                  
                |-----------------V3----------------|-----------C3----------       
                         ● 
                         *       320         *       340         *       360       
HXBc2         : CTRPNNNTRKRIRIQRGPGRAFVTIGKIGNM-RQAHCNISRAKWNNTLKQIASKLREQFG : 354 
gp120ZACAP45  : .R........S...--...Q..YATND.IGDI.......NNST..R..E..-K.KLREHF : 342 
gp140ZACAP45  : .R........S...--...Q..YATND.IGDI.......NNST..R..E..-K.KLREHF : 342 
gp120ZACAP210 : .I..G....RS...--...Q..YAM.D.IGNI.E......EKA..E...KV-VEKLVKYF : 345 
gp140ZACAP210 : .I..G....RS...--...Q..YAM.D.IGNI.E......EKA..E...KV-VEKLVKYF : 345 
gp120ZA706010 : ....G.....S...--...QT.-AT.DVIGDI.E......K.E..K..Q.V-GRKLAEHF : 343 
gp140ZA706010 : ....G.....S...--...QT.-AT.DVIGDI.E......K.E..K..Q.V-GRKLAEHF : 343 
gp120IN26191  : ....G.....S...--...QT.YAT.E.IGNI........KEE..K..QGV-GEKLAEHF : 337 
gp140IN26191  : ....G.....S...--...QT.YAT.E.IGNI........KEE..K..QGV-GEKLAEHF : 337 
gp120IN25925  : ..........S...--...QT.YAT.A.IGNI.E.......D...E..QRV-G.KL.EQF : 343 
gp140IN25925  : ..........S...--...QT.YAT.A.IGNI.E.......D...E..QRV-G.KL.EQF : 343 
gp120IN25710  : .A..S....TS...--...QT.YAT.A.TGDI........KD...E..QRV-GEKLAEHF : 341 
gp140IN25710  : .A..S....TS...--...QT.YAT.A.TGDI........KD...E..QRV-GEKLAEHF : 341 
Key: Residues on gp120/gp140GCN4(+) important for binding to the following bNAbs: 
○ VRC03; ♣ VRC01 and IgG1b12; ● IgG1b12; ♥ HJ16; ♦ NIH45-46G54W; ♠ VRC-CH31. 
3-72 
 
 
 
Figure 3.2: Continued   
                -------------C3---------------|-------------V4--------------     
                       ♣♣♣♣♣♣♣♣♣♣♣♣♣ 
                             ♦      
                          ○○○○○○○  ○                 
                         *       380         *       400         *       420       
HXBc2         : NNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSD-- : 412 
gp120ZACAP45  : L.R..E.ESP....L.VT..............-.TRLFKWSS.V.ND------------- : 388 
gp140ZACAP45  : L.R..E.ESP....L.VT..............-.TRLFKWSS.V.ND------------- : 388 
gp120ZACAP210 : P....E.APPV...L..T..............-.TKLFNSTH...D..VN.TDSTAETGN : 404 
gp140ZACAP210 : P....E.APPV...L..T..............-.TKLFNSTH...D..VN.TDSTAETGN : 404 
gp120ZA706010 : P.T..K.NP.....L..T......R.......-.EKLFNGTY...YWPRYNASHN.---- : 398 
gp140ZA706010 : P.T..K.NP.....L..T......R.......-.EKLFNGTY...YWPRYN-ASHNG--- : 398 
gp120IN26191  : P....E.TSP....L..T......R.......-.SDLFNGIY.G.YIPK.NL.S------ : 390 
gp140IN26191  : P....E.TSP....L..T......R.......-.SDLFNGIY.G.YIPK.NL.S------ : 390 
gp120IN25925  : P....N.TS.....L..T......R.......-.SKLFNSTYIP.YRPNNTQGNSS.--- : 399 
gp140IN25925  : P....N.TS.....L..T......R.......-.SKLFNSTYIP.YRPNN-TQGNS.--- : 398 
gp120IN25710  : P....K.NS.....L..T......R.......-.SGLFNGT..G.YVSPN.TDSNS.--- : 397 
gp140IN25710  : P....K.NS.....L..T......R.......-.SGLFNGT..G.YVSPN.TDSNS.--- : 397 
 
 
                                                                                   
                ---------|-----------------C4---------------------|--V5-----       
                                                               ♦ ♦♦ 
                                                                 ♣♣♣♣♣♣♣♣ 
                                ○○○ ○○○                       ○○○○○○○ ○ ○ 
                                                               ♠ ♠♠ 
                         *       440         *       460         *       480       
HXBc2         : ----TITLPCRIKQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNES--- : 465 
gp120ZACAP45  : ----...I......F.....G..R.......E.N.T.N.S...........K--TDRNDT : 442 
gp140ZACAP45  : ----...I......F.....G..R.......E.N.T.N.S...........K-TDRND-T : 442 
gp120ZACAP210 : STNTN.......R.......E..R......SK.N.T.I.............ENKT.NNDT : 464 
gp140ZACAP210 : STNTN.......R.......E..R......SK.N.T.I.............ENKT.NNDT : 464 
gp120ZA706010 : ---TN...S...........E..R.I.N...A.N.T.K........V....IT..N---T : 452 
gp140ZA706010 : ---TN...S...........E..R.I.N...A.N.T.K........V....I--TNNN-T : 452 
gp120IN26191  : ----...IQ.K...F.....E..R.......Q.N.T.E........V.......S---TE : 443 
gp140IN26191  : ----...IQ.K...F.....E..R.......Q.N.T.E........V.......S--T-E : 443 
gp120IN25925  : ----...I............E..R.......A.N.T.K.H......V....TGL.S.TET : 455 
gp140IN25925  : ---S...I............E..R.......A.N.T.K.H......V....TGL.S.--T : 453 
gp120IN25710  : ---SI..I............E..R.......A.N.T.K........V....TGSESNK-T : 453 
gp140IN25710  : ---SI..I............E..R.......A.N.T.K........V....TGSESNK-T : 453 
 
                                                                                  
                -----|--------------C5-------------|gp120 end|gp41 start----       
                ♣♣♣♣ 
                ○○ ○  ○○○○ 
                        ♥♥♥ 
                         *       500         *       520         *       540       
HXBc2         : EIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGA : 525 
gp120ZACAP45  : ........N.K....N........E.K.......E.R....E....-------------- : 488 
gp140ZACAP45  : ........N.K....N........E.K.......E.R....E..........VL...... : 502 
gp120ZACAP210 : ..........K.............E.K.......R......E....-------------- : 510 
gp140ZACAP210 : ..........K.............E.K.......R......E..........V....... : 524 
gp120ZA706010 : .T......................E.N..............E....-------------- : 498 
gp140ZA706010 : .T......................E.N..............E.......V..M.....S. : 512 
gp120IN26191  : ........................E.K.......D......E.G..-------------- : 489 
gp140IN26191  : ........................E.K.......D......E.G...AL-..V....... : 502 
gp120IN25925  : F--.....................E.K.......A...........-------------- : 499 
gp140IN25925  : .T......................E.K.......A..............L..V....... : 513 
gp120IN25710  : ........................E.K..............E....-------------- : 499 
gp140IN25710  : ........................E.K..............E..........V....... : 513 
Key: Residues on gp120/gp140GCN4(+) important for binding to the following bNAbs: 
○ VRC03; ♣ VRC01 and IgG1b12; ● IgG1b12; ♥ HJ16; ♦ NIH45-46G54W; ♠ VRC-CH31. 
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Figure 3.2: Continued  
                                                                                 
                ------------------------------------------------------------       
                         *       560         *       580         *       600       
HXBc2         : AGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVER : 585 
gp120ZACAP45  : ------------------------------------------------------------ :   - 
gp140ZACAP45  : .........I.................S...........M............T.V..I.. : 562 
gp120ZACAP210 : ------------------------------------------------------------ :   - 
gp140ZACAP210 : .........I.................S...........M............T.V..I.. : 584 
gp120ZA706010 : ------------------------------------------------------------ :   - 
gp140ZA706010 : .........I.................S...........M..............V..I.. : 572 
gp120IN26191  : ------------------------------------------------------------ :   - 
gp140IN26191  : .........I.................S........................T.V..I.. : 562 
gp120IN25925  : ------------------------------------------------------------ :   - 
gp140IN25925  : .........I.................S...........M............T.V..I.. : 573 
gp120IN25710  : ------------------------------------------------------------ :   - 
gp140IN25710  : .........I.................S........................T.V..I.. : 573 
 
                                                                                   
                ------------------------------------------------------------       
                         *       620         *       640         *       660       
HXBc2         : YLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSL : 645 
gp120ZACAP45  : ------------------------------------------------------------ :   - 
gp140ZACAP45  : .........L...........N....S......QTD..DNM..IQ.....S..SNT.YK. : 622 
gp120ZACAP210 : ------------------------------------------------------------ :   - 
gp140ZACAP210 : .....................N....S......YGD..DNM...Q.........NT.YR. : 644 
gp120ZA706010 : ------------------------------------------------------------ :   - 
gp140ZA706010 : .........L................N......QSD..ENM...Q.........NT.YR. : 632 
gp120IN26191  : ------------------------------------------------------------ :   - 
gp140IN26191  : ..........................I......YHE..DNM...Q..K..S...DQ.YR. : 622 
gp120IN25925  : ------------------------------------------------------------ :   - 
gp140IN25925  : ..........................T....R.QAD..GNM...Q.....S...NT.FR. : 633 
gp120IN25710  : ------------------------------------------------------------ :   - 
gp140IN25710  : ..........................Y....R.QDD..DNM...Q..K..S...NT.YK. : 633 
 
                                                                                  
                --------------------------------------|transmembrane domain|       
                         *       680         *       700         *       720       
HXBc2         : IEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIV : 705 
gp120ZACAP45  : ------------------------------------------------------------ :   - 
gp140ZACAP45  : L.D......Q..KD..A..S.NN...............I.MKQIEDKIEEILSKIYHIEN : 682 
gp120ZACAP210 : ------------------------------------------------------------ :   - 
gp140ZACAP210 : L.D..........D..A....Q...S..S.SS......I.MKQIEDKIEEILSKIYHIEN : 704 
gp120ZA706010 : ------------------------------------------------------------ :   - 
gp140ZA706010 : L....T......KD..A..S.KN...............IGMKQIEDKIEEILSKIYHIEN : 692 
gp120IN26191  : ------------------------------------------------------------ :   - 
gp140IN26191  : L.V......S..KD..A.NS.N......D.........I.MKQIEDKIEEILSKIYHIEN : 682 
gp120IN25925  : ------------------------------------------------------------ :   - 
gp140IN25925  : L.D..I...S..KD..A..S.KN..S..D.........IGMKQIEDKIEEILSKIYHIEN : 693 
gp120IN25710  : ------------------------------------------------------------ :   - 
gp140IN25710  : L.D..I......KD..A..S.EN...............I.MKQIEDKIEEILSKIYHIEN : 693 
 
 
                                                                                   
                cytoplasmic tail start--------------------------------------       
                         *       740         *       760         *       780       
HXBc2         : NRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCL : 765 
gp120ZACAP45  : ------------------------------------------------------------ :   - 
gp140ZACAP45  : EIA.IKKLIGEV------------------------------------------------ : 694 
gp120ZACAP210 : ------------------------------------------------------------ :   - 
gp140ZACAP210 : EIA.IKKLIGEV------------------------------------------------ : 716 
gp120ZA706010 : ------------------------------------------------------------ :   - 
gp140ZA706010 : EIA.IKKLIGEV------------------------------------------------ : 704 
gp120IN26191  : ------------------------------------------------------------ :   - 
gp140IN26191  : EIA.IKKLIGEV------------------------------------------------ : 694 
gp120IN25925  : ------------------------------------------------------------ :   - 
gp140IN25925  : EIA.IKKLIGEV------------------------------------------------ : 705 
gp120IN25710  : ------------------------------------------------------------ :   - 
gp140IN25710  : EIA.IKKLIGEV------------------------------------------------ : 705 
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Figure 3.2: Continued 
 
 
3.1.1 Analysis of amino acid residues important for CD4 binding site 
directed bNAbs 
The CD4bs epitope is highly conserved due to its critical function in viral 
entry, thus making it an attractive target for vaccine elicited antibody 
responses (Li et al., 2007; Wyatt and Sodroski, 1998). One of the most 
characterized CD4bs bNAbs, IgG1b12, is capable of neutralizing 30 – 40 % 
of primary isolates of subtype B and C viruses (Bures et al., 2002). 
Interestingly, HIV-1 subtype C viruses of Indian origin have been found to 
display increased levels of IgG1b12 resistance (Kulkarni et al., 2009; Sneha 
et al., 2015). To this end, we decided to examine the amino acid differences 
of each gp120/gp140GCN4(+) Env variants in respect of their CD4bs 
epitopes.  
 
                ------------------------------------------------------------       
                         *       800         *       820         *       840       
HXBc2         : FSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEG : 825 
gp120ZACAP45  : ------------------------------------------------------------ :   - 
gp140ZACAP45  : ------------------------------------------------------------ :   - 
gp120ZACAP210 : ------------------------------------------------------------ :   - 
gp140ZACAP210 : ------------------------------------------------------------ :   - 
gp120ZA706010 : ------------------------------------------------------------ :   - 
gp140ZA706010 : ------------------------------------------------------------ :   - 
gp120IN26191  : ------------------------------------------------------------ :   - 
gp140IN26191  : ------------------------------------------------------------ :   - 
gp120IN25925  : ------------------------------------------------------------ :   - 
gp140IN25925  : ------------------------------------------------------------ :   - 
gp120IN25710  : ------------------------------------------------------------ :   - 
gp140IN25710  : ------------------------------------------------------------ :   - 
 
                                                                                   
                -----------cytoplasmic tail end|          
                         *       860         *            
HXBc2         : TDRVIEVVQGACRAIRHIPRRIRQGLERILL---- : 856 
gp120ZACAP45  : ----------------------------------- :   - 
gp140ZACAP45  : ----------------------------------- :   - 
gp120ZACAP210 : ----------------------------------- :   - 
gp140ZACAP210 : ----------------------------------- :   - 
gp120ZA706010 : ----------------------------------- :   - 
gp140ZA706010 : ----------------------------------- :   - 
gp120IN26191  : ----------------------------------- :   - 
gp140IN26191  : ----------------------------------- :   - 
gp120IN25925  : ----------------------------------- :   - 
gp140IN25925  : ----------------------------------- :   - 
gp120IN25710  : ----------------------------------- :   - 
gp140IN25710  : ----------------------------------- :   - 
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Recently isolated bNAbs targeting the CD4bs have shown increased 
potency and breadth, and retain neutralizing activity against IgG1b12 
resistant viruses (Li et al., 2007). We propose that including an Env 
immunogen that is resistant to neutralization by IgG1b12 could potentially 
reveal further characteristics of the CD4bs epitope that may be applicable 
to vaccine design and preferentially select for the more potent VRC01-type 
Abs. 
 
Here we analysed the amino acid residues important for binding to six 
CD4bs-directed bNAbs; IgG1b12, VRC01, HJ16, VRC-CH31, NIH45-
46G54W and VRC03 (Figure 3.2) (Wu et al., 2011). Critical amino acid 
residues for bNAb binding are indicated as follows: open circles for VRC03, 
club suit symbol for important resides shared by VRC01 and IgG1b12, 
closed circles for IgG1b12, heart for HJ16, diamond for NIH45-46G54W and 
spade suit symbol for VRC-CH31.  
 
Several amino acid differences were noted amongst the Env variants. Env 
ZACAP45 has a glycine (G) at position 441 (HXBc2 position 429) whereas 
the other Env’s have a negatively charged glutamic acid (E). This affects 
the charge of the protein in that region. Env IN26191 is lacking the N294 N-
linked glycan, which is present in the other Env variants and Env’s 
ZACAP45 and IN26191 lack an N-linked glycan at position 185-190. 
 
The following amino acid mutations, known to confer resistance to IgG1b12 
according to a study published by Gnanakaran et al. (2010), were noted in 
the sequences: serine or histidine at position 173 in all the Env variants of 
Indian origin; glycine (G) at amino acid position 185 in Env 
gp120/gp140GCN4(+)IN26191; and lysine (K) at amino acid position 273 
(HXBc2 position 268) in Env gp120/gp140GCN4(+)IN25925. 
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Amino acid mutations reported to confer resistance to bNAb HJ16 binding 
(Balla-Jhagjhoorsingh et al., 2013) are present in Env ZACAP45 (D489N, 
HXBc2 position 474) and Env’s ZACAP45 and ZACAP210 R491K (HXBc2 
position 476), respectively.  
 
Guided by the bioinformatic analyses we sought to obtain definitive bNAb 
biochemical binding data, as slight variations in amino acid sequence, 
including non-contact residues, may influence conformational epitopes of 
the CD4bs (Li et al., 2011).  This was performed by expressing and purifying 
each gp120/gp140GCN4(+) Env variant, followed by antigenicity analysis 
with the six CD4 directed bNAbs mentioned above. 
 
3.2 Expression and purification of the recombinant 
gp120/gp140GCN4(+) Env variants and 2dCD4 proteins 
3.2.1 Expression of recombinant gp120/gp140GCN4(+) Env variants 
Transient recombinant expression of HIV-1 Env protein was optimized in 
HEK293T cells. Expression was confirmed by reducing-SDS-PAGE 
followed by Western blotting (Figure 3.3). As expected, the gp120 
constructs expressed Env that migrated to approximately 120 kDa, and the 
gp140GCN4(+) constructs expressed Env which migrated to approximately 
140 kDa (Figure 3.3). Two bands were observed for some of the 
gp140GCN4(+) Envs, one at 140 kDa representing the uncleaved protein 
(encompassing both gp120 and gp41), and cleaved gp120 portion (120 
kDa). A high molecular weight band, resistant to reducing agent (β-
mercaptoethanol), was observed at approximately 260 kDa for Env 
gp140GCN4(+)IN26191 and was suspected to be higher order oligomers of 
this Env. 
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Figure 3.3: Western blot analysis of transient HIV-1 envelope glycoprotein (Env) 
expression in HEK293T cells with Indian and South African Env constructs. Cell culture 
supernatants were analysed for expression of each Env by SDS-PAGE (10 % gel) followed 
by Western blotting by probing with HIV-1 positive patient sera and detection with a 
secondary antibody (goat anti-human IgG (Fc specific) alkaline phosphatase conjugated 
antibody. The molecular weight sizes are indicated on the left in kiloDaltons (kDa). Arrows 
on the right indicate the relative positions of gp120 and gp140.  
 
Subsequently, stable cell lines (293F) expressing each of the 12 Envs were 
established, and used for large-scale expression of recombinant Env 
(results not shown). Cell culture supernatant from the transient expression 
experiments and Env expressing stable cell lines was collected, filtered and 
stored at -20°C for subsequent use in the purification protocols.  
 
3.2.2 Purification of gp120/gp140GCN4(+) Env variants 
3.2.2.1 Primary purification of Env variants by lectin-affinity 
chromatography 
Env was purified from the stored cell culture supernatants using Galanthus 
nivalis lectin-affinity chromatography, and SDS-PAGE (10 %) under 
reducing conditions was used to assess the purity and confirm elution of the 
recombinant proteins corresponding to expected sizes (Figure 3.4). 
Following lectin affinity chromatography, protein yields of the different Env’s 
ranged from 0.5 to 10 mg per litre of culture supernatant as determined by 
colorimetric BCA total protein quantification. Varying degrees of furin-
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cleavage efficiency were observed for the purified gp140GCN4(+) Envs  as 
determined by SDS-PAGE analysis (Figure 3.4). In addition, high molecular 
weight bands at approximately 260 kDa were observed for some of the 
Env’s (gp140GCN4(+)IN26191, gp120ZACAP45, gp140GCN4(+)ZACAP45, 
gp1401GCN4(+)ZA06010164) and was attributed to higher order oligomers of 
the Env.  
 
It is well recognised that mammalian expression and purification of Env 
results in various species and/or higher order oligomers, and that lectin 
affinity purification does not differentiate the Env conformations of interest. 
Thus, the presence of these mixed Env species warranted further 
purification since monomeric and trimeric conformations of each Env 
variant were required for characterization. Samples were aliquoted, snap 
frozen, and stored at -80°C until further purification.  
 
 
Figure 3.4: Coomassie stained SDS-PAGE (10 %) analysis of the Indian and South African 
HIV-1 envelope glycoproteins to assess purity after Galanthus nivalis lectin-affinity 
purification. Molecular weight marker (Mw - Spectra™ Multicolor Broad Range Protein 
Ladder) is shown on the left in kiloDaltons (kDa). Arrows on the right indicate the gp120 
and gp140GCN4(+). 
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3.2.2.2 Secondary purification of Env variants by size exclusion 
chromatography (SEC) 
To further purify the monomeric and trimeric conformations of each Env to 
homogeneity, eluate from the lectin affinity chromatography was separated 
using SEC. Examination of the SEC chromatograms of the gp120 
glycoproteins (Figure 3.5) revealed that the gp120 glycoproteins consisted 
of two dominant peaks, corresponding to dimeric and monomeric 
conformations. Based on the SEC chromatogram a higher proportion of 
dimer compared to monomer was observed for the majority of the gp120 
expressed proteins. 
 
The dimeric gp120 peak retention volumes ranged between 59 – 63 ml for 
the different Env’s, whereas the monomeric gp120 peak retention volumes 
ranged between 67 – 71 ml. Fractions were collected for the dimeric gp120 
as well as the monomeric gp120 (indicated by shaded areas in Figure 3.5) 
to isolate homogeneous dimers and monomers for each Env.  
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Figure 3.5: Size exclusion chromatograms of the six lectin-affinity purified gp120 HIV-1 
envelope glycoproteins (Envs). Peak-retention volumes are indicated above the peaks; 
areas shaded with diagonal lines represent the dimeric and higher order oligomeric 
conformations of the Env and the grey-shaded areas represent the fractions collected for 
the monomeric Env conformation. One representative chromatogram is shown for each 
Env.  
 
The lectin-purified gp140GNC4(+) Env yielded similar SEC profiles (Figure 
3.6) comprising three distinct peaks.  The first peak representing an 
oligomeric form with a peak retention volume between 46 – 49 ml, the 
second peak representing the trimeric conformation eluted between 46 – 53 
ml and a third peak corresponding to the cleavage monomeric gp120 eluted 
at approximately 67 ml.  
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Figure 3.6: Size exclusion chromatograms of the six lectin-affinity purified gp140GCN4(+) 
HIV-1 envelope glycoproteins (Envs). Peak-retention volumes are indicated above the 
peaks; shaded areas represent the fractions collected for the gp140GCN4(+) Env 
conformation. One representative chromatogram is shown for each Env.  
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An overlay of a normalised SEC chromatograms for each Env (Figure 3.7) 
illustrates that each Env has a similar SEC profile. The slight differences in 
peak retention volumes may be attributed to amino acid sequence variation 
of the Env, as well as differences in glycosylation of each Env, resulting in 
different molecular weights.  
  
 
Figure 3.7: Overlay of normalized size exclusion chromatograms for each of the 12 HIV-1 
envelope glycoproteins.  (A) Env’s of South African origin. (B) Env’s of Indian origin. 
Showing a comparison of the profiles for the different conformations (oligomer, trimer 
(gp140GCN4(+)), dimer, monomer (gp120)). Similar profiles were obtained for each 
conformation, with slight variations being attributed to amino acid sequence differences, 
and therefore molecular weight and glycosylation differences.  
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The relevant trimer, dimer and monomer containing fractions were pooled, 
concentrated and assessed for purity using Coomassie blue stained SDS-
PAGE (4-12 %) under reducing conditions (Figure 3.8). Despite numerous 
optimization attempts, SEC was unable to remove the contaminating bands 
observed in the lectin purified glycoproteins seen in Figure 3.7. The amount 
of recombinant protein was colorimetrically quantified. Fractions were then 
aliquoted, snap frozen, and stored at -80°C for use in subsequent 
biochemical characterization, complex formation and/or immunization 
protocols.  
 
Figure 3.8: Coomassie stained SDS-PAGE (4 – 12 %) analysis of the monomeric and 
trimeric Indian and South African HIV-1 envelope glycoproteins post SEC.  Molecular 
weight marker (Mw - SeeBlue prestained protein standard) is shown on the left in 
kiloDaltons (kDa). 
 
Both the monomeric and dimeric species migrated to approximately 120 
kDa for all the Env’s, which is to be expected under reducing conditions. 
The gp140GCN4(+) species resolved to approximately 140 kDa for all the 
constructs, and as described in section 3.2.1 above, in some cases a 
cleaved gp120 portion was noted, suggesting the presence of a cleaved 
trimeric conformation. The corresponding partial gp41 component of the 
cleaved portion was not clearly visible on the gel, perhaps due to insufficient 
concentration. The gp140GCN4(+)IN25710 produced a band which resolved 
to approximately 200 kDa. This large difference in size of this Env was also 
noted during SEC, where the gp140GCN4(+) constructs had a peak 
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retention volume ranging between 50 – 53 ml, however, the 
gp140GCN4(+)IN25710 construct had a peak retention volume of around 46 
ml. This may be a result of higher order oligomers or dimers of trimers as 
noted above. 
 
The final yield of purified gp120 or gp140GCN4(+) recombinant protein 
obtained from one litre of cell culture supernatant varied between the 
different Envs and ranged between 0.1 to 2 mg, with higher yields generally 
obtained for the gp120’s compared to the gp140GCN4(+)’s (Table 3.1).  
 
Table 3.1: Average yield of conformation specific purified forms of Env from 1 litre of cell 
culture supernatant by lectin affinity chromatography followed by further purification using 
size exclusion chromatography. 
Env Final yield (mg/litre) 
gp120ZACAP45 2.00 
gp140GCN4(+)ZACAP45 1.00 
gp120ZACAP210 2.00 
gp140GCN4(+)ZACAP210 0.15 
gp120ZA706010164 1.00 
gp140GCN4(+)ZA706010164 0.45 
gp120IN25925 2.00 
gp140GCN4(+)IN25925 2.00 
gp120IN25710 0.20 
gp140GCN4(+)IN25710 0.04 
gp120 IN26191 0.40 
gp140GCN4(+)IN26191 0.10 
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3.2.3 Expression and purification of recombinant 2dCD4Wt/FD/S60C  
Three recombinant 2dCD4 proteins for Env/2dCD4 complex formation were 
successfully expressed and purified in E. coli BL21 (DE3), namely wild type 
(Wt), folding-defective (FD) and one in which the serine at position 60 is 
substituted with cysteine (S60C). These proteins were purified under 
denaturing conditions using Ni2+ affinity chromatography and re-folded 
using an oxidative post-purification refolding protocol (Cerutti et al., 2010).  
 
The 2dCD4(Wt/FD/S60C) purified proteins were analysed using SDS-PAGE (4-
12 %), and as expected all three 2dCD4 proteins resolved to approximately 
25 kDa (Figure 3.9). One litre of E. coli routinely yielded between 1 – 2 mg 
of purified recombinant protein for each 2dCD4 variant. Aliquots of each 
2dCD4 were aliquoted, snap frozen, and stored at -80°C until used in 
subsequent biochemical characterization, complex formation or 
immunization protocols.  
 
Figure 3.9: Coomassie stained SDS-PAGE analysis of purified 2dCD4 variants.  The 
2dCD4FD refers to the folding defective control, 2dCD4S60C refers to the 2dCD4 in which the 
serine at position 60 is substituted with cysteine (S60C) and 2dCD4Wt refers to the wild-
type 2dCD4. Molecular weight marker (Mw - Spectra™ Multicolor Broad Range Protein 
Ladder) is shown on the left in kiloDaltons (kDa). Arrow on the right shows the 2dCD4 
variants. 
 
2dCD4 
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3.3 Antigenicity analysis of the gp120/gp140GCN4(+) Env variants 
3.3.1 Surface plasmon resonance interactions of Env 
gp120/gp140GCN4(+) variants with 2dCD4Wt/S60C 
We first aimed to assess the structural integrity of the CD4bs of the 
monomeric and trimeric (gp120/gp140GCN4(+) Env variant) conformations 
by performing real-time binding experiments to surface immobilised 
2dCD4Wt and 2dCD4S60C using SPR. Non-specific analyte interaction with 
the control surface was too high for kinetics to be determined as shown by 
the interspot data (interspots > 10% RMAX) (Appendix B1 and B2) (Bio-Rad 
Laboratories Inc., 2009; Marquart, 2006-2016). However, the sensorgrams 
showed that all the Env variants were able to bind 2dCD4Wt and 2dCD4S60C 
to varying degrees (Figures 3.10 and 3.11) which confirmed that the CD4bs 
epitope on the Env’s was conformationally intact and functional. 
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Figure 3.10: SPR sensorgrams showing binding of increasing concentrations of gp120 and 
gp140GCN4(+) conformations of the HIV-1 envelope glycoproteins of South African origin 
to 2dCD4Wt and 2dCD4S60C. 2dCD4Wt and 2dCD4S60C were covalently captured onto 
separate flow cells on the chip at a concentration of 0.02 mg/ml at a flow rate of 30 µl/min 
for 300 s to a final RU of 2000. The gp120 and gp140GCN4(+) Env’s were passed over the 
ligands at a flow rate of 30 µl/min for 300 s with a dissociation time of 600 s.  
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Figure 3.11: SPR sensorgrams showing binding of increasing concentrations of gp120 and 
gp140GCN4(+) conformations of the HIV-1 envelope glycoproteins of Indian origin to 
2dCD4Wt and 2dCD4S60C. 2dCD4Wt and 2dCD4S60C were covalently captured onto separate 
flow cells on the chip at a concentration of 0.02 mg/ml at a flow rate of 30 µl/min for 300 s 
to a final RU of 2000. The gp120 and gp140GCN4(+) Env’s were passed over the ligands 
at a flow rate of 30 µl/min for 300 s with a dissociation time of 600 s. 
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3.3.2 Surface plasmon resonance binding kinetics of the CD4bs 
directed bNAbs 
The antigenicity of the Env variants was evaluated in respect of their CD4bs 
region using the bNAbs mentioned above (IgG1b12, VRC01, HJ16, VRC-
CH31, NIH45-46G54W, VRC03) and trimeric conformation using bNAb 
PGT145. The low yields obtained for some of the Env variants during 
mammalian cell culture expression limited the extent of the SPR analysis 
that could be performed. Initial screening was performed using single-
analyte concentration of the Env variants to surface immobilized bNAbs 
(Table 3.2). Table 3.3 provides an overview of the full kinetic experiments 
performed.   
 
 
Table 3.2: Summary of single-analyte concentrations of the gp120/ gp140GCN4(+) 
Env variants used to screen binding to surface immobilized bNAbs. 
Env IgG1b12 VRC01 HJ16 VRC-CH31 
NIH45-
46G54W VRC03 PGT145 
gp120ZACAP45       ND 
gp140ZACAP45       ND 
gp120ZACAP210        
gp140ZACAP210       ND 
gp120ZA706010164       ND 
gp140ZA706010164       ND 
gp120IN26191       ND 
gp140IN26191 ND ND ND ND ND ND ND 
gp120IN25925        
gp140IN25925        
gp120IN25710        
gp140IN25710        
 = SPR done 
ND =no SPR done, therefore binding not determined. 
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3.3.2.1 Env gp120/gp140GCN4(+) variant interactions with bNAbs 
Having ascertained the structural integrity of the CD4bs of each of the Env 
variants, we next examined the interaction between the 
gp120/gp140GCN4(+) and selected CD4bs bNAb’s by determining binding 
affinities using SPR. Single-analyte concentrations of 1000 nM of each of 
the gp120/gp140GCN4(+) Env variants were used to screen for binding to 
surface immobilized CD4bs-directed bNAbs (0.02 mg/ml) IgG1b12, VRC01, 
HJ16, VRC-CH31, NIH45-46G54W and VRC03. Furthermore bNAb PGT145, 
which recognises a quaternary-structure-specific epitope in the V1V2 region 
of Env (Yasmeen et al., 2014) was used to assess the trimeric conformation 
of some the gp140GCN4(+) proteins relative to their gp120 monomers. 
Sufficient quantities were only available for gp120/gp140GCN4(+)IN25925 and 
gp120/gp140GCN4(+)IN25710.  
 
Initial screening confirmed that the CD4bs-directed bNAbs were able to bind 
with varying degrees to both the monomeric and trimeric Envs (Figure 3.12 
and 3.13). Furthermore this experiment confirmed that the antibodies were 
immoblilized on the chip in a biologically active conformation and provided 
an indication of the concentration range required to obtain accurate kinetic 
data.  
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Figure 3.12: SPR sensorgrams of the binding response (RU) of single analyte 
concentrations (1000 nM) of gp120 Env variants to surface-immobilised monoclonal 
antibodies (A) IgG1b12, (B) VRC01, (C) HJ16, (D) VRC-CH31, (E) NIH5-46G54W and (F) 
VRC03 over time (s).  Association time was 300 s and dissociation time was 600 s. 
Monomeric and trimeric (Figure 3.13) proteins were run on the same chip, and PBS-T was 
included as a non-specificity binding control (Refer to Figure 3.13). 
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Figure 3.13: SPR sensorgrams of the binding response (RU) of single analyte 
concentrations (1000 nM) of gp140GCN4(+) Env variants to surface immobilised 
monoclonal antibodies (A) IgG1b12, (B) VRC01, (C) HJ16, (D) VRC-CH31, (E) NIH5-
46G54W and (F) VRC03 over time (s).  Association time was 300 s and dissociation time was 
600 s. No bNAb binding was performed with Env gp140GCN4(+)IN26191 due to insufficient 
quantities of this Env. Monomeric (Figure 3.12) and trimeric proteins were run on the same 
chip, and PBS-T was included as a non-specificity binding control.  
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In order to characterize the gp120/gp140GCN4(+) Env variant interactions 
with CD4bs bNAbs in more detail, their binding affinities were determined 
using SPR (fits depicted in Figures 3.14 – 3.20 and kinetics tabulated in 
Table 3.4 and 3.5). The 1:1 Langmuir binding model was applied to the data 
to determine their binding kinetics. In some cases mass transfer was 
observed and binding kinetics were calculated by correcting for this using 
the ProteON manager software. In cases where mass transfer (Kt) was 
calculated by the ProteON manager software to be less than 1 x 108 (Table 
3.4) a 1:1 Langmuir model with correction for mass transfer was applied to 
these analyses.  
 
As mentioned earlier, the low yields obtained for some of the Env variants 
during mammalian cell culture expression limited the extent of the SPR 
analysis that could be performed (refer to table 3.3 for further details). 
 
IgG1b12 
The first bNAb evaluated, was the CD4bs directed bNAb IgG1b12. Accurate 
binding kinetics was only obtained for Env variant gp140GCN4(+)ZACAP45 
against IgG1b12 with an overall KD binding affinity of 0.424 nM. (Figure 
3.14). Although binding was observed for the other Env variants tested, they 
did not fit the 1:1 Langmuir model (even with factoring in the mass transfer 
effect), therefore the strength of the interaction could not be accurately 
determined. Interestingly, Env variants IN25710 and IN25925, reported to 
be resistant to neutralization by IgG1b12 (Kulkarni et al., 2009) showed 
binding to this bNAb, which was improved for the trimeric conformations 
compared to the monomeric ones (Figure 3.14).  
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Figure 3.14: SPR sensorgrams of gp120/gp140GCN4(+) Env variant binding to 
immobilised bNAb IgG1b12 over time (s). Association time was 300 s and dissociation time 
was 600 s. For Env gp120IN25710 association time was 200 s. Concentrations of Env variants 
used are shown in each sensorgram. Kinetic constants and binding affinities (Table 3.4 and 
3.5) were calculated by fitting (black curves) using a 1:1 Langmuir model. 
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VRC01 
Next we evaluated the CD4bs directed bNAb VRC01, which bound strongly 
to the Env variants derived from Indian patients (Figure 3.15). An 
approximate ten-fold increase in binding affinity was observed for the 
ZACAP45 trimeric protein ((gp140GCN4(+)) compared to the monomeric 
conformation (gp120), (18.7 nM and 139 nM, respectively (Figure 3.15). A 
similar pattern was observed for the IN25925 trimeric and monomeric Env 
conformations, however the dissociation rate could not be calculated for the 
trimer, as insufficient time was allowed for observable decay and thus an 
overall binding affinity could not be determined (Bio-Rad Laboratories Inc., 
2011; Marquart, 2006-2016). The monomeric and trimeric conformations of 
Env IN25710 showed very little difference in their interaction with VRC01. 
Again the markedly slow dissociation observed for Env variants 
gp120/gp140GCN4(+)IN25710 and gp140GCN4(+)IN25925 could not be 
accurately quantified. 
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Figure 3.15: SPR sensorgrams of gp120/gp140GCN4(+) Env variant binding to 
immobilised bNAb VRC01 over time (s). Association time was 300 s and dissociation time 
was 600 s. For Env gp120IN25710 association time was 200 s. Concentrations of Env variants 
used are shown in each sensorgram. Kinetic constants and binding affinities (Table 3.4 and 
3.5) were calculated by fitting (black curves) using a 1:1 Langmuir model. 
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HJ16 
SPR analysis for the interaction between HJ16 was limited to Env variants 
gp120/gp140GCN4(+)ZACAP45 and gp120/gp140GCN4(+)IN25925 (Figure 
3.16). Negligible binding was observed for both the monomeric and trimeric 
conformations of Env ZACAP45 with HJ16. However, Env IN25925 was 
able to bind to HJ16, with improved binding observed for the trimeric 
conformation with a binding affinity of 21.6 nM compared to 93.2 nM for the 
monomeric conformation. 
 
 
Figure 3.16: SPR sensorgrams of gp120/gp140GCN4(+) Env variant binding to 
immobilised bNAb HJ16 over time (s). Association time was 300 s and dissociation time 
was 600 s. Concentrations of Env variants used are shown in each sensorgram. Kinetic 
constants and binding affinities (Table 3.4 and 3.5) were calculated by fitting (black curves) 
using a 1:1 Langmuir model and correcting for mass transfer where appropriate (indicated 
by an asterix *). 
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VRC-CH31 
The interaction of VRC-CH31 was performed with Env variants 
gp120ZACAP210 and gp120/gp140GCN4(+)ZACAP45/IN25710/IN25925 (Figure 3.17). 
VRC-CH31 showed favourable binding to the trimeric conformations of 
Env’s ZACAP45, IN25710 and IN25925 than the corresponding monomers. 
In addition, negligible binding was observed for the monomer ZACAP210 to 
this VRC-CH31. A very strong interaction (kd <10-5) was observed between 
VRC-CH31 with Env IN25710, however the dissociation rate could not be 
measured accurately due to the limited dissociation time of the experiment 
(Bio-Rad Laboratories Inc., 2011; Marquart, 2006-2016).  
  
3-100 
 
 
 
Figure 3.17: SPR sensorgrams of gp120/gp140GCN4(+) Env variant binding to 
immobilised bNAb VRC-CH31 over time (s). Association time was 300 s and dissociation 
time was 600 s. For Env gp120IN25710 association time was 200 s. Concentrations of Env 
variants used are shown in each sensorgram. Kinetic constants and binding affinities (Table 
3.4 and 3.5) were calculated by fitting (black curves) using a 1:1 Langmuir model and 
correcting for mass transfer where appropriate (indicated by an asterix *). 
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NIH45-46G54W 
The interaction of NIH45-46G54W was performed with Env variants 
gp120ZACAP210 and gp120/gp140GCN4(+)ZACAP45/IN25710/IN25925 (Figure 3.18). 
Overall, improved binding was observed for the trimeric Env conformations 
compared to their matched monomeric conformations. In respect of the 
trimeric conformations, the Indian Env’s IN25710 and IN25925 had lower 
overall binding affinities compared to the South African Env ZACAP45. 
However, although very little dissociation is seen in the sensorgram with 
Env variant gp140GCN4(+)IN25710, the dissociation rate could not be 
accurately measured due to limited dissociation time (Bio-Rad Laboratories 
Inc., 2011; Marquart, 2006-2016).  
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Figure 3.18: SPR sensorgrams of gp120/gp140GCN4(+) Env variant binding to 
immobilised bNAb NIH45-46G54W over time (s). Association time was 300 s and dissociation 
time was 600 s. For Env gp120IN25710 association time was 200 s. Concentrations of Env 
variants used are shown in each sensorgram. Kinetic constants and binding affinities (Table 
3.4 and 3.5) were calculated by fitting (black curves) using a 1:1 Langmuir model and 
correcting for mass transfer where appropriate (indicated by an asterix *). 
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VRC03 
The interaction of bNAb VRC03 was only evaluated with Env variants 
gp120/gp140GCN4(+)ZACAP45 and gp120/gp140GCN4(+)IN25925 (Figure 
3.19) and binding kinetics was only obtained for gp120IN25925 since the 
interaction with the other Env’s tested did not fit the 1:1 Langmuir model. In 
general, binding of VRC03 to these Env variants was poor. 
 
 
Figure 3.19: SPR sensorgrams of gp120/gp140GCN4(+) Env variant binding to 
immobilised bNAb VRC03 over time (s). Association time was 300 s and dissociation time 
was 600 s. Concentrations of Env variants used are shown in each sensorgram. Kinetic 
constants and binding affinities (Table 3.4 and 3.5) were calculated by fitting (black curves) 
using a 1:1 Langmuir model and correcting for mass transfer where appropriate (indicated 
by an asterix *). 
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PGT145 
SPR was performed to evaluate the interaction of the V1V2-directed 
quaternary-structure-specific bNAb PGT145 with the Env variants. 
Unfortunately insufficient quantities of the Env variants limited evaluation of 
this bNAb to gp120/gp140GCN4(+)IN25710/IN25925. Initial single analyte 
screening using a concentration of 1000 nM was performed (data not 
shown) followed by a range of concentrations to obtain binding kinetics data.  
 
A considerable increase in binding of PGT145 was observed between the 
trimers of the Env variants evaluated compared to the monomers (Figure 
3.20). However, a comparison of the binding kinetics could not be performed 
due to the interactions not fitting the 1:1 Langmuir model for the trimeric 
conformations. 
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Figure 3.20: SPR sensorgrams of gp120/gp140GCN4(+) Env variant binding to 
immobilised bNAb PGT145 over time (s).  Association time was 300 s and dissociation time 
was 600 s. For Env gp120IN25710 association time was 200 s. Concentrations of Env 
variants used are shown in each sensorgram. Kinetic constants and binding affinities (Table 
3.4 and 3.5) were calculated by fitting (black curves) using a 1:1 Langmuir model and 
correcting for mass transfer where appropriate (indicated by an asterix *). Response unit 
axes (y-axis) were standardized between the monomeric and trimeric conformations of a 
particular Env variant to highlight the differences between PGT145 binding to a trimer 
compared to a monomer. 
 
A summary of the binding kinetics obtained for the bNAbs evaluated are 
shown in Tables 3.4 and 3.5. Overall, the trimeric conformations showed 
favourable binding to bNAbs IgG1b12, VRC01, VRC-CH31, NIH45-46G54W 
and PGT145 compared to the monomers. Accurate binding kinetics could 
not be determined for Env variants gp140GCN4(+)IN25925 with VRC01, 
gp120/gp140GCN4(+)IN25710 with VRC01 and VRC-CH31, and 
gp140GCN4(+)IN25710 with NIH45-46G54W due to an insufficient dissociation 
time to observe decay of the interaction. In addition, kinetics was not 
obtained for some of the interactions since they did not fit a 1:1 Langmuir 
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model. Despite the lack of fits, binding was observed and suggests that the 
epitopes recognized by the CD4bs-directed bNAbs evaluated (IgG1b12, 
VRC01, HJ16, VRC-CH31, NIH45-46G54W and VRC03) are accessible on 
the Env variants tested. Overall, this data suggests that the Env variants 
selected are antigenically correct and suitable for complex formation and 
immunogenicity testing in a small animal model. 
 
Table 3.4: Binding rate constants for the South African gp120/gp140GCN4(+) Env variants 
with CD4bs bNAbs and PGT145 as measured by SPR. 
 
Kd: Dissociation constant  
KD: Equilibrium constant (kd/ka)  
Rmax: Maximum theoretical response assuming all of the ligand is active, ligand is 100% pure and 
all binding sites are available  
Chi2: Chi-squared is the average of squared residuals and indicates fitting confidence. Chi2 values 
lower than approximately 4 or 5 are seldom achieved due to background noise   
Rmax: For kinetic analysis, Rmax ≤200 RU is recommended  
Chi2: chi-squared values less than 10% of Rmax are considered acceptable 
Kt: 1:1 Langmuir with mass transfer model applied if kt ≤1.00E+08 RU/Ms 
Negligible: binding of Env variant to bNAb was negligible 
No measureable dissociation: The dissociation phase was not long enough to observe sufficient 
decay for kd values ≤ 1.00E-05, therefore kinetics could not be determined. 
  
Env 
variant
Antibody ka (1/Ms) ka Error 
(1/Ms)
kd (s-1) kd Error 
(s-1)
KD (nM) Rmax 
(RU)
kt 
(RU/Ms)
Chi2 
(RU)
IgG1b12
VRC01 6.20E+03 6.18E+01 8.64E-04 3.98E-06 139 187.38 6.33E+18 3.87
HJ16
VRC-CH31 1.24E+04 1.32E+03 2.65E-03 2.30E-04 200 68.95 2.28E+06 7.26
NIH45-46G54W 6.20E+04 4.99E+03 3.96E-03 2.95E-04 Negligible 20.27 9.39E+05 5.05
VRC03
IgG1b12 8.12E+05 3.72E+03 3.41E-04 3.77E-06         0.42 151.89 5.13E+21 13.65
VRC01 1.86E+04 4.98E+01 3.47E-04 1.81E-06 18.7 258.25 1.52E+20 6.35
HJ16
VRC-CH31 1.38E+04 7.53E+01 9.07E-04 5.30E-06 65.8 165.94 3.97E+18 16.91
NIH45-46G54W 4.31E+04 3.23E+02 1.48E-03 7.95E-06 34.4 51.58 1.42E+22 8.45
VRC03
IgG1b12
VRC01 1.26E+03 3.54E+01 5.89E-04 6.26E-06 46.8 190.17 2.88E+17 4.51
VRC-CH31 1.05E+01 1.66E+01 2.19E-01 3.45E-01 Negligible 1.00E+06 5.47E+04 1.95
NIH45-46G54W 3.23E+03 8.46E+01 8.82E-04 1.38E-05 273 41.67 2.52E+16 3.62
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Table 3.5: Binding rate constants for the Indian gp120/gp140GCN4(+) Env variants with 
CD4bs bNAbs and PGT145 as measured by SPR. 
 
Kd: Dissociation constant  
KD: Equilibrium constant (kd/ka)  
Rmax: Maximum theoretical response assuming all of the ligand is active, ligand is 100% pure and 
all binding sites are available  
Chi2: Chi-squared is the average of squared residuals and indicates fitting confidence. Chi2 values 
lower than approximately 4 or 5 are seldom achieved due to background noise   
Rmax: For kinetic analysis, Rmax ≤200 RU is recommended  
Chi2: chi-squared values less than 10% of Rmax are considered acceptable 
Kt: 1:1 Langmuir with mass transfer model applied if kt ≤1.00E+08 RU/Ms 
Negligible: binding of Env variant to bNab was negligible 
No measureable dissociation: The dissociation phase was not long enough to observe sufficient 
decay for kd values ≤ 1.00E-05, therefore kinetics could not be determined. 
 
  
Env 
variant
Antibody ka (1/Ms) ka Error 
(1/Ms)
kd (s-1) kd Error 
(s-1)
KD (nM) Rmax 
(RU)
kt 
(RU/Ms)
Chi2 
(RU)
IgG1b12
VRC01 1.32E+04 8.67E+01 2.72E-04 2.88E-06 20.7 205.37 4.35E+19 5.02
HJ16 2.18E+05 3.19E+04 2.03E-02 3.00E-03 93.2 66.22 2.52E+06 6.99
VRC-CH31 3.75E+04 6.46E+02 5.35E-04 1.59E-05 14.3 18.96 4.37E+19 3.81
NIH45-46G54W 3.66E+04 3.07E+02 4.11E-04 7.61E-06 11.2 43.50 4.40E+18 4.97
VRC03 3.99E+05 1.21E+05 1.50E-02 4.52E-03 37.6 27.88 7.45E+05 4.69
PGT145 3.99E+01 1.42E+04 4.07E+00 1.45E+03 Negligible 1.00E+06 3.67E+05 2.35
IgG1b12
VRC01 3.17E+04 1.39E+02
HJ16 3.88E+04 1.89E+02 8.35E-04 5.09E-06 21.6 168.82 5.28E+19 16.40
VRC-CH31 2.32E+04 1.93E+02 2.28E-04 5.73E-06 9.83 94.98 3.06E+19 9.59
NIH45-46G54W 3.16E+04 1.40E+03 2.56E-04 5.01E-06 7.09 123.60 6.75E+07 10.09
VRC03
PGT145
IgG1b12
VRC01 1.22E+04 3.95E+01
VRC-CH31 7.84E+03 8.39E+01
NIH45-46G54W 2.54E+04 1.83E+02 2.32E-04 7.63E-06 9.12 32.99 1.09E+20 3.50
PGT145 9.99E+07 1.83E+02 4.76E01 7.63E-06 Negligible 53.26 3.27
IgG1b12
VRC01 1.32E+04 5.60E+01
VRC-CH31 4.22E+03 3.97E+01
NIH45-46G54W 2.81E+04 1.21E+02
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3.3.3 Selection of gp120/gp140GCN4(+) Envs for immunogenicity 
studies 
In order to further compare the Env variants from South Africa and India, a 
single matched monomeric (gp120) and trimeric (gp140GCN4(+)) Env from 
each country was selected for immunogenicity testing in small animal 
model. The selection of the two Env’s was based on extensive amino acid 
sequence analysis, including the identification of critical amino acid residues 
that are known to confer resistance to known CD4bs directed bNAbs. In 
addition, the Env expression yields in mammalian cell culture were taken 
into consideration.  
 
Env ZACAP45 was selected as the South African representative since it 
was the only South African Env that did not contain any of the signature 
amino acids, (346E, 357A and 441E (Figure 3.2) (HXBc2 numbering 340E, 
350A and 429E)) as reported by Shankarappa et al. (2001) to be 
characteristic of Indian Env’s. Env ZACAP45 also consistently expressed 2 
mg and 1 mg of purified Env per litre of cell culture supernatant for the gp120 
and gp140GCN4(+) conformations, respectively. 
 
Envelope sequences gp120/gp140GCN4(+)IN25710 and 
gp120/gp140GCN4(+)IN25925 encompass representatives of Indian origin, 
which are typically resistant to neutralization by bNAb IgG1b12 whereas 
gp120/gp140GCN4(+)IN26191 does not (Kulkarni et al., 2009). However, 
since the Env produced by the gp140(GCN4(+)IN25710 appeared to be an 
oligomer as observed in SEC (Figure 3.5) and SDS-PAGE analysis (Figure 
3.8), it was excluded from selection. In addition, Env 
gp120/gp140GCN4(+)IN25925 consistently expressed 2 mg/litre compared to 
poor expression of the other Indian Envs. Thus gp120/gp140GCN4(+)IN25925 
was selected as the Indian Env for immune complex formation and 
subsequent immunization studies. 
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3.4 Generation of gp120/gp140GCN4(+) variant Env/2dCD4S60C 
complexes 
The 2dCD4-liganded gp120/gp140GCN4(+) complexes for the 
immunogenicity studies were generated by incubating equivalent 
microgram amounts of 2dCD4S60C and Env (equivalent to a five-molar 
excess of 2dCD4) in the presence or absence of a reducing agent at room 
temperature for an hour. The reducing reagent (final concentration of 1mM 
β-mercaptoethanol) was included to help facilitate the intermolecular 
disulphide exchange between Env variants and 2dCD4S60C (Cerutti et al., 
2010), and formation of a disulphide-stabilized Env/2dCD4S60C complex.  
 
After complex formation of the Env/2dCD4S60C, SEC was used to remove 
any unbound 2dCD4S60C (Figure 3.21). Fractions corresponding to the 
relevant Env conformation were collected (indicated by the shaded areas in 
Figure 3.21), concentrated and assessed for the presence of bound 
2dCD4S60C using SDS-PAGE (Figure 3.22). SDS-PAGE analysis of 
Env/2dCD4S60C complexes revealed the presence of Env (120 kDa for 
gp120; and 140 kDa for gp140GCN4(+)), and 2dCD4S60C at approximately 
25 kDa under reducing conditions representing 2dCD4S60C (Figure 3.23). 
The bands were of similar size and intensity and confirmed the presence of 
bound 2dCD4 to the Env. The absence of a distinct band at 120 kDa for the 
monomeric portion of gp140GCN4(+) complex on the SDS-PAGE gel 
suggests the trimers are predominantly comprised of uncleaved gp140 
subunits (Figure 3.22). 
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Figure 3.21: Size exclusion chromatograms of envelope glycoproteins complexed with 
2dCD4S60C.  The Env/2dCD4S60C liganded complexes were generated by incubating the 
relevant Env with 2dCD4S60C under reducing conditions at room temperature, with the 
exception of B, which was incubated under non-reducing conditions at room temperature. 
The complexes were resolved over a Superdex 200 gel filtration column to remove any 
unbound 2dCD4S60C. The shaded area of the gel filtration profiles (A280nm) represents the 
fractions collected of the Env/2dCD4S60C liganded complex, corresponding to the relevant 
Env conformation. A. gp120IN25925/2dCD4S60C, B. gp120IN25925/2dCD4S60C under non-
reducing conditions, C. gp140GCN4(+)IN25925/2dCD4S60C, D. gp120ZACAP45/2dCD4S60C, E. 
gp140GCN4(+)IN25925/2dCD4S60C. 
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Figure 3.22: Coomassie stained SDS-PAGE analysis of Env/2dCD4S60C complexes used 
for rabbit immunizations. Complexes were separated on a SDS-PAGE gel under reducing 
conditions and the presence of 2dCD4S60C in the SEC purified Env/2dCD4 complex 
confirms the successful formation 2dCD4S60C-liganded complexes.  
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The use of the reducing reagent during complex formation had no apparent 
aberrant effect on binding of 2dCD4S60C to Env and complex formation as 
determined by SDS-PAGE analysis (Figure 3.23).  
 
 
 
Figure 3.23: Coomassie stained SDS-PAGE analysis of the Env/2dCD4 complexes 
generated using the two protocols, with and without a reducing agent (ß-mercaptoethanol). 
The presence or absence of a reducing agent had no effect on the formation of the 
2dCD4S60C-liganded Env.  
 
Purified complexes were quantified, aliquoted, snap frozen and stored at -
80°C until used in the immunizations.  
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3.5 Comparative Immunogenicity of recombinant 
gp120/gp140GCN4(+) Env variants, peptides, DNA vaccines and 
cyclic permutants  
The overall goal of this study was to compare the immunogenicity of two 
arms of immunogens. The first arm comprised two gp120/gp140 Env 
variants representative of Env’s isolated from patients in South Africa and 
India. This comparison was made by comparing the use of a monomeric 
(gp120) and trimeric (gp140GCN4(+)) form of each Env as a subunit 
vaccine as well as comparing them alone or liganded with 2dCD4 to expose 
conserved CD4i epitopes. The second arm comprised stabilized 
gp120/gp140 Env derivatives based on HIV-1 subtype B (peptides, DNA 
vaccines and cyclic permutants) from our collaborating laboratory in India 
as part of the South African Department of Science and Technology/TIA 
India-SA bilateral on HIV Vaccine Development, and these immunogens 
aimed to present the CD4bs epitopes to the immune system. 
 
To this end, the following were successfully tested for their immunogenicity 
in New Zealand White rabbits: 
Arm 1: subtype C gp120/gp140 Env variants: 
 gp120/gp140GCN4(+)ZACAP45 (2dCD4S60C – liganded and 
unliganded) 
 gp120/gp140GCN4(+)IN25925 (2dCD4S60C – liganded and 
unliganded) 
Arm 2: subtype B stabilized gp120/gp140 Env derivatives 
 cyclic permutant Cyc40D JRFL gp120 prime followed by the 
trimeric hCMP V1cyc 14-142 boost. 
 ODECCOBPICS gp120 prime followed by the trimeric hCMP JRLF 
V1cyc 14-142 boost. 
 V570D DNA prime followed by the trimeric hCMP JRFL V1 cyclic 
permutant boost. 
 peptide prime 1WR2 followed by gp140FV protein boost. 
 peptide prime 1ORC followed by gp140FV protein boosts. 
 
3-114 
 
Serum was collected at a relevant time points (Tables 2.2 and 2.3), and 
tested for the presence of anti-HIV Env antibodies (and anti-CD4, where 
relevant), as well as neutralizing breadth and potency. 
 
3.5.1 Antibody titres against relevant immunogens in rabbit sera 
In order to quantify and compare the antibody response elicited in the first 
arm immunization study, end-point antibody titers were determined for the 
terminal bleeds for rabbits immunized with the 
gp120/gp140GCN4(+)ZACAP45/IN25925 Env variants. The sera was titred 
against matched Env variants for both the 2dCD4S60C-liganded and 
unliganded groups (Figure 3.24).  
 
Anti-2dCD4 responses elicited by Env/2dCD4S60C immune complexes and 
2dCD4S60C/Wt/FD control groups, were determined by titering against 
immobilized 2dCD4S60C. Rabbits immunized with the 2dCD4FD variant raised 
the highest anti-2dCD4 antibody titre of 1.77 x 107, compared to 2dCD4Wt 
(7.68 x 106) and 2dCD4S60C (1.79 x 106) (Figure 3.24 A).  
 
Furthermore, anti-2dCD4 responses were observed in rabbit sera 
immunized with the gp120/gp140-Env 2dCD40S60C-liganded immunogens 
(Figure 3.24 A). The anti-2dCD4 titres obtained for the gp120/2dCD4S60C-
liganded groups were 1.29 x 106 and 1.88 x 106 for the monomeric 
gp120ZACAP45/2dCD4S60C and gp120IN25925/2dCD4S60C immunogens, 
respectively, similar to that of the 2dCD4S60C control group. Interestingly, the 
titres detected in rabbit sera for groups immunized with the trimeric 
2dCD4S60C-liganded Env’s (gp140GCN4(+)ZACAP45/2dCD4S60C and 
gp140GCN4(+)IN25925/2dCD4S60C elicited anti-2dCD4 titres of 1.22 x 105 and 
2.44 x 105 respectively, approximately 10-fold lower than the 2dCD4-
liganded monomeric Env’s as well as the 2dCD4S60C control group (Figure 
3.24) 
 
3-115 
 
The matched anti-Env (unliganded) responses that were elicited in rabbits 
for the South African Env ZACAP45 (6.4 x 105 for the monomer and 2.56 x 
106 for the trimeric conformation) were approximately 10-fold lower than 
responses detected in the rabbits immunized with the Indian Env IN25925 
(4.3 x 106 for the monomer and 3.4 x 106 for the trimer). In addition, the sera 
obtained from the rabbit groups immunized with the Env/2dCD4S60C 
liganded immunogens elicited similar levels of anti-Env titres, except 
gp140GCN4(+)IN25925/2dCD4S60C which showed levels similar to the 
unliganded Envs (Figure 3.24 B).  
 
 
Figure 3.24: End-point ELISA titers of rabbit sera immunized with the first arm of 
immunogens.  ELISA titrations represent the reciprocal of the highest dilution above the 
cut-off. Cut-off values were calculated using the equation: Cut-off = 𝑋𝑋�*SDƒ, where X is the 
average and SD is the standard deviation for the control serum, and ƒ is SD multiplier 
corresponding to the 99 % confidence level and number of replicates (Frey et al., 1998). 
Data points represent end-point titers for each rabbit, the group mean is indicated with a 
horizontal line and standard errors are indicated with vertical lines. A) Anti-CD4 titers were 
determined by titrating the terminal bleed sera of immunized rabbits against 2dCD4S60C B) 
Anti-Env titers were determined by titrating the terminal bleed sera of immunized rabbits 
against the matched gp120/gp140GCN4(+) Env variant immunogens. 
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Similarly, the antibody responses were determined in the sera of the rabbits 
immunized in the second arm immunization study that received the 
stabilized gp120/gp140 derivative immunogens (proteins and DNA 
constructs). Mid-point (post-priming and before boosting) serum antibodies 
were titred against gp140FV and the gp120JRFL cyclic permutant protein. 
End-point antibody titres of the terminal bleed rabbit sera were titred 
exclusively against gp120JRFL cyclic permutant protein (Figure 3.25).  
 
The sera obtained from the rabbits immunized with the peptide immunogens 
were tested for mid-point (post-priming and before boosting) antibodies 
titres against the matched peptide (1WR2 or 1ORC), while the terminal 
bleed sera were titred against gp140FV and the gp120JRFL cyclic permutant 
proteins, respectively (Figure 3.25). 
 
The week 10 (mid-point) anti-gp140FV mean antibody serum titres 
determined for the rabbits that received the stabilized gp120/gp140 
derivative immunogens (Figure 3.25) were higher for the groups 1 and 2 
immunized using a protein immunogen as a prime: Cyc4OD (8.25 x 104) 
and ODECCOBPICS-C (1.6 x 103) compared to the rabbits that were primed 
with DNA WT-JRFL Env DNA (3.5 x 102) (Group 5); JRFL-Env-V570D (2.5 
x 102 and 2.4 x 102 for groups 6 and 8, respectively) and JRFL Env-SEKS 
DNA (3.3 x 102) (Group 7). The matched anti-peptide titres for the scaffold 
peptides 1WR2 (Group 3) (1 x 104) and 1ORC (Group 4) (2.24 x 106) were 
comparable to those obtained from groups primed with protein immunogens 
when titred against their matched peptides. 
 
Comparing the anti-gp140FV and gp120JRFL titres determined at mid-point 
(Week 10) we observed a similar titre for group 1 (gp120JRFL Cyc4OD cyclic 
permutant) when titrering against gp140FV (8.25 x 104) versus gp120 JRFL 
(1.08 x 105). Whereas, a ten-fold lower titre was obtained for group 2 sera 
(ODECCOBPICS-C) (1.6 x 103 and 4.3 x 102)) when one compares the titres 
determined against gp140FV and gp120JRFL respectively (Figure 3.25).  
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Mid-point titres (week 10) determined against gp140FV and gp120JRFL cyclic 
permutant for groups that received a DNA prime (group 5 - WT-JRFL Env 
DNA (group 6 and 8 (JRFL-Env-V570D) and group 7 (JRFL Env-SEKS 
DNA) showed similar antibody ranges (2.5 x 102 - 1.0 x 103) (Figure 3.25, 
groups 5-8, mid-point bleeds).   Anti-gp120JRFL cyclic permutant titres were 
not determined for the groups immunized with the peptide immunogens. 
 
Anti-gp120JRFL cyclic permutant titres were determined for all the terminal 
bleed rabbit sera immunized with the stabilized gp120/gp140 Env derivative 
immunogens (Second arm immunization study) (Figure 3.25). Animals 
primed with protein and DNA immunogens showed a marked increase in 
the antibody titres after the protein boosts compared to the mid-point titres 
(week 10): approximately five-fold increase for group 1 (Cyc4OD (1.00 x 
106), approximately 1 x 104 fold increase for  group 2 (ODECCOBPICS-C 
(5.76 x 106), approximately 4.0 x 103 times increase for group 5 (WT-JRFL 
Env DNA (3.2 x 106)); 1.2 x 103 times increase for group 6 (JRFL-Env-
V570D (1.28 x 106)) and 3.84 x 103 times increase for group 7 (JRFL Env-
SEKS DNA (1.28 x 106)). A smaller increase of approximately 400 times 
was observed for group 8 (JRFL-Env-V570D prime, gp140FV boost). The Ab 
titres of the terminal bleeds for the animals immunized with the VRC01 
epitope engrafted scaffold peptides 1WR2 and 1ORC, followed by gp140FV 
protein boosts had similar anti-gp120JRFL cyclic permutant titres of 3.2 x 105 
and 3.4 x 105, respectively and anti-gp140FV titres of 8.53 x 105 and 2.24 x 
106, respectively. 
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Figure 3.25: End-point ELISA titers of rabbit sera immunized with the second arm of 
immunogens.  ELISA titrations represent the reciprocal of the highest dilution above the 
cut-off. Cut-off values were calculated using the equation: Cut-off = 𝑋𝑋�*SDƒ, where X is the 
average and SD is the standard deviation for the control serum, and ƒ is SD multiplier 
corresponding to the 99 % confidence level and number of replicates (Frey et al., 1998). 
Data points represent end-point titers for each rabbit, the group mean is indicated with a 
horizontal line and standard errors are indicated with vertical lines.  
Immunogens: Group 1: CycV40D gp120 protein prime and gp120JRFL cyclic permutant 
protein boost; Group 2: ODECCOBPICS-C gp120 prime and gp120JRFL cyclic permutant 
protein boost; Group 3: 1WR2 peptide prime and gp140FV protein boost; Group 4: 1ORC 
prime and gp140FV protein boost; Group 5: Wt-JRFL Env DNA prime and gp120JRFL cyclic 
permutant protein boost; Group 6: JRFL Env-V570D DNA prime and gp120JRFL cyclic 
permutant protein boost; Group 7: JRFL Env-SEKS DNA prime and gp120JRFL cyclic 
permutant protein boost, Group 8: JRFL Env-V570D DNA prime and gp140FV protein boost. 
End-point titers of groups immunized with protein or DNA immunogens (Groups 1, 2, 5, 6, 
7, 8) were determined by titrating the mid-point bleed sera (post-priming and before 
boosting) of immunized rabbits against gp140FV protein and gp120JRFL cyclic permutant 
protein and the terminal bleed sera against gp120JRFL cyclic permutant protein. End-point 
titers of groups immunized with peptides (Groups 3, 4) were determined by titrating the 
mid-point bleed sera (post-priming and before boosting) of immunized rabbits against the 
matched peptide (1WR2 or 1ORC) and the terminal bleed sera against gp140FV protein 
and gp120JRFL cyclic permutant protein.  
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These antibody responses in the rabbit sera illustrate that an immune 
response was elicited against all immunogens tested. We next sought to 
further characterize the response by determining whether the antibodies 
raised in the rabbits were capable of neutralizing a panel of HIV-1 
pseudoviruses in an in vitro inhibition assay. 
 
3.5.2 Neutralizing antibody assays  
The HIV-1 pseudovirus assay was used to evaluate the neutralization 
capabilities of the antibodies elicited in the rabbits.  
 
The first immunization arm was performed using the Env variant 
gp120IN25925, liganded and unliganded with 2dCD4S60C and included three 
2dCD4 variant (2dCD4FD/Wt/S60C) control groups, as well as a control in which 
the reducing agent was omitted during complex formation of the 
Env/2dCD4S60C immunogen. The terminal rabbit sera obtained from rabbits 
immunized with these immunogens were sent to Monogram BioSciences 
Inc. who performed the PhenoSense Neutralizing antibody assay against a 
panel of 15 HIV-1 pseudotyped viruses (Table 3.6). This panel represented 
a genetically and geographically diverse range of HIV-1 viruses from 
different tiers (Tier 1 – 3) and included HIV-2 and SIV (Killick et al., 2015).  
 
In addition, terminal bleed sera obtained from rabbits immunized with the 
remaining immunogens from the first immunization arm 
(gp120/gp140GCN4(+)ZACAP45 and gp140GCN4(+)IN25925, liganded and 
unliganded with 2dCD4S60C) were assayed in-house against a smaller panel 
of four of HIV-1 pseudoviruses from Tier 1 and 2 (Table 3.7).  
 
The neutralization data is presented as a heat map in which the reciprocal 
of the dilution of serum resulting in 50% inhibition (ID50) of the pseudovirus 
is shown.   
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In general, the gp120/gp140GCN4(+) Env variant immunogens exhibited 
low neutralization breadth, except for the Env/2dCD4S60C liganded 
immunogens, which consistently resulted in broad neutralization Tier 1 and 
Tier 2 pseudoviruses irrespective of the origin of the Env sequence used 
(South African versus Indian).  
 
As expected antibodies raised in the 2dCD4 folding defective (2dCD4FD) 
control group showed no neutralization (Table 3.6). However three of the 
five rabbits in the 2dCD4Wt control group raised an Ab response that showed 
considerable neutralization of the Tier 1, 2 and 3 pseudoviruses (ID50 values 
ranging between 60 - 4381) (Table 3.6). Similarly, three of the five rabbits 
in the group 2dCD4S60C immunized group also displayed neutralization of 
Tier 1, 2 and 3 pseudovirus isolates (ID50 values ranging between 30 – 
3063).  Interestingly, the neutralization titres elicited in these 2dCD4 only 
groups showed lower ID50 values against Tier 1 pseudoviruses compared 
to Tier 2 and 3 (Table 3.6).  
 
The antibodies raised in the rabbits immunized with the Env/2dCD4S60C 
complex generated in the presence of the reducing agent showed a slightly 
improved neutralization profile compared to the complex generated without 
the reducing agent (Table 3.6). This was evident against both Tier 1 and 
Tier 2 pesudoviruses.   
 
The reduced panel of pseudoviruses analysed in-house corroborated the 
findings of Monogram Biosciences Inc, with neutralization titres obtained 
against Tier 1 and 2 pseudoviruses for the 2dCD4S60C-liganded Env 
complex but not the unliganded Envs (Table 3.7).   
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Table 3.6: Heat map of neutralizing antibody data of rabbit sera immunized with Env 
variants (gp120/gp140GCN4(+)IN25925) in unliganded and 2dCD4-liganded versions against 
HIV-1 pseudovirus isolates. Neutralization data is indicated as the reciprocal of the serum 
dilution required to achieve 50% inhibition. Z23 is derived from a human patient sera 
exhibiting broadly neutralizing activity and used as a positive control (Monogram 
Biosciences, Inc.). Murine leukaemia virus (aMLV) was included as a specificity control. 
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Table 3.7: Heat map of in-house neutralizing antibody data of rabbit sera immunized with 
gp120/gp140GCN4(+)ZACAP45 immunogens in unliganded and 2dCD4-liganded versions 
against HIV-1 pseudovirus isolates. Neutralization data is indicated as the reciprocal of the 
serum dilution required to achieve 50% inhibition.  
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The neutralization data obtained for the second immunization arm which 
included the stabilized gp120/gp140 derivatives (peptides, DNA and cyclic 
permutant immunogens) was performed in-house against a small panel of 
HIV-1 pseudoviruses (Tier 1 and 2) and included a baseline prebleed 
reference control. This group of immunogens showed very low 
neutralization breadth against the viruses tested (Table 3.8). Although 
neutralization was observed against the Tier 1 neutralization-sensitive 
pseudovirus SF162, reduced neutralization capacity was observed against 
BaL and no neutralization was observed against the Tier 2 pseudoviruses 
tested (ZM53 and CAP210).  
 
Immunization regimes comprising alternate DNA/peptide prime and Env 
protein boost strategies appeared to enhance the neutralization titres 
obtained against the SF162 pseudovirus.  Overall group 4 (1ORC peptide 
prime, gp140FV protein boost) immunized rabbit sera yielded the highest 
average neutralization titre against SF162 (Average ID50 1755.5), followed 
by group 7 (SEKS DNA prime, gp120JRFL cyclic permutant boost) (average 
ID50 977) and group 3 (1WR2 peptide prime, gp140FV boost) (average 
ID50 879).  
 
Comparison of neutralization titres obtained from group 6 and 8, which 
comprised the same DNA prime immunogen (Wt-JRFL-DNA) but different 
protein’s as a boost (gp140FV versus gp120JRFL cyclic permutant) showed 
similar, average neutralization titres against SF162 (589.25 and 555 
respectively). Interestingly, group 8 (JRFL Env-SEKS DNA prime, gp120JRFL 
cyclic permutant boost) showed a greater consistency in the levels of 
elicited titres against SF162 compared to group 6. Furthermore, the DNA 
prime groups that included the trimeric stabilized DNA cassettes  (groups 6 
and 7) showed enhanced elicitation of neutralizing antibodies against 
SF162, compared to the monomeric gp120JRFL cassette primed group 
(group 5 – Wt-JRFL-DNA).  
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Table 3.8: Heat map of in-house neutralizing antibody data of rabbit sera immunized with 
stabilized gp120/gp140 derivatives against selected HIV-1 pseudovirus isolates SF162, 
BaL, ZM53 and CAP210. Neutralization data is indicated as the reciprocal of the serum 
dilution required to achieve 50% inhibition. 
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Chapter 4 : Discussion 
Challenges facing the development of an effective HIV-1 prophylactic 
vaccine include extensive global-viral diversity, early establishment of latent 
viral reservoirs, limited small-animal models and immune evasion strategies 
of the virus including: low density expression of Env spikes; antigenic 
variability; glycan shielding; transient exposure of epitopes and 
conformational masking, and the correlates of immune protection are not 
well defined (Barouch, 2008; Chun et al., 1997a). Recent characterization 
of bNAbs isolated from HIV-1 infected patients, has facilitated the 
identification of vulnerable epitopes on Env. Their neutralization 
mechanisms can be exploited by novel HIV-1 vaccine strategies to elicit 
effective B-cell immunity using reverse vaccinology (Corti et al., 2010; de 
Taeye et al., 2016; Lanzavecchia et al., 2016; Van Regenmortel, 2016). 
In an attempt to overcome these challenges and elicit bNAbs, the HIV-1 
vaccine field has developed several stabilized Env immunogens that aim to 
expose neutralization-sensitive epitopes, while at the same time minimizing 
the exposure of epitopes that elicit non-neutralizing Abs (de Taeye et al., 
2015; Sanders et al., 2015). However, in recent years it has become unclear 
as to the precise Env immunogen required to engage the naïve B population 
and the subsequent immunization protocol that will drive the extensive 
somatic hypermutation necessary for antibody affinity maturation in humans 
(Doria-Rose et al., 2014; Klein et al., 2013; Liao et al., 2013b; Mascola and 
Haynes, 2013). 
 
In this thesis, we aimed to evaluate subtype B and C Env-based 
immunogens stabilized to expose a CD4bs or CD4i epitope using various 
immunization regimens in small animals. In addition, we compared the 
antigenicity and immunogenicity of these Env-based immunogens between 
those of South African and Indian origin in order to elucidate any differences 
between HIV-1 subtype C Envs from these geographically distinct regions. 
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4.1 Analysis of selected HIV-1 Env derived sequences from Indian 
and South African origin. 
Designing an immunogen to represent the vast HIV-1 diversity is a 
challenging process, and several approaches have been proposed. One 
approach is to use the sequence of a transmitted founder virus, the strain of 
the single viral variant from which the quasispecies in an infected individual 
evolved (Abrahams et al., 2009). However, using a variant from a newly 
infected individual excludes variants that have evolved in the presence of 
adaptive immune responses over time (Haynes et al., 2016).  It could be 
argued that using a sequence of Env from late-stage infection could better 
represent the evolution of the virus over time however would not include the 
specific intermediaries. Another approach is to derive an amino acid 
consensus sequence that is representative of a vast number of circulating 
isolates within a certain population or a particular geographical region 
(Gaschen et al., 2002).  
 
HIV-1 subtype C is the most dominant subtype globally, with almost half of 
people infected with HIV-1 worldwide, being infected with this subtype 
(Hemelaar, 2012). South Africa and India are estimated to have a combined 
burden of approximately 9 million people living with HIV-1, predominantly 
infected with subtype C (UNAIDS, 2015). As such, a subtype C based HIV-
1 Env immunogen would likely be key to vaccine strategies and approaches 
carried out in these regions. HIV-1 subtype B has a wider geographic 
distribution than subtype C, but accounts for approximately 11 % of the 
global HIV-1 burden (Hemelaar, 2012). We included a comparison of the 
immunogenicity of subtype B stabilized Env derivatives from our 
collaborators in this study. Although these were based on a different 
subtype, the aim was to provide proof-of-concept that presenting conserved 
regions of Env to the immune system would elicit bNAbs independent of 
subtype, and allowed us to compare different immunogen designs in this 
regard. 
 
4-127 
 
Here, we selected six Env sequences based on their geographical origin, 
three variants derived from South African HIV-infected patients and three 
variants from Indian HIV-1 infected patients. These variants were selected 
as they were isolated fairly early following infection (Fiebig stages I-V (up to 
129 days post infection) – Table 2.1) and thus are representative of the 
transmitted founder virus population. In particular, the South African Env’s 
(ZACAP45, ZACAP210 and ZA706010164) were selected because they 
had been reported by Abrahams et al. (2009) to be derived from patients 
with low diversity env genes, suggesting that they followed a neutral 
evolution model from a single founder virus and were under early selection 
pressure, therefore representing a founder-type virus. In addition the 
selected variants were derived from individuals infected via heterosexual 
transmission, and thus represent the viral strain that was able to overcome 
the mucosal bottleneck and lead to the establishment of productive infection 
(Haynes et al., 2016; Joseph et al., 2015; Keele et al., 2008; Shaw and 
Hunter, 2012).  
 
For the Indian variants, we included two Env sequences (IN25925 and 
IN25710) that have previously shown an inherent resistance to 
neutralization by bNAb IgG1b12, one of the first bNAbs characterized 
(Kulkarni et al., 2009; Patil et al., 2014; Ringe et al., 2010) and one reported 
to be sensitive to IgG1b12 neutralization (IN26191) (Kulkarni et al., 2009). 
The precise mutations responsible for IgGb12 resistance are discussed in 
greater detail in the SPR analysis section (section 4.4). 
  
The CD4bs epitope on HIV-1 Env is an attractive target vaccine design due 
to its high degree of conservation and it’s critical role in viral entry (Lynch et 
al., 2012; Mascola and Haynes, 2013)Li et al 2007). BNAbs targeting the 
CD4bs epitope display potent neutralization and extensive breadth (Diskin 
et al., 2011; Scheid et al., 2016; Wu et al., 2010), however the CD4bs may 
not be readily accessible to naïve B cell surface-receptors, as it is recessed 
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in a pocket on Env and further masked by an evolving shield of N-linked 
glycans and variable sequence loops of Env.   
 
The CD4bs epitope is discontinuous and distributed over six segments in all 
five of the conserved regions of gp120 (Kwong et al., 1998). Critical contact 
residues on gp120 include Asp 368, Glu 370 and Trp 427 and these amino 
acids are conserved amongst all the Env’s in this study (Figure 3.2), which 
was expected since they are conserved among all primate 
immunodeficiency viruses (Foley et al., 2015; Kwong et al., 1998). CD4 also 
binds to regions on gp120 that are variable, particularly the large interfacial 
cavity. Variable amino acid residues in this region (Ala 281, Ser 364, Ser 
365, Thr 455 and Arg 469) are surrounded by the three conserved residues 
mentioned above (Kwong et al., 1998).  
 
Analysis of the V1 and V2 loops of the six Env sequences used in this study 
found that the V1 loop ranged between 16 – 20 amino acids, consistent with 
a study by Yao et al. (2015) (15 - 40 amino acids in length) for subtype C 
Env’s. The V2 loop length was relatively conserved between the Env 
variants of 45 amino acids in length for all the Env’s except Env variant 
IN26191, which has a shorter V2 loop containing 40 amino acids (Figure 
3.2). Again, this was within the expected range as reported by Yao et al. 
(2015) of 33 to 57 amino acids for this variable loop. The length of these 
variable loops has been shown to affect bNAbs targeting the CD4bs 
(VRC01 and IgGb12) and the quaternary V1/V2 loop epitope (e.g. 
PG9/PG16) by masking crucial amino acid residues (Patil et al., 2014).  
 
The V3 loop length is highly conserved in HIV-1 Env’s in general and has 
been attributed as an important region for HIV-1 infection and a critical 
determinant of co-receptor usage (Regoes and Bonhoeffer, 2005). In 
addition, PGT monoclonal antibodies 121–123, 125–128, 130, 131 are 
directed against the V3 loop region (Walker et al., 2011). With the exception 
of Env ZA706010164, which contained 34 amino acids in the V3 loop, the 
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Env variants in this study had a V3 loop length of 35 amino acids, consistent 
with the report for HIV-1 subtype C gp120’s by Yao et al. (2015).  
 
The V4 loop lengths varied between 22 – 39 amino acids (within the 
reported range of 18 – 44 amino acids) by Yao et al. (2015). Env ZACAP210 
has the longest V4 loop and ZACAP45 the shortest V4 loop. The number of 
amino acids in the V5 loop ranged between 12 – 15, again within the 
expected range of 10 – 23 amino acids as reported by Yao et al. (2015). 
Env ZACAP210 has the longest V5 loop, whereas Env’s ZA706010164 and 
IN26191 contained the least number of amino acids in this region.  
 
Although the six Env sequences selected each contain the critical amino 
acids for CD4 binding and their variable loop lengths were found to be within 
the expected ranges ultimately, antigenic and functionality assessment of 
the HIV-1 Env requires empirical testing of the expressed recombinant HIV-
1 Env glycoproteins. Thus, the selected Env sequences were designed and 
codon optimized for mammalian expression, for downstream biochemical 
characterization and small animal immunization studies.  
 
4.2 Design and expression of matched monomeric and trimeric HIV-1 
Envs from South African and Indian origin 
Using monomeric gp120 as a subunit vaccine has had limited success since 
it resulted in Abs directed against non-neutralizing epitopes of the hidden 
face of gp120 (Sanders et al., 2013; Schultz and Bradac, 2001; VanCott et 
al., 1995a; Yang et al., 2000). This failure, coupled to the discovery of 
quaternary specific antibodies has driven the field to consider alternative 
stabilization methods that better mimic the native trimeric structure. 
However, soluble gp140 trimers are labile in nature and disintegrate into 
their respective gp120 and gp41 subunits (Earl et al., 1994; Sanders et al., 
2013). Therefore, stabilization methods of the trimer were designed and 
included elimination of the cleavage site, cross-linking gp120 and gp41 and 
introducing trimerization motifs (Chen et al., 2004; Harbury et al., 1993; 
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Saha et al., 2012; Sanders et al., 2013; Selvarajah et al., 2008; Yang et al., 
2000). Further studies have shown that proteolytic cleavage is essential for 
the native conformation of gp140, which led to the development of the 
SOSIP trimer. More recently, and after inception of this study, the SOSIP 
stabilizing mutations were shown to be the most promising method of 
stabilizing the trimer in a native-like conformation (Beddows et al., 2007; 
Sanders et al., 2013; Sanders et al., 2015; Sanders et al., 2002).  
 
In this study, we employed the use of the GCN4 motif to stabilize the trimeric 
gp140 constructs and compare the antigenicity and functionality to their 
matched gp120 monomeric conformations.  
 
All six Env constructs were used to successfully express recombinant Env 
proteins following transfection of HEK293T as confirmed by reducing-SDS-
PAGE and Western blot analyses. The trimeric conformation in this study 
was stabilized using the GCN4(+) trimerization motif, since it was a well-
established protocol in our laboratory and shown to generate stable trimers 
in mammalian cell culture (Killick et al., 2015). Western blot analysis using 
HIV-1 infected patient sera as a source of primary antibody, confirmed the 
presence of expressed HIV-1 Env glycoproteins that resolved to within the 
expected molecular weight range of approximately 120 kDa and 140 kDa 
for the gp120 and gp140GCN4(+) Env constructs, respectively (Figure 3.3). 
The slight variations in the migration profile between the different Env’s 
could be attributed to slight differences in glycosylation patterns and 
variation in the amino acid sequences (Figure 3.2) which have been 
reported to affect the molecular weight of Env (Benureau et al., 2016). 
Inefficiency of gp140 cleavage by host-furin protease was also noted, as 
bands corresponding to gp140 and gp120 were present (Figure 3.3, 3.4). 
This inefficiency has been reported previously by Binley et al. (2000) who 
suggested that in natural infection in vivo, unprocessed gp160 is sorted into 
the lysosomal pathway meaning that no uncleaved gp160 is expressed on 
the virion surface. In mammalian cell expression however, furin proteases 
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may become saturated resulting in uncleaved gp160/gp140 expression 
(Binley et al., 2000).   
 
The presence of uncleaved trimers in our study was of concern since Ringe 
et al. (2013) cautioned using uncleaved trimers in antigenicity and 
immunogenicity studies because they have been found to expose non-
neutralizing gp120 and gp41 epitopes. Since the SOSIP trimer has proven 
to be an improved method for stabilizing Env in a native-like conformation 
(Julien et al., 2015; Klasse et al., 2013; Klasse et al., 2016; Sanders et al., 
2013), future work could look at incorporating the SOSIP mutations in the 
immunogen construct design. The SOSIP trimer contains an intermolecular 
disulphide bond between gp120 and the gp41 ectodomain and an isoleucine 
to proline substitution at residue 559 of gp41, which stabilizes the interaction 
between the gp41 subunits. Mutation of the native cleavage site to 6 
consecutive arginine residues results in efficient cleavage following co-
transfection with a furin-encoding plasmid. These SOSIP-stabilized Envs 
show improved antigenicity profiles particularly through the stabilization of 
quaternary structure-dependent epitopes (Sanders et al., 2013).  
 
Large-scale recombinant Env expression and purification was carried out 
according to protocols previously established in our laboratory (Killick et al., 
2014). Following preliminary purification using G. nivalis Lectin affinity 
chromatography, SEC was used as a “polishing step” to improve the purity 
and isolate specific monomeric and trimeric conformations of the various 
Env’s expressed (Figure 3.5 and Figure 3.6). The South African and Indian 
gp120 Env constructs produced a larger proportion of dimers than 
monomers compared to our previous findings using the founder virus gp120 
construct (Killick et al., 2015). Dimer formation has been reported to occur 
when over-expressing soluble gp120 in the absence of gp41 (Finzi et al., 
2010). A mutation of leucine to alanine at residue 111 results in a significant 
decrease of gp120 dimer formation. Leucine was conserved across all six 
sequences at this residue (Figure 3.2) including the founder virus sequence 
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(Killick et al., 2015). The formation of dimers has also been associated with 
the V1V2 region, and perhaps a reduction in the size of the V1V2 region 
may result in less propensity of the gp120 to form dimers (Finzi et al., 2010; 
Guo et al., 2013). Therefore the dimerization may be as a result of 
differences in the length of the V1V2 loop regions, which were shorter in the 
founder virus construct. Future work could look at the impact of the length 
of the V1V2 loops on dimerization.   
 
The trimeric gp140GCN4(+) constructs produced similar elution profiles to 
our previous findings, with the presence of oligomeric, trimeric and 
monomeric conformations. The gp140GCN4(+)IN25710 Env construct that 
produced a higher molecular weight band at approximately 260 kDa (Figure 
3.8) showed a distorted SEC profile (Figure 3.6F and Figure 3.7B) with the 
majority of the conformation appearing to be oligomeric in nature  This could 
be attributed to the formation of dimers of trimers, as reported by Feng et 
al. (2012).  
 
Interestingly, the isolation of fractions corresponding to the trimeric 
conformation for Env variants IN26191, ZACAP45, ZACAP210, 
ZA706010164 and to a lesser extent, IN25710, show the presence of low 
molecular weight bands when resolved under reducing SDS-PAGE at 
approximately 30, 50 and 60 kDa (Figure 3.8). As these bands are visibly 
present under reducing SDS-PAGE it suggests that they are associated with 
the trimeric conformation and could possibly be cleaved gp41-GCN4(+) 
products. Further studies could use a gp41 specific Ab to confirm this using 
Western blot analysis. Encouragingly our SPR analysis using PGT145 
BNAb, which recognizes a quaternary, trimeric specific epitope on Env, 
bound favourably to the gp140GNC4(+)IN25925/IN25710 trimeric conformations 
compared to the matched gp120 monomers (Figure 3.20). This suggests 
that the combination of the gp41 ectodomain and GCN4 motif assembles 
these Env’s into a native-like trimer (Yasmeen et al., 2014). Unfortunately 
our analysis in this regard was limited due to insufficient protein quantity 
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during the SPR analysis and provides an opportunity for future 
characterization of the remaining protein conformations. 
 
Variable amounts of the gp120/gp140GCN4(+) Env’s were purified to 
homogeneity for antigenicity and immunogenicity studies. Generally, higher 
yields were obtained for the monomers compared to the trimers. Very low 
yields were obtained for Env’s gp140GCN4(+)ZACAP210/IN25710/IN26191 and 
gp120IN25710/IN26191 (Table 3.1) and could be attributed to differences in 
amino acid sequences (Gustafsson et al., 2012). Large scale protein 
expression resulted in sufficient quantities of these Env variants for limited 
biochemical characterization studies.  
 
4.3 Expression and purification of recombinant 2dCD4Wt/FD/S60C 
In addition to Env purification, three variants of 2dCD4Wt/FD/S60C were 
expressed and purified to homogeneity and confirmed to be of correct 
molecular weight (Figure 3.9). The 2dCD4S60C variant contains a serine-
cysteine mutation at position 60 which, when liganded to Env, forms an 
improved stabilized Env/2dCD4 complex compared to the wild-type 2dCD4 
as a result of the formation of a intramolecular disulphide bridge presumably 
between cysteine residues 126 on gp120 and cysteine 60 in CD4 (Cerutti et 
al., 2010). The 2dCD4Wt/S60C variants were used for SPR experiments and 
for generation of the relevant Env/2dCD4S60C complexes for immunogenicity 
testing. The 2dCD4-folding defective (FD) was used as a control in the 
immunization studies and will be discussed in more detail in the relevant 
section below.   
 
4.4 Antigenicity analysis of the gp120/gp140GCN4(+) Env variants 
4.4.1 Surface plasmon resonance as an aid in vaccine design 
We next sought to characterize the gp120/gp140GCN4(+) Env variants by 
comparing their binding kinetics to 2dCD4Wt/S60C and a panel of six CD4bs-
directed bNAbs. This experiment was necessary to confirm the effect of any 
amino acid differences between the sequences empirically, and the kinetic 
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information obtained from SPR would enable the quantification of the 
binding interaction between macromolecules. 
 
In SPR, a ligand is immobilised onto a sensor surface chip containing a thin 
metal film (usually gold) coated with a suitable surface chemistry that allows 
for direct coupling of the ligand (e.g. carboxyl groups). A solution containing 
analyte is passed over this surface and binding of the ligand and analyte 
results in a change in mass concentration on the chip. This change is 
measured as a change in refractive index on the sensor surface with light 
that is reflected off the metal film using a glass prism (Nguyen et al., 2015). 
Therefore a change in the mass concentration results in a shift in the angle 
of incidence required for resonance, and therefore a change in the reflected 
light intensity. A sensorgram is generated from a plot of the changes in 
reflected light (designated an arbitrary unit termed response units (RU)) 
over time, and this enables the real-time monitoring of biomolecular 
interactions occurring on the surface of the chip (Lang et al., 2005). 
 
The advantage of using SPR in Env-Ab interaction analyses, as opposed to 
Enzyme-linked immunosorbent assays (ELISA’s), is that it can be monitored 
in real-time, using label-free technology (Tudos and Schasfoort, 2008). 
Labels have the disadvantage of potentially causing steric hindrance or 
changing the structural configurations of the proteins being studied. 
Therefore label-free strategies, including SPR, enable better simulation of 
native biomolecule interactions (Nguyen et al., 2015).  
 
A further advantage of SPR is that all bound analyte can be removed and 
the chip surface regenerated, while leaving the active ligand intact. This 
regeneration step allows repeated binding experiments using different 
analytes or different conditions/concentrations of the analyte (Lang et al., 
2005). Specific to the ProteON XPR36 system platform is interspot 
referencing (Bio-Rad Laboratories Inc., 2009). Interspots are positioned 
adjacent to the interaction surfaces. These interspots do not have ligand 
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immobililized onto their surface and are used as a reference to control for 
non-specific binding. 
 
SPR data obtained for biochemical interactions are routinely fitted using the 
Langmuir 1:1 model, which assumes that one molecule of ligand binds to 
one molecule of analyte. However, interactions cannot always be described 
using this model and a multitude of factors and the complexity of interactions 
may result in reduced fitting confidence to this model. Experimental 
considerations include the following; protein samples may not be 
homogenous; proteins may aggregate; multivalent interactions (e.g. 
bivalent antibodies); ligand may be immobilised in a sub-optimal orientation 
on the chip; mass transport effects during the experiment; steric hindrance; 
bulk refractive index changes; nonspecific binding of the analyte to the chip 
surface; experimental conditions including pH and temperature; complex 
binding mechanism and drift, which can occur if the immobilised ligand 
escapes from the capture surface, causing a drift in the baseline RU prior to 
injection of the analyte (Bio-Rad Laboratories Inc., 2013; Lang et al., 2005).  
 
Experimental procedures can be implemented to correct for some of these 
problems, e.g. baseline drift can be corrected for by referencing with a blank 
buffer to improve accuracy (Bio-Rad Laboratories Inc., 2013; Lang et al., 
2005); the effect of mass transport, which occurs when the analyte diffuses 
onto the chip surface from the solution at a slower rate than the rate of 
binding between the analyte and ligand creating a shortage of analyte at the 
ligand surface, can be reduced through immobilization of less ligand, or 
through an increase in the analyte flow rate. Mass transfer can be corrected 
for post-experimentation, by analysing the kinetic data, using the 1:1 
Langmuir mass transport model (Bio-Rad Laboratories Inc., 2013; Lang et 
al., 2005). Although it is possible to correct for many of the experimental 
problems using reference blanks, in some cases the data simply does not 
fit a one-on-one model and further experiments to elucidate the cause of the 
lack of fit need to be investigated. 
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To date, the majority of published SPR data of HIV-1 Env-Ab interactions 
has been performed using GE Healthcare's Biacore platforms. We were 
concerned that results obtained from different SPR platforms may not be 
comparable. However a recent comparison of the performance of four 
biosensor instruments: GE Healthcare's Biacore T100, Bio-Rad's ProteOn 
XPR36, ForteBio's Octet RED384, and Wasatch Microfluidics's IBIS MX96, 
in which ten mAbs were evaluated against the same antigen under the same 
experimental conditions, has been published (Yang et al., 2016). When 
comparing the Biacore and ProteON, they found the data comparable within 
the working limits of the instruments, however it was noted that the Biacore 
instrument generated more consistent data. The authors of this comparative 
study attributed deviations in published binding kinetics to differences in 
methodologies, rather than differences in the platforms used. These 
differences include inconsistencies in ligand capture formats and ligand 
capture levels. The ProteON XPR36 is to be discontinued in the near future 
(Yang et al., 2016), for this reason, as well as the improved consistency of 
the Biacore instruments one could expect publications to continue to rely on 
the Biacore platforms for kinetics analysis.  
 
Overall, SPR provides a reliable, high-throughput method for characterizing 
and quantifying biomolecule interactions and was applied to Ab-Antigen 
binding in this instance. However, the data needs to be supported with 
additional biochemical characterization including sample purity analysis, the 
stoichiometry of the paratope-epitope interaction, and the ligand capture 
formats and levels which may reduce inter-laboratory variation. 
 
4.4.2 Surface plasmon resonance interactions of Env 
gp120/gp140GCN4(+) variants with 2dCD4Wt/S60C 
To confirm the integrity of the CD4bs on the Env variants, we performed 
SPR with two variants of the first two domains of CD4 (2dCD4). The 
2dCD4S60C variant was previously designed in our laboratory and shown to 
have an increased affinity (KD) for gp120 (6 nM) compared to 2dCD4Wt (53 
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nM) and was attributed exclusively to the significantly slower off-rate of 
2dCD4S60C, as a result of an intermolecular disulphide exchange between 
gp120 and the mutant 2dCD4 (Cerutti et al., 2010). 
 
Pertinent to this study, the incorporation of HIV-1 Envs of Indian origin 
(IN25925 and IN25710) that have reported resistance to IgG1b12 
neutralization, may also show decreased affinity for binding to CD4, due to 
the shared, partial epitope overlap. This could impact down-stream 
Env/2dCD4 liganded complex formation. Although the study by Kulkarni et 
al. (2009) showed no correlation between IgG1b12 resistance and 
resistance to sCD4, we sought to confirm the binding of CD4 to our Env 
variants.  
 
While our SPR experiments showed that all the Env variants were able to 
bind both variants of 2dCD4, disappointingly non-specific binding was too 
high (exceeding 10% RMAX) to accurately calculate binding affinities 
(Appendix - Figures B1 and B2) (personal communication, Dalia Shezifi, 
PhD, Applied Biology Group Leader, Bio-Rad Laboratories, Haifa). Non-
specific binding can be corrected by capturing a reference protein, such as 
BSA, to equivalent levels of the ligand on the chip surface and subtracting 
this interaction as a reference surface. Alternatively non-specific binding 
interactions can be limited by adjusting the buffer conditions including salt 
concentration, pH or the addition of a surfactant (Bio-Rad Laboratories Inc., 
2012). The non-specific binding of soluble CD4 has been reported by 
Yasmeen et al. (2014), who aimed to compare binding of a monomeric and 
trimeric HIV-1 Env to sCD4. The high background binding in their 
experiments, despite using different SPR sensor chips, resulted in them 
drawing the same conclusion as we have done here, that their HIV-1 Envs 
were able to bind to soluble CD4, however they were unable to assess the 
binding kinetics. Unfortunately in our experiments, limited amounts of Env 
glycoproteins prohibited further optimization in an attempt to obtain accurate 
binding affinities. Despite this, we were able to ascertain that all the Env 
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variants had an accessible and functional CD4bs as shown by the SPR 
sensorgrams (Figures 3.10 and 3.11).  
 
4.4.3 Surface plasmon resonance binding kinetics of the CD4bs 
directed bNAbs 
In an effort to further characterize the CD4bs of the Indian and South African 
purified Envs (gp120/gp140GCN4(+)) we performed additional SPR 
experiments against a panel of CD4bs directed bNAbs (IgG1b12, VRC01, 
HJ16, VRC-CH31, NIH45-46G54W, VRC03). The partial overlap of epitopes 
shared between CD4 and CD4bs-directed bNAbs may reveal slight 
differences that could contribute to future vaccine immunogen design.   
 
Sequence analysis of Env variants does not necessarily predict 
neutralization sensitivity of HIV-1 Envs. Published findings by Wu et al. 
(2009) and Li et al. (2011), have shown how non-contact residues outside 
the bNAb binding site epitope can affect tertiary folding of Env and therefore 
binding and neutralization CD4bs-directed bNAbs. Therefore it is critical the 
antigenicity of the expressed Envs be empirically determined and 
contextualized in relation to the amino acid sequences.  
 
A summary of the SPR experiments conducted in this thesis is provided for 
initial screening experiments using single analyte concentrations in Table 
3.2 and binding kinetic experiments in Table 3.3. The initial single analyte 
screening experiments (Figure 3.12 and 3.13) showed binding of the Env 
variants to all six immobilized bNAbs. This confirmed that the paratopes of 
the bNAbs immobilized were accessible to the Env variants, although ligand 
accessibility could not be quantified. However, a comparison of the binding 
affinities between the Env’s could be made since the same chip, with the 
immobilized ligand, was used for all the Env variants tested and was 
regenerated between Env analyses. In addition, the single analyte 
experiments provided a basis for subsequent Env concentration ranges that 
would yield accurate kinetic data. In general, a serial dilution series 
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consisting of four to five concentrations of analyte, with the highest 
concentration returning no more than 200 RU, is required for accurate 
kinetic calculations (Bio-Rad Laboratories Inc., 2009).   
   
BNAb IgG1b12 is directed against a discontinuous epitope overlapping the 
CD4 binding region of HIV-1 Env and is reported to neutralize 30 – 40 % of 
primary isolates of subtype B and C viruses (Bures et al., 2002; Georgiev et 
al., 2013; McInerney et al., 1997; Zwick et al., 2003). Envs of Indian origin 
have shown some resistance to neutralization by IgG1b12 (Kulkarni et al., 
2009). Binding kinetics were only obtained for the gp140GCN4(+)ZACAP45 
Env interaction with IgG1b12. Data was fitted to a 1:1 Langmuir model with 
an on-rate (Ka: 8.12 x 105 M-1s-1) and off rate (Kd: 3.41 x 10-4 s-1) forming a 
very stable complex with a binding affinity of 0.419 nM (Table 3.4). This Env 
showed a slightly more stable interaction compared to that reported by 
Hoorelbeke et al. (2013) for a subtype B Env gp140JRFL (Ka: 1.17 x 106; Kd: 
1.89 x 10-3; KD: 1.6) as well as that of monomeric gp120YU-2 (KD: 46.6) (Gift 
et al., 2011).  
 
We were unable to calculate accurate binding kinetics for the other 
gp120/gp140GCN4(+) variants tested with IgG1b12 since they did not fit the 
1:1 Langmuir model (Figure  3.14). We expected IgG1b12 to bind poorly to 
Indian Env variants IN25925 and IN25710 due to their reported resistance 
to neutralization by IgG1b12 (Kulkarni et al., 2009). Consistent with the 
reported neutralization resistances we found that single analyte analysis 
using 1000 nM concentrations of each Env, showed that the monomeric 
gp120 Envs IN25925 and IN25710 showed the lowest binding levels (Figure 
3.12). However improved binding for IN25710 to IgG1b12 was noted for the 
trimeric conformation compared to IN25925 and ZA706010164 (Figure 
3.13). In addition SPR sensorgrams depicted an exponential decay in the 
dissociation phase suggesting an overall lower binding affinity of the other 
Env variants tested (gp120ZACAP210/ZACAP45/IN25710/IN25925) and 
(gp140GCN4(+)IN25710/IN25925). The exponential decay resembles an 
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apparent biphasic response and has been reported previously for a 
IgG1b12 Fab fragment binding to gp140 Env (Feng et al. (2012)).  
 
It may be tempting to try and explain lack of fits to the 1:1 Langmuir model 
as a result of bivalent binding in which a biphasic dissociation curve is 
observed with a rapid first dissociation phase, followed by a second slower 
dissociation phase, ending in a curve almost parallel to the baseline 
(Homola et al., 1999; Zeng et al., 2014). However, one cannot simply apply 
the bivalent model to an interaction without confirming the stoichiometry of 
the paratope-epitope interaction first, by using a technique such as 
Isothermal titration calorimetry (ITC) (Yasmeen et al., 2014). Whilst 
determining the stoichiometry fell outside the scope of this thesis, future 
work could address this and also compare whole IgG binding versus using 
the Fab fragment of the IgG molecule in SPR experiments (Yasmeen et al., 
2014).  
 
We then evaluated whether each Env amino acid sequence could predict 
binding to specific bNAbs, and compared that to the actual SPR data 
obtained. IgG1b12 resistance is regulated by multiple regions of gp120 
(Utachee et al., 2010) and several factors contribute to this resistance 
including differences in amino acid residues, glycosylation and 
conformation. The mutations Y173H/S and D/E/N185G/S/T in the V2 loop, 
E/S268K/R (HXBc2 numbering) in the outer domain of the CD4bs have 
been reported to confer resistance to IgG1b12 neutralization (Gnanakaran 
et al., 2010). Evaluation of the amino acid residues confirmed that the three 
Env variants of Indian origin evaluated in this study do indeed contain a 
histidine (H) or serine (S) at position 173, and the 273K (HXBc2 268) 
mutation is present in the Indian Env variant IN25925. Interestingly only the 
susceptible Env variant IN26191 was found to contain the resistance 
conferring amino acid glycine (G) at position 185. None of the above 
signature amino acids were found to be present in the South African Env 
variants. While these amino acids have been shown to impact on IgG1b12 
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resistance, any single mutation alone or in combination with other 
documented resistance mutations may not necessarily confer a resistance 
phenotype (Li et al., 2011; Wu et al., 2009). 
 
The glycosylation of Env also plays an important role in the correct folding 
of gp120 as well as the structural rearrangements upon CD4 binding, 
directly affecting Ab recognition of gp120, viral entry and infectivity of the 
host cell (Huang et al., 2012; Kumar et al., 2011). Glycosylation sites (N197 
located at the V1/V2 stem and N186 located near the V2 tip overlapping the 
CD4bs) have been implicated in the resistance of HIV-1 (CRF01_AE) to 
IgG1b12 neutralization (Utachee et al., 2010; Wang et al., 2013). Together, 
these two N-linked glycans are thought to play a role in stabilizing the 
structure of the V1/V2 regions of Env and interfere with IgG1b12 binding by 
masking the epitope on gp120 (Utachee et al., 2010). Bearing in mind that 
the glycan composition of the Env variants in this study was predicted by 
the N-Glycosylate tool and that differential glycosylation patterns occur 
depending on the cell type used to express the Env (Raska et al., 2014), the 
glycosylation of our Env’s cannot be confirmed. In our analysis both 
IgG1b12 sensitive and resistant Envs were found to have PNLG’s present 
within the 185-190 region of the V2 loop, thus reinforcing the inconsistency 
of using amino acid/glycosylation profiles as a predictor of neutralization 
phenotype. However, the absence of PNLG at position 186 in the V2 loop 
for Env variants gp120/gp140GCN4(+)ZACAP45 and 
gp120/gp140GCN4(+)IN26191 may indeed increase their susceptibility to 
IgG1b12 binding, by reducing the steric hindrance inferred by this glycan 
(Figure 3.2) (Utachee 2010). 
 
Conformational changes in the V2C2 region of gp120 have been suggested 
as another possible factor for IgG1b12 resistance (Patil et al., 2014). The 
V1V2 domain is important for recognition by CD4bs-directed bNAbs, 
including IgG1b12. Variation in the V2 loop length may change the 
conformation of this region, resulting in the inaccessibility of the epitope 
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(Patil et al., 2014). Analysis of the V2 loop of the Env variants in this study 
reveals that Env variant IN26191 has a V2 loop containing 40 amino acids, 
whereas the V2 loop of the other Env variants comprise 45 amino acids 
(Figure 3.9). The shorter V2 loop length for Env IN26191 may have a 
conformational effect on the CD4bs epitope accessibility compared to the 
other Indian Env variants.  
 
VRC01 shares overlapping binding sites with CD4 and IgG1b12, however 
has been found to be far more potent, neutralizing over 90% of circulating 
HIV-1 variants compared to IgG1b12 and CD4-Ig. An important contact 
residue for VRC01 to gp120 is an N-linked glycan at position 276 on gp120 
(Wu et al., 2010; Zhou et al., 2010). Sequence analysis of the Env variants 
did not show the presence of any documented VRC01 resistance mutations, 
including PNLG at position 460 and 475, and the crucial PNLG for VRC01 
binding to gp120 at position 281 (HXBc2 276) was found to be conserved 
in all the Env variants (Figure 3.2) (Guo et al., 2012; Zhou et al., 2010).  
 
Single analyte screening experiments revealed that the Env’s of Indian 
origin showed favourable binding to VRC01 compared to the South African 
Env’s (Figures 3.12-3.13). Sequence analysis of Env IN26191 revealed the 
absence of the PNLG at position 294 (HXBc2 289), which has previously 
been reported to increase susceptibility to VRC01 (Wang et al., 2013). Our 
single analyte binding experiments confirmed preferential binding of this 
Env to VRC01 compared to the other monomeric gp120 tested (Figure 
3.12).  Binding kinetics obtained using VRC01 yielded the most consistent 
and reliable binding kinetic results against the South African and Indian Env 
variants tested. All binding kinetics experiments fitted the 1:1 Langmuir 
binding model and achieved a Chi2 value of less than 10% of Rmax.  
However, Env’s of Indian origin showed very little dissociation when binding 
to VRC01 (Figure 3.15) compared to the South African Env’s. Dissociation 
rates could only be accurately measured for the South African Env’s 
(gp120ZACAP210/ZACAP45 and gp140GCN4(+)ZACAP45) tested and one Indian 
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Env (gp120IN25925) (Figure 3.15, Table 3.4 and 3.5). The off-rates (Kd) for 
monomeric gp120IN25710, and trimeric gp140GCN4(+)IN25710/IN25925, could not 
be determined as these did not obtain the minimal 5% dissociation decay 
required for accurate measurement (Bio-Rad Laboratories Inc., 2011; 
Marquart, 2006-2016). The recommended dissociation time for Kd values 
lower than 1 x 10-5 s-1 and 1 x 10-6 s-1 should be extended to 85 and 850 
minutes, respectively to ensure adequate decay (>5%) and accurate Kd 
determination. The 10 minute dissociation times employed in our SPR study 
are thus too brief to accurately determine the Kd values, however the 
following conclusions can still be applied. Overall the Indian Env showed 
higher binding affinities for VRC01 compared to South African Envs, as a 
consequence of their lower dissociation rates (Kd <1.0 x 10-5). This 
markedly slow dissociation has been reported in other studies for VRC01 
Fab regions, with dissociation rates of <1 x 10-5 s-1 (Kovacs et al., 2012; 
Yasmeen et al., 2014).  
 
Comparison of the binding kinetics of VRC01 with the 
gp120/gp140GCN4(+) Env variants showed an overall higher binding 
affinity for the trimers compared to the monomers (Figure 3.15 and Tables 
3.4-3.5). Interestingly this was a result of both a favourable on-rate and off-
rate, which is in contrast to the results reported by Yasmeen et al. (2014), 
who showed a ten-fold difference in overall binding affinity of the BG505 
gp120-gp41ECTO monomer compared to the BG505 SOSIP 664 trimer. Our 
data is similar to those reported previously for subtype C monomers and 
trimers with an overall binding affinity ranging between 20 – 139 nM, 
consistent with the findings of (Kovacs et al., 2012 and Scheid et al., 2011 
who reported a 0.4 – 96 nM binding affinity range when using VRC01 Fab 
fragment.  
 
VRC-CH31 is a VRC01-like antibody that recognizes the CD4bs epitope. 
Critical contact residues on gp120 for VRC-CH31 binding include 279N/D, 
280N, 456R, 458G and 459G and were found to be conserved in all Env 
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variants (West et al., 2012). The on-rates (Ka) were similar for all the VRC-
CH31 gp120 and gp140GCN4(+) Env’s tested and were comparable to 
those obtained for VRC01 (less than a 3-fold difference). Only gp120ZACAP210 
showed negligible binding to VRC-CH31. However the overall binding 
affinities (KD) were at least five-fold greater than those observed for the 
South African Env variants. Similar to VRC01, Indian Env IN25710 
(monomeric and trimeric) showed no detectable dissociation and thus the 
dissociation rate (Kd) could not be accurately determined. However, this 
highly stable interaction suggests an overall binding affinity in the sub-nano 
molar range for Env IN25710 to VRC-CH31. The South Africa 
gp140GCN4(+)ZACAP45 showed a four-fold increase in binding affinity over 
the matched monomer, however the same pattern was not observed for the 
Indian IN25925 monomeric and trimeric Envs which showed equivalent 
binding affinities.  Our binding affinities of the Env variants to VRC-CH31 
ranged between 9.8 – 200 nM. The published findings by Kovacs et al. 
(2012) showed different binding affinities of VRC-CH31 to an HIV-1 subtype 
C monomer (C977ZA012), with a KD of 4.6 x 10-6 M, whereas the matched 
trimer had an overall binding affinity of 13 nM, consistent with our study. 
 
VRC03 is somatically related to VRC01 and also binds to the CD4bs of 
gp120, but its neutralization is less broad than that of VRC01 (Wu et al., 
2010). The gp120 amino acid contact residues for VRC03 binding are 
strikingly similar to VRC01 (Figure 3.2) and are largely conserved among 
the Env variants in this study. However VRC03 is able to neutralize 50 % of 
HIV-1 isolates, compared to 90 % by VRC01. The amino acid residue 
alteration at position 441 (HXBc2 position 429) in Env variant 
gp120/gp140GCN4(+)ZACAP45 has a glycine (G) whereas the other Env’s 
have a negatively charged glutamic acid (E). This affects the charge of the 
protein in a region important for VRC03 binding (Wu et al., 2011) (Figure 
3.2). The SPR experiments showed negligible binding to both the 
monomeric and trimeric conformations of Env ZACAP45, and is most likely 
due to this mutation.  
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Binding of VRC03 with Env IN25925 was also poor, however we were able 
to calculate the binding affinity for the monomeric conformation 
(gp120IN25925). The binding affinity of gp120IN25925 was determined to be KD: 
37.6 nM (Figure 3.19 and Tables 3.4-3.5), approximately two-fold higher 
than that reported with Env gp120YU-2 (KD: 16.1 nM) (Wu et al., 2010). The 
difference could be attributed to the different gp120 isolate (YU-2) used in 
the report by Wu et al. (2010). Overall VRC03 binding was poor for the Env 
variants compared to the binding observed with VRC01, which is consistent 
with the lower neutralization profile of VRC03 than VRC01. 
 
HJ16 is a glycan dependent CD4bs antibody that recognizes an epitope on 
the CD4bs that is related, but non-overlapping, to IgG1b12 and is also 
dependent on the N276 glycan located on the outer domain of gp120 (Balla-
Jhagjhoorsingh et al., 2013; Corti et al., 2010). In addition, amino acid 
residues important for HJ16 binding include D489, R490 (HXBc2 positions 
474 and 476) and a combination of M490 and R491 (HXBc2 position 475 
and 476) (Pietzsch et al., 2010). The amino acid residue M490 and N276 
glycan are conserved in all the Env variants. However, Env ZACAP45 
contains both D489N and R491K mutations, and Env ZACAP210 contains 
the R491K mutation (Figure 3.2).  
 
The kinetic data obtained for the Env’s tested (ZACAP45 and IN25925) 
supported these amino acid mutations and revealed insufficient binding of 
HJ16 with gp120ZACAP45 (RU binding signal < 10, (Yang et al., 2016)), and 
minimal binding to the trimeric conformation gp140GCN4(+)ZACAP45. Env 
gp140GCN4(+)IN25925 formed the most stable complex with a 4.3-fold 
greater affinity compared to its matched monomers.  
 
NIH45-46G54W is a more potent clonal variant of the VRC01 CD4bs-directed 
antibody, in which a single substitution (Glycine to Tryptophan at position 
54) gave rise to increased contact with the gp120 bridging sheet and thus 
improved breadth and potency of the Ab (Diskin et al., 2011). Kinetic data 
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was obtained for NIH45-46G54W binding to Envs 
gp120ZACAP210/ZACAP45/IN25710/IN25925 and gp140GCN4(+)ZACAP45/IN25925, which 
all had similar association and dissociation rates (Figure 3.18 and Tables 
3.4 – 3.5). The dissociation rate for gp140GCN4(+)IN25710 was extremely 
slow, but could not be validated due to the limited dissociation time of the 
experiment. Binding affinities ranged between 6.74 – 24.1 nM, consistent 
with a published findings by Diskin et al. (2011), with the exception of 
gp120ZACAP210 which had an approximately ten-fold lower binding affinity of 
273 nM. Comparison of the amino acid sequences in which the substitutions 
D/N279K, Q456S, Q458Y and Q459E (Diskin et al., 2011) (Figure 3.2) have 
been suggested to confer resistance to NIH45-46G54W revealed that none of 
these resistance mutations occurred in any of the Env variants in this study. 
 
Poor binding was observed for the monomeric Env variants to bNAb 
PGT145 compared to the trimeric Env variants tested (Figure 3.20). This 
was expected since this bNAb binds to an epitope that is presented in the 
context of the trimeric spike (Yasmeen et al., 2014). This confirmed that the 
gp140 Env variants tested (gp140GCN4(+)IN25925/IN25710) were successfully 
stabilized by the GCN4 trimerization motif and were in a native-like 
conformation. Unfortunately insufficient quantities of the other Env variants 
prohibited binding analysis with bNAb PGT145, limiting the evaluation of the 
native-like conformation to the two Indian Env’s IN25925 and IN25710. 
 
Overall, the trimeric gp140GCN4(+) Env variants showed higher binding 
affinities to the bNAbs evaluated compared to the matched gp120 
monomers (Table 3.4 and 3.5). This observation has been reported for 
several bNAbs in the literature including IgG1b12, 2G12, VRC01, VRC-
CH31 and 2F5, which have a stronger affinity for trimeric Env’s presumably 
due to their resemblance to the native trimer, than for the gp120 monomer 
(Fouts et al., 1997; Kovacs et al., 2012; Sanders et al., 2015; Zolla-Pazner 
and Cardozo, 2010). Whether this is due to increased binding stoichiometry 
or the overall quaternary conformation of the trimeric Env is unclear.  BNAbs 
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recognizing quaternary epitopes formed on a mature HIV-1 virion include 
2909, PG9 and PG16. These Abs generally do not bind to gp120 
monomers, and if they do, it is a weak interaction because these Abs only 
recognize epitopes on a quaternary structure on Env, which develop as a 
result of multimerization of the protein-protein Env subunits (Fouts et al., 
1997; Kovacs et al., 2012; Sanders et al., 2015; Zolla-Pazner and Cardozo, 
2010).  
 
The trimeric Env spike consists of three gp120 monomers, therefore it has 
three equivalent CD4 binding sites. In a study of a subtype C trimer, it was 
found that all three binding sites were accessible to CD4, but that each 
binding site had a different affinity for CD4 compared to a subtype B trimer 
in which the binding affinities were the same for each CD4bs (Saphire et al., 
2001). Another study using a subtype C trimer determined that only two of 
the three CD4 binding sites were accessible for CD4 binding (Pancera et 
al., 2005). It has been suggested that the orientation of the gp120 monomer 
determines the CD4bs accessibility, which in turn is dependent on the 
trimerization motif used to stabilize the three gp120 monomers into a 
trimeric conformation (Saphire et al., 2001). In addition, the Fab region of 
VRC01 has been shown to bind to gp140 in a 3:1 stoichiometry (Kovacs et 
al., 2012) but a single antibody has been found to inactivate an Env trimeric 
spike suggesting that the efficiency of antibody binding is the important 
determinant of neutralization potency (Yang et al., 2005). Based on this it is 
likely that the improved binding of bNAbs to the trimers compared to the 
monomers is a result of improved presentation of the discontinuous CD4bs 
epitope in the context of a trimeric Env spike which presents the epitope in 
a native-like conformation. 
 
The comparison of the CD4bs-directed bNAbs with our Env’s confirm that 
resistance to an Ab is influenced by a combination of factors including amino 
acid mutations within the targeted epitope or of non-contact residues, 
variations in glycosylation and size of the variable loops. Together, these 
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factors contribute to the overall conformation of Env, ultimately determining 
the accessibility of epitopes targeted by bNAbs (Wu et al., 2009), whereas 
a single difference may be tolerated. Moreover, although they appeared 
functional and conformationally correct, the impact of imperceptible 
differences during the expression and purification of these recombinant 
proteins on appropriate epitope exposure cannot be excluded.  
 
With the exception of VRC03 and IgG1b12, the Indian Env variants 
displayed higher affinities for the bNAbs compared to the South African Env 
variants. Generally, this is a consequence of the slower dissociation rates 
observed for binding of the bNAbs with the Indian Env variants. An Env with 
a higher avidity could stabilize the Env-naïve B cell interaction and could 
trigger the appropriate maturation pathway, driving the evolution of bNAbs 
over time, potentially making it a better Env for vaccine immunogen design 
(Liao et al., 2013b). Having said this, the SPR binding studies were 
performed with Abs that have already undergone high affinity maturation, 
and Env’s with a high avidity for these Abs may not be sufficient to engage 
the naïve B cell and drive the appropriate response (Bhiman et al., 2015; 
Liao et al., 2013b).  
 
Altogether, this suggests that the Env variants are antigenically correct and 
suitable for complex formation and immunogenicity testing in small animals. 
The immunogenicity study was carried out with one representative Env from 
each region namely IN25925 for India and ZACAP45 for South Africa. The 
2dCD4-liganded gp120/gp140ZACAP45/IN25925 Env variants were successfully 
generated and purified for the immunogenicity assays. SDS-PAGE analysis 
(Figure 3.23) confirmed the successful formation of the complexes. 
 
4.5 Comparative Immunogenicity of recombinant 
gp120/gp140GCN4(+) Env variants, peptides, DNA vaccines and 
cyclic permutants  
As mentioned earlier, HIV-1 subtype C has developed into the most 
significant subtype worldwide and is associated with almost half of the HIV-
4-149 
 
1 infections worldwide. It accounts for the majority of infections in South 
Africa and India and is mainly acquired via heterosexual transmission, with 
the infections in India having originally been introduced by a single South 
African lineage (Hemelaar, 2012; Kulkarni et al., 2009; Shen et al., 2011; 
UNAIDS, 2015; van Harmelen et al., 1997; van Harmelen et al., 1999). Early 
research using T-cell line adapted strains of HIV-1 Env in vaccine design 
failed to elicit bNAbs following vaccination. Given the appreciation in the 
difference of neutralizing sensitivity between laboratory-adapted and 
primary viral strains, the majority of HIV-1 Env subunit vaccines are based 
on sequences derived from primary HIV-1 infected patients and thus better 
represent viral strains circulating within the general population (Mascola et 
al., 1996; Sawyer et al., 1994; Wrin et al., 1995).  
 
Numerous strategies aimed at better mimicking the native-like trimeric 
conformation of Env, or improving the exposure of bNAb epitopes using 
cyclic permutants, crosslinking Env with CD4, or using epitope scaffolds are 
gaining significance (Correia et al., 2014; Devico et al., 1996; Ofek et al., 
2010; Saha et al., 2012; Sanders et al., 2015). To this end, we compared a 
number of different vaccine strategies, including monomeric Envs 
(gp120ZACAP45/IN25925), trimeric stabilized Envs 
(gp140GNC4(+)ZACAP45/IN25925), gp120 outer domain fragments 
(ODECCOPBPICS gp120), monomeric and trimeric cyclic permutants 
(Cyc4OD gp120JRFL, and gp120JRFL h-CMP V1cyc 144-142), VRC01 
engrafted epitope scaffolds (1ORC and 1WR2), heterologous DNA prime 
(Wt-JRFL-Env-DNA, JRFL Env-570D DNA, JRFL Env-SEKS DNA), protein 
boost (gp140FV, gp120JRFL h-CMP V1cyc 144-142) immunization protocols 
and CD4-liganded gp120/gp140GCN4(+) complexes (using Env’s 
ZACAP45 and IN25925) to elicit neutralizing antibody’s following 
vaccination of rabbits. The focus of the first arm of the immunization study 
was on HIV-1 subtype C sequences, the second arm of immunogens were 
designed using an HIV-1 subtype B sequence. 
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Env/2dCD4S60C liganded complexes were successfully generated as shown 
by SDS-PAGE analysis (Figure 3.22). The presence of contaminating bands 
was noted as discussed in section 4.2, and could possibly be cleaved gp41-
GCN4(+) products. The 2dCD4S60C variant, used to stabilize the various 
Env’s to expose a CD4i epitope, was used to control for neutralization 
breadth obtained by NAbs directed towards 2dCD4S60C rather than the 
desired CD4i epitope of the Env/2dCD4S60C liganded immunogens. The 
2dCD4Wt variant provided a comparison to the 2dCD4S60C variant. The 
2dCD4FD variant control does not fold correctly and has previously been 
shown to be unable to bind to gp120 (Cerutti et al., 2010), therefore no 
neutralizing response was expected from this group. These 2dCD4 variant 
controls would also demonstrate the importance of using a correctly folded 
2dCD4 in these immunogen complexes. 
 
Midpoint antibody titre’s were determined for the second arm of 
immunogens (stabilized gp120/gp140 derivative immunogens) in the 
heterologous prime, protein boost immunized rabbits at week 10 (two weeks 
after the last prime immunogen and two weeks prior to the first boost 
immunogen) by midpoint titre ELISA’s against their cognate antigens 
(Figure 3.25). In addition, terminal antibody titres elicited in the rabbits were 
determined by endpoint titre ELISA’s for all the immunogens (first and 
second arm) against their cognate antigens (Figures 3.24 and 3.25).  
 
Due to differences in immunogen types, doses administered to rabbits, 
immunization protocols and titre proteins used in ELISA assays, direct 
comparison of midpoint and endpoint titres should be considered with 
caution. However, several observations were made. Midpoint anti-gp140FV 
mean antibody serum titres were higher for groups immunized using 
proteins primes (ranging between 103 – 104) compared to the rabbits that 
were primed using DNA (102 for all DNA immunogens). Anti-matched 
peptide titres (1ORC and 1WR2) were found to be the higher for 1ORC (106) 
compared to 1WR2 (104) (Figure 3.25). 
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Compared to the anti-gp140FV titres, midpoint anti-hCMP-JRFL-V1 cyc titres 
were approximately ten-fold higher for Cyc4OD (105), 10-fold lower for 
ODECCOBPICS-C (102), but similar for the DNA prime immunogens (all 
ranging between 102 and 103). The low Ab titres detected using DNA 
immunogens compared to protein immunogens was consistent with a study 
in Indian rhesus macaques, which compared immunization regimens using 
trimeric JRFL DNA and protein immunogens in various prime-boost 
combinations  (Chakrabarti et al., 2013). They reported detecting much 
lower Ab titres after DNA only immunizations compared to immunizing with 
the corresponding protein only. However, the Ab titres of the macaques 
immunized with DNA prime vaccines increased 20-fold after a single protein 
boost (Chakrabarti et al., 2013). In contrast, Vaine et al. (2010) compared 
different vaccination regimens in rabbits using JRFL gp120 DNA and protein 
immunogens alone or in combination and found no differences in the 
terminal bleed Ab titres. However, their titres were detected after five 
immunizations, compared to only three DNA immunizations in our study, 
which may account for the difference. Despite the low levels, the Ab titres 
observed suggest that JRFL Env expression in vivo was induced by the 
DNA prime immunogens, and the responses observed were detectable by 
the HIV-1 subtype B Env JRFL as well as the subtype C Env gp140FV. 
 
In order to compare the endpoint titres of the terminal bleed sera obtained 
from rabbits immunized with the stabilized gp120/gp140 Env derivative 
immunogens, they were titred against hCMP-JRFL-V1 cyc (Figure 3.25). 
The animals primed with protein and DNA immunogens showed a marked 
increase in the Ab titres after the protein boosts compared to the week 10 
sera as follows: approximately five-fold increase for Cyc4OD (1.00 x 106), 
approximately 1 x 104 fold increase for ODECCOBPICS-C (5.76 x 106), 
approximately 4.0 x 103 times increase for WT-JRFL Env DNA (3.2 x 106); 
1.2 x 103 times increase for JRFL-Env-V570D (1.28 x 106) and 3.84 x 103 
times increase for JRFL Env-SEKS DNA (1.28 x 106). A smaller increase of 
approximately 400 times was observed for group 8 (JRFL-Env-V570D 
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prime, gp140FV boost). This lower increase compared to the other groups 
can be attributed to the use of the gp140FV protein used as a boost 
immunogen whereas the other groups were boosted with the hCMP-JRFL-
V1 cyc protein. This was expected since one would expect to obtain higher 
titres when using a matched immunogen compared to that obtained using a 
different Env isolate. The Ab titres of the terminal bleeds for the animals 
immunized with the VRC01 epitope engrafted scaffold peptides 1WR2 and 
1ORC, followed by gp140FV protein boosts had similar anti-hCMP-JRFL-V1 
cyc titres (105). Our terminal bleed end-point titres were comparable to the 
findings of a study by Kesavardhana et al. (2016) in which a DNA prime-
protein boost guinea pig immunization study using hCMP-V1-cyc-144-142 
reported end-point titres ranging between 106 and 107. 
 
The marked increase in endpoint titres between those detected after boost 
immunizations compared to those detected after prime immunizations is 
similar to the NHP study comparing immunization with JRFL gp140 DNA-
prime, protein-boost regimens by Chakrabarti et al. (2013) mentioned 
above. Although exact values cannot be compared between the studies due 
to the use of different immunogens and a different animal model, the same 
trend was observed of a marked increase in Ab titres (approximately 100-
fold in their case) post boosting with three JRFL gp140 protein inoculations. 
 
The matched terminal anti-Env responses that were elicited in the rabbits 
for the South African Env ZACAP45 (6.4 x 105 for the monomer and 8.5 x 
105 for the trimer) were approximately 10-fold lower than those detected in 
the Indian Env IN25925 (4.3 x 106 for the monomer and 3.4 x 106 for the 
trimer). Interestingly there was little difference in the endpoint titres for the 
monomeric compared to the matched trimeric Env conformations (Figure 
3.24). This is in contrast to published studies which have found that trimers 
generally induce higher titres of binding antibody responses than their 
corresponding monomers (Kim et al., 2005; Kovacs et al., 2012). In addition, 
these anti-Env endpoint titres determined for the South African and Indian 
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Envs are approximately 10-fold to 100-fold, higher than those obtained in a 
previous study in our laboratory (Killick et al., 2015) and can be attributed to 
the different cut-off value determination used in the ELISA.  
 
For the purposes of comparison, anti-2dCD4S60C responses were 
determined by ELISA for rabbits immunized with all the 2dCD4S60C/Wt/FD 
control groups. All the 2dCD4 variants elicited fairly high titres against 
2dCD4S60C ranging between 106 and 107, with the 2dCD4FD variant eliciting 
the highest titres (Figure 3.24 A). 
 
When comparing the endpoint titres of the Env/2dCD4 liganded groups, the 
sera obtained from the rabbits of groups immunized with these complexes 
elicited similar matched anti-Env titres, with the exception of 
gp140GCN4(+)IN25925/2dCD4 which elicited remarkably lower matched anti-
Env titres (Figure 3.24 B). However, the anti-2dCD4S60C responses in rabbit 
sera immunized with the Env/2dCD4 liganded groups were ten-fold higher 
for the gp120/2dCD4 liganded groups compared to the 
gp140GCN4(+)/2dCD4 liganded groups (Figure 3.24 A). In contrast to our 
previous findings (Killick et al., 2015), the gp120/2dCD4 liganded groups 
elicited similar anti-2dCD4S60C titres to the 2dCD4S60C control group, 
however the lower anti-2dCD4S60C titres elicited for the gp140/2dCD4 
liganded groups is consistent with this study.  
 
We compared the ability of the Ab’s elicited with the different immunogens 
to neutralize a diverse panel of HIV-1 strains encompassing different HIV-1 
subtypes with different neutralization sensitivities. As mentioned in section 
3.5.2, terminal bleed sera from rabbits immunized with Env gp120IN25925, 
liganded and unliganded with 2dCD4S60C, the three 2dCD4 variant control 
groups, as well as the control in which the reducing agent was omitted 
during complex formation of Env/2dCD4S60C, were sent to Monogram 
BioSciences Inc. who performed the PhenoSense Neutralizing antibody 
assay against a panel of 15 HIV-1 pseudotyped viruses from different tiers 
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(Tier 1 – 3, with Tier 1 ranked as being the most sensitive and Tier 3 being 
the least sensitive to neutralization by NAbs (Seaman et al., 2010)), as well 
as HIV-2 and SIV (Table 3.6) (Killick et al., 2015). The sera of rabbits 
immunized with the remaining immunogens of the first arm of immunizations 
and all the sera from rabbits immunized with the second arm of immunogens 
were assayed in-house against a smaller panel of four HIV-1 pseudoviruses 
representing Tier 1 and 2 (Table 3.7 and 3.8). Prebleed sera were also 
assayed and found to have no neutralization activity (Tables 3.6 – 3.8). 
 
Despite having high endpoint titres, overall the Env variants (gp120 and 
gp140GCN4(+)) and the stabilized gp120/gp140 Env derivatives elicited 
Abs with very low neutralization responses, limited to Tier 1 neutralization 
of isolate SF162 and virtually no neutralization of isolate BaL (Tables 3.6 – 
3.8). Although our comparison of these immunogens is limited to SF162, a 
subtype B isolate, varying potencies were observed between these groups. 
 
The Abs raised against the monomeric and trimeric Env immunogens of 
South African and Indian origin were similar in their neutralization 
responses, both when tested at Monogram Biosciences Inc. or in-house 
(Tables 3.6 and 3.7). This is in contrast to published studies which have 
found that trimers generally induce higher titres of neutralizing antibody 
responses than their corresponding monomers (Kim et al., 2005; Kovacs et 
al., 2012; Li et al., 2006; Zhang et al., 2007), however is consistent with our 
previous findings (Killick et al., 2015).  
 
The rabbits primed with protein immunogens (Groups 1 and 2, Table 3.8) 
elicited a very low neutralization response with an average ID50 
neutralization titre against SF162 of 89 and 196, respectively. Cyclic 
permutants provide a method of stabilizing gp120 while maintaining its 
native fold by effectively moving the N- and C-termini of gp120 into one of 
the variable loops by complete or partial deletion of that loop. Cyclic 
permutants further stabilized with the addition of a trimerization domain, 
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have been shown to bind to sCD4 as well as bNAbs IgG1b12, PG9 and 
PG16 (Saha et al., 2012). Unfortunately, this alternative method of Env 
stabilization did not elicit the desired NAbs following immunization of rabbits.  
 
This poor neutralization response was also observed with the gp120 outer 
domain fragment (ODECCOBPICS) immunogen. The ODECCOBPICS 
fragment protein aimed to present non-glycosylated conserved epitopes of 
gp120, found on the outer domain, to the immune system. Since this 
fragment-based immunogen excludes the inner domain of gp120, it would 
limit the non-neutralizing Abs that are normally directed towards this region 
of gp120 (Bhattacharyya et al., 2010). A gp120 outer domain fragment 
based on the HXBc2 isolate was shown to elicit Abs with moderate 
neutralization against one subtype C (Tier 1)  and three subtype B (Tier 2) 
pseudoviruses (Bhattacharyya et al., 2010). Similarly, the neutralization 
response in our immunization experiments using this fragment immunogen 
(based on the JRFL sequence) was directed towards Tier 1 pseudoviruses, 
despite several boost immunizations with the gp140 cyclic permutant 
protein. 
 
A small increase in neutralization of SF162 was observed in sera of rabbits 
primed with a DNA immunogen. Compared to protein-based immunogens, 
DNA-based immunogens are simple to produce, stable and easily 
characterized (Kalams et al., 2013). They are also regarded as a safer 
option compared to attenuated viral vectors (Kalams et al., 2013). DNA 
vaccines have been reported to generally be unable to elicit bNAbs when 
used in isolation, however, when immunized in combination with an Env 
protein (boost) a more robust response is observed (Kalams et al., 2013; 
Leung et al., 2004; Munseri et al., 2015; Richmond et al., 1998). We 
evaluated three DNA-based immunogens in a heterologous prime-boost 
regimen, each one expressing Env based on the JRFL isolate. These 
included an Env in which a V570D mutation was introduced to stabilize the 
trimer, an uncleaved Env (SEKS) as well as the wild-type Env. These were 
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followed by protein boosts using the subtype B stabilized gp140 cyclic 
permutant or the subtype C gp140FV. The use of DNA-immunogens has 
been shown to reduce viremia in NHP models (Patel et al., 2013; Rosati et 
al., 2009) and over 70 human phase I and II trials have been completed in 
which a DNA-based immunogen either in isolation or in combination with a 
protein or viral vector have been tested (IAVI, 2017). However, a phase III 
human efficacy trial (HVTN 505) testing a heterologous prime-boost 
regimen in which the DNA immunogen expressed gag, pol, nef and env 
genes as well as two Env proteins from subtype A and C, was prematurely 
withdrawn due to futility and safety concerns (Excler and Michael, 2016; 
Sheets et al., 2016; Shin, 2016). A comparison between our DNA 
immunogen groups showed a four-fold greater neutralization of SF162 
when immunized with the JRFL-Env-570D DNA prime (average ID50 of 588) 
compared to the wild type (average ID50 of 149). The uncleaved DNA prime 
JRFL-Env-SEKS DNA elicited an even higher neutralization response to 
SF162 (average ID50 of 977). This is probably due to an improved native-
like structure of the JRFL-Env-570D and the uncleaved JRFL-Env-SEKS 
trimers compared to the WT-JRFL Env. Boosting with gp140FV compared to 
h-CMP-JRFL-V1 cyc 144-142 after priming with JRFL-Env-V570D DNA 
resulted in a similar neutralization response to SF162 (average ID50 of 544) 
(Table 3.5). The increased neutralization response seen in our DNA prime, 
protein boost regimens compared to protein prime, protein boost regimens 
has been reported previously (Vaine et al., 2008; Vaine et al., 2010; Wang 
et al., 2005). It has been suggested that immunizing with a DNA vaccine 
induces a higher quality initial Ab response compared to immunizing with a 
protein vaccine. A possible explanation for this has been suggested by 
Vaine et al. (2010) to be due either to the induction of Abs with a superior 
biophysical quality or to the DNA immunogen presenting an improved 
antigen conformation to the immune system compared to a protein 
immunogen.  
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The VRC01 scaffold peptides, in particular 1ORC, designed to focus the Ab 
response to the VRC01 epitope showed improved neutralization of SF162 
compared to the other immunogens. The neutralization response of rabbits 
immunized with 1WR2 was comparable to those immunized with the 
uncleaved DNA prime JRFL-Env-SEKS DNA. However rabbits immunized 
with 1ORC elicited an average two to four-fold increase in ID50 neutralization 
titre against SF162 compared to the gp120/gp140GCN4(+) Env variants as 
well as the stabilized gp120/gp140 Env derivative immunogens. This shows 
anti-HIV Ab responses can be induced by presenting only a specific epitope 
to the immune response. This is consistent with published findings which 
report that although a low neutralization response is seen with scaffold 
peptides, they are able to direct the immune response to various epitopes 
on Env (Jiang et al., 2016; Morris et al., 2017; Ofek et al., 2010). 
 
Altogether, these results are consistent with the ongoing frustration in the 
HIV-1 vaccine field in which immunogens are typically unable to induce 
NAbs that display the neutralization breadth across heterologous primary 
isolates of HIV-1 required for an effective vaccine (Beddows et al., 2007; 
Cho et al., 2001; Sanders et al., 2015). The findings of a study in which 
guinea pigs were immunized with the h-CMP v1cyc 144-142 immunogen, 
were shown to generate a gp120 directed neutralizing response able to 
neutralize Tier 1 isolates but displayed weak neutralizing activity against 
Tier 2 isolates (Kesavardhana et al., 2016). This response was also 
reported by Vaine et al. (2010) who compared JRFL gp120 DNA and protein 
prime-boost vaccination regimens in rabbits.  
 
Using gp120 in immunizations typically elicits Abs targeted to linear 
epitopes in the V3 loop, and SF162 is extremely sensitive to neutralization 
by V3 loop directed antibodies  (Pinter et al., 2004; Sanders et al., 2015; 
Vaine et al., 2010; Vancott et al., 1995b). It is therefore possible that most 
of the Abs elicited in our study using the (gp120 and gp140GCN4(+)) Env 
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variants and stabilized gp120/gp140 Env derivatives are directed to the V3 
loop, however epitope mapping experiments would have to confirm this.  
 
More promising neutralization responses were obtained from the 
gp120/gp140GCN4(+)/2dCD4S60C liganded immunogens aimed to expose 
cryptic epitopes on Env that are only exposed post binding to CD4. A direct 
comparison between the neutralizing responses induced by the 2dCD4-
liganded immunogens is limited since the first immunization experiment’s 
rabbit sera, which was tested by Monogram Biosciences Inc., was assayed 
against as panel of 12 HIV-1 pseudovirus isolates (Table 3.6) whereas the 
subsequent terminal bleed rabbit serum samples, were tested in-house and 
only assayed against a panel of four HIV-1 pseudovirus isolates (Table 3.7).  
 
However, the same trend was observed and in addition, the trends were 
consistent with the previous findings in our laboratory (Killick et al., 2015), 
in which the 2dCD4-liganded Envs complexes elicited a bNAb response 
capable of cross-subtype neutralizing response of subtype B and C isolates 
from Tiers 1 and 2. The neutralizing response was improved for the trimeric-
liganded complexes (gp140GCN4(+)/2dCD4S60C) compared to the 
monomeric liganded complexes (gp120/2dCD4S60C) regardless of the Env 
sequence used. 
 
We were concerned that the use of the reducing agent, β-mercaptoethanol 
(to facilitate the formation of inter-molecular disulphide stabilization of the 
complex), during complex formation may have had an aberrant effect on 
intra-molecular disulphide bond formation of Env, resulting in a 
conformational change in the Env variants. We therefore included a control 
using the gp120IN25925/2dCD4S60C complex in which no β-mercaptoethanol 
was used during complex formation. No difference was observed on SDS-
PAGE analysis (Figure 3.21) and the difference in immunogenicity as tested 
in neutralizing antibody assays was negligible (Table 3.3). 
 
4-159 
 
We included a set of 2dCD4Wt/FD/S60C variant controls to control for 2dCD4 
only NAbs in downstream pseudovirion assays. Three of the five rabbits 
immunized with 2dCD4Wt as well as three of the five rabbits immunized with 
2dCD4S60C showed activity in the pseudovirion assays (Table 3.6). Of these, 
three showed ID50 neutralization values greater than 100 of Tier 2 
pseudoviruses, whereas none of the rabbits immunized with the 2dCD4FD 
control elicited neutralizing Abs. This was expected since 2dCD4FD does not 
fold correctly and has been shown to be unable to bind to gp120 (Cerutti et 
al., 2010). This shows that the 2dCD4Wt/S60C variants were correctly folded 
and in the correct conformation and displayed the correct epitopes. We 
therefore hypothesised that the Abs elicited with the 2dCD4Wt/S60C variants 
target the CD4 receptors on TZM-bl cells in the pseudovirion assays and 
block infection, although this was not tested. Despite this, not every rabbit 
in these groups responded, even though they received 2dCD4 
immunogens. On average, a more consistent neutralization response was 
achieved from groups immunized with the Env/2dCD4 liganded complexes. 
 
One would expect to see Ab responses against the human 2dCD4 in rabbit 
sera as it differs significantly from rabbit 2dCD4 and only shares 55 % 
similarity (Liu et al., 1999) and is thus recognized as foreign. This was noted 
in a similar study by Schwartz et al. (2016) who assessed a gp120-CD4 
immunogen in cynomolgus macaques and compared the use of different 
CD4 molecules complexed to gp120 in order to assess whether a response 
is induced when heterologous CD4 molecules are used. They compared 
three gp120-CD4 complexes, one using a human CD4, one using a rhesus 
macaque CD4 and one using a cynomolgus macaque CD4. They detected 
anti-CD4 Abs against the human CD4, but not the rhesus or cynomolgus 
macaque CD4. The latter two CD4 sequences are 100 % homologous, 
therefore confirming that the elicitation of heterologous anti-CD4 titres 
occurs in immunization studies when using interspecies immunogens. This 
raises the question of whether the same neutralizing response would be 
induced if humans were vaccinated with our Env/2dCD4 liganded complex. 
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An anti-2dCD4 response raises the concern of autoreactivity. Anti-CD4 Abs 
have been detected early in HIV-1 infected individuals (Keiser et al., 1992) 
and have been implicated in neutralizing HIV-1 infection via post-attachment 
activity (Hou et al., 2015). Approximately 10-15 % of HIV-1 infected 
individuals contain Abs against CD4 which target domains three and four of 
CD4 (Chams et al., 1988; Kowalski et al., 1989). In addition, Abs directed 
against the extracellular portion of CD4 have been detected in 
approximately 10 % of HIV-1 infected patients and are thought to be 
directed to a transiently exposed epitope on CD4 on binding to gp120 
(Kowalski et al., 1989).  
 
Human phase 1 clinical trials in which HIV-1 infected patients were 
administered CD4 were found to be safe and well tolerated (Hodges et al., 
1991; Kahn et al., 1990; Schacker et al., 1995). By the same token, HIV-1 
bNAbs are often autoreactive (Mascola and Haynes, 2013). As an example, 
the bNAb VRC01 has been found to bind human ubiquitin ligase E3A, an 
enzyme involved in normal cell functioning (Liu et al., 2015b). Therefore, 
preclinical studies and early clinical trials will have to assess the safety and 
tolerance of any Abs regardless of their target epitope.  
 
Interestingly, the end-point titre data does not correlate with the pseudovirus 
neutralization data, and there appears to be an inverse relationship between 
the anti-Env and anti-2dCD4S60C endpoint titre and the neutralization data. 
For example, the gp140IN25925/2dCD4S60C complex generated very low anti-
2dCD4 and anti-Env titres (Figure 3.24), yet showed very high neutralization 
of pseudoviruses Sf162, BaL, ZM53 and CAP210 (Table 3.7). Whereas the 
2dCD4S60C immunogen resulted in approximately ten-fold higher end-point 
titres compared to gp140IN25925/2dCD4S60C but only two of the five rabbits 
immunized with this immunogen showed high neutralization of the 
pseudoviruses (Table 3.6). This is possibly due to the NAb response being 
directed to one or more novel epitopes exposed either on gp120 or 2dCD4 
or both, post binding of these two molecules. This indicates that the use of 
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the matched Env or 2dCD4 molecules to determine the antibody titres in 
end-point ELISA’s would not quantify the response appropriately. Rather, 
the neutralization-directed epitope, which has not yet been ascertained, 
would give a more accurate indication of the neutralizing response titres. 
Efforts to explore this are ongoing. 
 
In summary, all the immunogens assessed in this study induced an Ab 
response capable of neutralizing Tier 1 pseudovirus SF162. The only 
immunogens that stood out in terms of neutralization breadth and potency 
were the 2dCD4S60C-Env liganded immunogens, which was improved for 
the trimeric Env conformations. This response was consistent with both Env 
isolates (ZACAP45 and IN25925) tested as well as our previous findings 
(Killick et al., 2015). This data suggests that the Ab responses induced by 
the different gp120/gp140GCN4(+) Env variant immunogens and stabilized 
gp120/gp140 derivatives with limited neutralization are possibly directed 
towards one or more regions on Env, whereas those induced by the 
Env/2dCD4S60C liganded immunogens could be directed towards one or 
more transiently exposed epitopes either on Env post binding to 2dCD4, or 
as suggested by Kowalski et al. (1989), transiently exposed epitopes on 
2dCD4 post binding to gp120. However, our previous findings suggest that 
the NAb response is directed against 2dCD4, since neutralization activity 
was diminished post depletion of anti-CD4 antibodies (Killick et al., 2015).  
 
Despite this, it is possible that the Env/2dCD4-liganded immune response 
may be directed to a region on CD4, distinct from the region to which gp120 
binds, and may be “Ibalizumab” in nature. The mAb Ibalizumab, a 
humanized mAb engineered from its mouse progenitor, blocks HIV-1 entry 
by binding to domain 2 of human CD4 (Song et al., 2010). Ibalizumab has 
been reported to reduce viral loads in HIV-1 infected patients approximately 
ten-fold with no serious side effects, as determined in a phase 1b safety, 
pharmacokinetics and antiviral activity trial (Jacobson et al., 2009). 
Ibalizumab-treated patients showed no indication of CD4+ T-cell depletion 
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and Ibalizumab was not immunogenic. Since Ibalizumab binds to an epitope 
on the opposite side of the CD4 molecule to which gp120 and the MHC 
class II molecule bind, it does not interfere with the “normal” immune 
response (Song et al., 2010). The response could also be similar to that of 
21c, a bimolecular Ab isolated from an HIV-1 infected individual which 
targets domain one of the CD4 molecule and binds to a subtype C gp120 
(CAP210) in the presence of sCD4 (Diskin et al., 2010).  
 
Ongoing studies in our laboratory are attempting to map the epitopes 
responsible for the neutralization breadth observed when immunizing 
rabbits with Env/2dCD4S60C liganded immunogens to elucidate the 
neutralization mechanism observed. 
 
Overall, the immunogens tested in this study all elicited anti-Env Abs in 
rabbits, however the majority of the activity was non-neutralizing. This was 
not unexpected since during the course of the study emerging evidence on 
the extent of affinity maturation required for the evolution of an anti-HIV 
bNAb response in an infected patient emerged (Bhiman et al., 2015; Liao et 
al., 2013b; Moore et al., 2012). These studies propose an interplay between 
constant antigenic challenge and resulting immune escape by Env 
concurrently with an increased percentage of affinity maturation of the B 
cells over time. This implies that multiple sequential immunizations with Env 
immunogens would be required to stimulate the appropriate B cell precursor 
and to drive the affinity maturation process. These findings could explain 
why numerous immunization experiments with Env, in this study and 
internationally (Bhattacharyya et al., 2010; Bowles et al., 2014; Burke et al., 
2009; Celada et al., 1990; Cho et al., 2001; Derby et al., 2006; DeVico et 
al., 2007; Earl et al., 1994; Hammonds et al., 2005; Heyndrickx et al., 2013; 
Kim et al., 2005; Klasse et al., 2016; Kulkarni et al., 2013; Leung et al., 2004; 
Liao et al., 2013a; Narayan et al., 2013; Rosati et al., 2009; Sanders et al., 
2013; Schwartz et al., 2016; Sneha et al., 2015; VanCott et al., 1995a; Wang 
et al., 2005), have never elicited bNAbs targeting clinically relevant HIV-1. 
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Thus future work could build on using the vaccine immunogens described 
in this study and design sequential immunization regimens using an 
evolving Env sequence over time to try and elicit bNAbs. Moreover, the 
“Ibalizumab-like” bNAbs described here warrant further investigation. 
 
4.6 Concluding remarks 
It is likely that an effective vaccine would require the elicitation of bNAbs in 
order to be protective against HIV-1. An Env based-immunogen has been 
the focus of intensive vaccine efforts since it is the primary viral component 
exposed on the virus. A region-specific Env immunogen could address the 
large diversity challenge of HIV-1 vaccine design. Here we compared the 
antigenicity of HIV-1 subtype C Env’s from South Africa and India using 
isolates representative of these geographically distinct regions. The ability 
of these Envs, liganded and unliganded to 2dCD4S60C, as well as Env-based 
immunogens designed as stabilized Env derivatives (based on HIV-1 
subtype B isolates) to elicit bNAbs were evaluated and compared in rabbits.  
 
While differences in amino acid sequences, PNLG’s and variable loop 
lengths were noted between the Env’s of South African and Indian origin, 
the SPR experiments showed that a combination of these factors influence 
the overall exposure of relevant epitopes, and therefore binding of bNAbs. 
SPR was found to be a useful tool for quantifying and comparing the Ab-
Env interactions. It would be interesting to determine the stoichiometry of 
the Ab-Env interaction to understand the Ab-Env interaction in more detail. 
Future work could look into this as well as compare Env binding with the 
Fab region of the Ab to the whole immunoglobulin. 
 
The Env’s of Indian origin had higher affinities for the CD4bs bNAbs VRC01, 
VRC-CH31, HJ16 and NIH45-46G54W and elicited approximately ten-fold 
higher anti-Env titres when immunized in rabbits compared to the South 
African Env’s. However, immunization of rabbits with the South African and 
Indian Env’s were equivalent in their neutralization responses. In addition, 
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the Env only neutralization responses were comparable to those obtained 
with the JRFL stabilized Env derivatives. However, of these immunogens 
the VRC01 engrafted scaffold peptide 1ORC induced an improved 
neutralization response against Tier 1 pseudoviruses, presumably 
indicating a focusing of the immune system to a predetermined epitope on 
the scaffold peptide. Future directions using this approach could possibly 
present an epitope based on an intermediary epitope, (rather than one 
based on an affinity matured bNAb) that better engages the naïve B cell and 
could be used to drive the evolution of bNAbs. 
 
In comparison to the Env based immunogens, the Env/2dCD4S60C liganded 
complexes elicited a potent and broadly neutralizing response and 
reinforced our earlier findings (Killick et al., 2015). Interestingly, this 
response was observed regardless of the Env isolate used. Although this 
neutralization response may be directed against 2dCD4 (Killick et al., 2015), 
it may target a region on 2dCD4 distinct to that which binds gp120 and MHC 
class II molecules. If the response is directed to a transiently exposed 
epitope on 2dCD4 post binding to gp120, it warrants further investigation as 
to the feasibility of such a strategy in HIV-1 vaccine design. Ongoing studies 
in our laboratory are attempting to elucidate the neutralization mechanism 
induced by our Env/2dCD4 liganded complexes. In addition, studies striving 
to replicate this response in a NHP model using a homologous NHP 2dCD4 
to cancel out the effects of using a ‘foreign” heterologous 2dCD4 from a 
different species, are ongoing. 
 
Overall, the findings in this study lay the groundwork for further testing of 
these HIV-1 Env based immunogens in various combinations using 
sequential prime-boost strategies to optimally drive affinity maturation of the 
appropriate B cell lineages.   
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Appendix B 
 
Figure B1: SPR sensorgrams showing binding and interspot data of increasing 
concentrations of gp120 and gp140GCN4(+) conformations of the HIV-1 envelope 
glycoproteins of South African origin to 2dCD4Wt and 2dCD4S60C.  2dCD4Wt and 2dCD4S60C 
were covalently captured onto separate flow cells on the chip at a concentration of 0.02 
mg/ml at a flow rate of 30 µl/min for 300 s to a final RU of 2000. The gp120 and 
gp140GCN4(+) Env’s were passed over the ligands at a flow rate of 30 µl/min for 300 s 
with a dissociation time of 600 s. Binding kinetics could not be accurately determined due 
to non-specific binding (dotted curves) exceeding10% RMAX as per manufacturer 
instructions (Bio-Rad Laboratories Inc., 2009).  
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Figure B2: SPR sensorgrams showing binding and interspot data of increasing 
concentrations of gp120 and gp140GCN4(+) conformations of the HIV-1 envelope 
glycoproteins of Indian origin to 2dCD4Wt and 2dCD4S60C.  2dCD4Wt and 2dCD4S60C were 
covalently captured onto separate flow cells on the chip at a concentration of 0.02 mg/ml 
at a flow rate of 30 µl/min for 300 s to a final RU of 2000. The gp120 and gp140GCN4(+) 
Env’s were passed over the ligands at a flow rate of 30 µl/min for 300 s with a dissociation 
time of 600 s. Binding kinetics could not be accurately determined due to non-specific 
binding (dotted curves) exceeding 10% RMAX as per manufacturer instructions (Bio-Rad 
Laboratories Inc., 2009). 
